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One of the over-arching goals of the research in Dr. Wang’s lab is to develop 
methodologies for the regioselective and diverse functionalization of C–H bonds. The 
Pd(II)-catalyzed C-H activation/functionalization organic transformations have be-
come a practical and powerful tool in organic chemistry. This thesis describes my ef-
forts during my Ph.D. research for Pd(II)-catalyzed C–H functionalization reactions 
that result in the formation of many biologically and pharmaceutically important 
molecules utilizing alkyne as a universal building block. 
Chapter 1 gave a brief introduction of transition metal catalysis, followed by a 
general evaluation of the research progress of Pd-chemistry, particularly Pd-mediated 
alkyne transformations, which were elucidated with selected examples. 
Chapter 2 described an efficient synthesis of an interesting spiro cyclopentadi-
ene-chroman-2,4-dione heterocycles. The method employed a direct Pd(II)-catalyzed 
oxidative [2+2+1] cycloaddition of readily available starting materials: 
4-hydroxycoumarins and unactivated internal alkynes. Various substituents were well 
tolerated in the reaction, which led to a number of unique molecular structures.  
Chapter 3 developed an efficient synthesis of highly substituted pyrroles. The 
method utilized simple and readily available enamines and alkynes, and employed 
direct Pd(II)-catalyzed oxidative annulation procedure. A mechanistic investigation of 
pyrrole- forming reaction established a viable catalytic cycle. The mild nature of the 
reaction and the significance of the pyrrole scaffold as structural element should ren-
 X 
 
der this method attractive for both synthetic and medicinal chemistry. 
Chapter 4 disclosed an efficient synthesis of highly substituted 1-naphthols. The 
method utilized simple and readily available benzoylacetates and unactivated internal 
alkynes as starting materials, and employed a direct Pd(II)-catalyzed oxidative annu-
lation procedure involving C-H activation. The mild nature of the reaction, functional 
group compatibility and the significance of the 1-naphthol scaffold as structural ele-
ment should render this method attractive in different disciplines. 
The diarylalkenyl propargylic complex framework has been found in many nat-
ural products and medicinal regents. In chapter 5, an unprecedented Fe-catalyzed 
ene-type reaction of propargylic alcohols with 1,1-diaryl alkenes was developed, 
which enabled us to furnish a diarylalkenyl propargylic complex in moderate to high 
chemical yields. 
3,4-Dihydrocoumarins have attracted considerable attention due to their various 
biological activities. In chapter 6, we have documented an efficient and convenient 
double decarboxylation process for the synthesis of 4-substituted 
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Chapter 1 Introduction 
1.1 Transition-Metal-Catalyzed C-H Bond Functionalization 
Most scientists describe a ‘transition metal’ as any element in the d-block of the 
periodic table, which includes groups 3 to 12 on the periodic table.[1] The transition 
metals and their compounds are known for their homogeneous and heterogeneous 
catalytic activity, which is ascribed to their ability to adopt multiple oxidation states 
and to form complexes. They could lower the activation energy and allow some tradi-
tionally impossible reactions to occur. Transition-metal-catalyzed C-H bond function-
alization chemistry complements traditional functional-group-based chemistry and 
significantly broadens the scope of organic chemistry. 
The traditional functional-group-based manipulation (Scheme 1.1a), that is ex-
changing one functional group for another, requires the starting material 
pre-functionalized, which decreases both efficiency and atom economy, because FG1 
must be first installed and then lost as a byproduct in the installation of FG2.[2] In con-
trast, transition-metal-catalyzed C-H bond functionalization would allow for the for-
mation of FG2 in one step with no byproduct but one H, which increases efficiency 
and atom economy (Scheme 1.1b).[3]  
Scheme 1.1 Traditional functional-group-based transformation vs transition metal 
catalyzed C-H bond functionalization 
R H
















In 1963, Kleiman and Dubeck reported C-H bond cleavage of azobenzene by 
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stoichiometric transition metal complex Cp2Ni (Scheme 1.2).[4] Although the reaction 
mechanism for this metalation reaction has not been elucidated, the ortho-C-H bond 
was apparently cleaved. After this pioneering study, many research groups have re-
ported about the cleavage of C-H bonds via the use of stoichiometric amount of tran-
sition metal complex.[5] The reaction mechanism of such C-H bond cleavage reactions 
has been elucidated by a large number of review articles.[5,6] 
Scheme 1.2 C-H bond functionalization of azobenzene by stoichiometric transition 







Transition-metal-catalyzed functionalization of C-H bonds appeared in the early 
1990s (Scheme 1.3).[7-9] In 1989, Jordan reported the Zr-catalyzed addition of a C-H 
bond of α-picoline to an olefin (Scheme 1.3a).[7] After this discovery, in 1992, Moore 
found that the Ru-catalyzed three-component coupling of pyridine, CO and olefins 
provided the corresponding α-acylpyridines (Scheme 1.3b).[8] Subsequently, in 1993, 
Murai reported the highly efficient, selective functionalization of C-H bonds in aro-
matic ketones with olefins in the presence of a Ru-catalyst (Scheme 1.3c).[9] Since 
these discoveries, the chemistry of transition-metal-catalyzed functionalization of C-H 
bonds in organic synthesis has rapidly expanded. 












































Although all of these transition metal catalysts promote the same general trans-
formations (C-H bonds to C-C/C-heteroatom bonds), they could proceed within two 
different mechanistic manifolds: ‘inner-sphere’ and ‘outer-sphere’, which were named 
by Sanford.[10] The key distinguishing feature of the ‘inner-sphere’ mechanism is the 
formation of a discrete organometallic intermediate containing an M-C σ-bond (M is 
transition metal) by the direct contact of metal ion and C-H bond. The cleavage of 
C-H bond could proceed via oxidative addition or electrophilic substitution (Scheme 
1.4). The oxidative addition is direct insertion of the metal into the C-H bond, there-
fore the oxidation state of the metal increases by two (Scheme 1.4a). Metals that acti-
vate C-H bonds by oxidative addition include Zr(II), Ru(0), Rh(I), Ir(I) and Pt(IV).[13] 
There is no oxidation state change in electrophilic substitution, because a ligand is 
replaced by a covalently bound carbon (Scheme 1.4b).Transition metals that are 
known to promote electrophilic C-H activation include Pd(II), Pt(II) and Rh(III).[13] 
These transformations often proceed with high selectivity for the less sterically hin-














The key distinguishing feature of ‘outer-sphere’ mechanism is that the substrate 
does not interact directly with the transition metal, but instead reacts with an active 
coordinated ligand of the transition metal ([M]=X, M is transition metal, X is lig-
and).[10] The ligand is typically an oxo-, imido- or carbene species (Scheme 1.5). The 
cleavage of C-H bond could proceed by either direct insertion (Scheme 1.5a) or 
H-atom abstraction/radical rebound process (Scheme 1.5b).[13] Transition metals that 
are known to catalyze through these indirect C-H functionalization reactions include 
Fe(III), Mn(III), Ru(IV) and Rh(II).[13] These transformations typically show high se-
lectivity for weaker C-H bonds, such as benzylic, allylic and adjacent to a heteroatom, 
because of the radical and/or cationic intermediate. 





























It should be noted that there are other different classifications of transi-
tion-metal-catalyzed C-H activation mechanisms. Shul’pin divided all the C-H bond 
splitting reactions which are promoted by metal complexes into three groups based on 
their mechanisms.[11] Crabtree labeled the mechanisms as ‘organometallic’ and ‘coor-
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dination’, which was similar with Sanford’s ‘inner-sphere’ and ‘outer-sphere’ classifi-
cation method mentioned above.[12] Bercaw gave a more detailed classification: ‘oxi-
dative addition’, ‘σ-bond metathesis’, ‘metalloradical activation’, ‘1,2-addition’ and 
‘electrophilic activation’.[13] Another thing to be noted is that the different classifica-
tion methods are all rather approximate division of all the known reactions in accord-
ance with their mechanisms. Nevertheless, the unambiguous assignment of a process 
to a particular type requires a detailed knowledge of the reaction mechanism. Unfor-
tunately, many processes’ mechanisms have not yet been elucidated even broadly.  
The biggest challenge of transition-metal-catalyzed C-H bond functionalization 
should be regioselectivity because most organic molecules contain many different 
types of C-H bonds. Therefore, developing transformations that regioselectively func-
tionalize a single C-H bond within a complex structure remains a long-standing criti-
cal challenge in this field. Until now, a number of approaches have been used to ad-
dress this problem. The popular ones include: (i) the use of substrates containing 
weaker or activated C–H bonds, such as benzylic, allylic and adjacent to a heteroa-
tom,[14] (ii) the use of σ-chelating directing groups, which lead to ortho-selectivity 
through the formation of a conformationally rigid five-, six- or seven-membered cy-
clic pre-transition state,[15] (iii) the use of transition metal catalysts/ligands to control 
regioselectivity.[16] Recently, Gaunt reported an elegant Cu-catalyzed arylation meth-
odology to functionalize all three positions of anilines with exquisite selectivity 
(Scheme 1.6).[17] Yu reported another Pd-catalyzed method to activate meta-C-H 
bonds via an end-on template strategy (Scheme 1.7).[18] This method overrides or-
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tho-directing effects as well as electronic and steric biases on the appended arene sub-
strates.  





























Conditions      
Cu(OTf)2 (10
 mol%)            


















































One thing to be mentioned is that there are a number of non-transition metal cat-
alyzed C-H bond functionalization reactions, including electrophilic aromatic substi-
tutions (such as the well-known Friedel–Crafts reactions), directed or-
tho-lithiation/iodination sequences,[19] reactions of dioxiranes[20] and free radical reac-
tions.[21] They are widely used in synthetic organic chemistry and often exhibit com-
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plementary levels of reactivity, functional group tolerance and selectivity to the tran-
sition-metal-catalyzed reactions. 
One of the over-arching goals of the research in Dr. Wang’s lab is to pursue 
methodologies that employ unactivated internal alkynes as building blocks to synthe-
size biologically and pharmaceutically important molecules via Pd-catalyzed C-H 
functionalization strategies. So, the next section will give a brief summary of 
Pd-chemistry, including traditional Pd-catalyzed crossing-coupling reactions and 
modern Pd-catalyzed C-H functionalization/C-C coupling reactions, and then put an 
emphasis on recent Pd-catalyzed alkyne chemistry. 
1.2 Traditional Pd(0)-Catalyzed Cross-Coupling Reactions 
Traditional Pd(0)-catalyzed cross-coupling reactions have found widespread 
popularity in synthetic chemistry and the common ones are listed in Table 1.1.[22] 
These reactions involve developing methods for C-C and C-heteroatom bonds for-
mation under mild reaction conditions and with high degrees of selectivity. All of the 
traditional Pd(0)-catalyzed cross-coupling reactions continue to enjoy avid attention 
from the academic and industrial communities. Substantial growth in this area has 
taken place during the last decade in terms of publications and patents, with the Suzu-
ki-Miyaura, Heck and Sonogashira cross-coupling reactions proving by far the most 
popular ones.[22] 
Table 1.1 Traditional Pd(0)-catalyzed cross-coupling reactions 
Entry Reaction Name Reaction Scheme 
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The generally accepted mechanisms for these Pd(0)-catalyzed cross-coupling re-
actions are depicted as four types based on different coupling partners (Scheme 1.8): 
(i) The coupling partner is an alkene (Scheme 1.8a, Table 1.1, entry 1). The oxidative 
addition of the aryl halide (pseudohalide) to the catalytically active Pd(0) species ini-
tiates the catalytic cycle. The reaction progresses by co-ordination of an alkene to the 
Pd(II) species, followed by its syn-migratory insertion. The newly generated organo-
palladium species then undergoes syn-β-hydride elimination to form the alkene prod-
uct. Subsequently, base-assisted elimination of HX from [HPdX] occurs to regenerate 
the Pd(0) catalyst. (ii) The coupling partner is an organometalic R-M species (Scheme 
1.8b, Table 1.1, entries 2-8). The first step is also the oxidative addition of the aryl 
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halide (pseudohalide) to the catalytically active Pd(0) species to initiate the catalytic 
cycle. The oxidative addition is followed by transmetalation of an organometallic 
species to generate a Pd(II) intermediate bearing the two organic coupling partner 
fragments. Subsequent reductive elimination results in C-C bond formation with the 
regeneration of Pd(0) species to re-enter into the catalytic cycle. One thing to be noted 
is that the organometallic R-M species could be generated in situ from a carboxylic 
acid, by, for example, the action of an additional metal or an additive, such as 
TBAC.[34] (iii) The Tsuji–Trost reaction is conceptually a Pd(0)-mediated coupling 
reaction, but is mechanistically different from the conventional cross-coupling pro-
cesses mentioned above and achieves an allylic substitution via an intermediate 
π-allyl-Pd complex (Scheme 1.8c, Table 1.1, entry 9). First, the Pd(0) coordinates to 
the alkene, forming a η2-π-allyl-Pd(0) complex. The next step is oxidative addition, in 
which the leaving group is expelled and a η3-π-allyl-Pd(II) is created. The nucleophile 
then adds to the allyl group regenerating the η2-π-allyl-Pd(0) complex. At the comple-
tion of the reaction, the Pd(0) detaches from the alkene and starts again in the catalytic 
cycle. (iv) The end result of an α-arylation reaction is a formal C(sp2)-C(sp3) coupling 
of aryl halides (pseudohalides) with enolates generated in situ from various carbonyl 
compounds such as ketones, amides, esters and aldehydes (Scheme 1.8d, Table 1.1, 
entry 10). The first step is the oxidative addition of the aryl halides (pseudohalides) to 
the catalytically active Pd(0) species. Next is transmetalation of an intermediate eno-
late formed in situ to allow the final reductive elimination to achieve the C-C coupling. 




































































However, despite the many significant discoveries and developments in tradi-
tional Pd(0)-catalyzed cross-coupling reactions, there still remain some major un-
solved problems: (i) From the view points of efficiency and atom economy, the prep-
aration of pre-functional partners remains a challenge in academic and industrial lev-
els. The installation of these pre-functional groups involves extra synthetic steps. The 
generation of waste after C-C bond formation is also not atom economic. (ii) Only 
partial success in C(sp2)-C(sp3) and C(sp3)-C(sp3) cross-coupling reactions involving 
alkyl halides has been achieved. (iii) The reaction mechanism is not clear. Although 
the steric and electronic effects of ligands involved in various steps of the catalytic 
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cycle are now reasonably rationalized, there remains, in many cases, a lack of under-
standing about the mechanism of the active Pd(0) catalytic species formation from the 
preformed Pd(II) complexes. (iv) In the area of asymmetric catalysis, simple methods 
using chiral ligands to form enantioenriched products need to be developed, and fur-
ther to achieve practical and hence widely applications.  
In order to improve the efficiency and atom economy, Pd-catalyzed C-H bond 
fuctionalization is developed for the direct conversion of C-H bonds into C-C and 
C-heteroatom bonds, a route which is highly efficient and atom economic by avoiding 
the use of aryl halides (pseudohalides) and/or organometallic reagents and leaving H 
as byproduct. This methodology is rapidly developed in the past decades, widely used 
in synthetic organic chemistry and exhibits complementary levels of reactivity, func-
tional group tolerance and selectivity to the traditional Pd(0)-catalyzed cross-coupling 
reactions. So, in next section, I will give a general introduction about the recent de-
velopment of modern Pd-catalyzed C-H activation/functionalization reactions. 
1.3 Modern Pd-Catalyzed C-H Functionalization Reactions 
In the past decades, Pd-catalyzed C-H functionalization reactions have emerged 
as promising new catalytic transformations, although development in this field is still 
at an early stage compared to the traditional Pd(0)-catalyzed cross-coupling reactions. 
This section includes a brief introduction of four extensively investigated modes of 
catalysis for C-H bond functionalization: Pd(0)/Pd(II), Pd(II)/Pd(IV), 
Pd(0)/Pd(II)/Pd(IV) and Pd(II)/Pd(0) catalysis. Then emphasis is directed towards the 
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recent development of Pd-catalyzed alkyne chemistry involving C-H functionaliza-
tion.  
1.3.1 C-H Bond Functionalization via Pd(0)/Pd(II) Catalysis 
The Pd(0)/Pd(II) C-H bond activation mode has been developed extensively in 
the past three decades. The initial proof of concept was established using electron-rich, 
hence more reactive, heterocycles as substrates by Sakai and Ohta in 1982 (Scheme 
1.9).[35] After these pioneering studies, many research groups have reported about C-H 
bond cleavage of electron-rich heterocycles via the Pd(0)/Pd(II) catalysis.[36] The sub-
tle effects of the choice of catalysts, aryl halides and N-protecting groups on both re-
activity and selectivity have been observed.[36d-e] 


























































In 1997, Rawal discovered an intramolecular non-heterocyclic arene bond aryla-
tion, that phenolic OH group promotes ortho-arylation from an ether tethered aryl 
bromide (Scheme 1.10a).[37] This reaction appears to be the first example of the aryla-
tion of non-heterocyclic arenes. Within the same year, intermolecular arylation of 
2-phenylphenol was demonstrated by Miura, making intermolecular arylation reac-
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tions with non-heterocyclic arenes via Pd(0)/Pd(II) catalysis possible (Scheme 
1.10b).[38] The arylation of C(sp3)-H bonds is also demonstrated, but much limited to 
intramolecular reactions, among which a recent elegant example by Fagnou was to 
develop a general method for the preparation of dihydrobenzofurans (Scheme 
1.10c).[39] 











































































































A general mechanism for this mode of Pd(0)/Pd(II) catalysis is depicted in 
Scheme 1.11, which is similar with the traditional Pd(0)-catalyzed cross-coupling re-
action mechanism (Scheme 1.8b), except that the second step is C-H activation, not 
transmetalation. This mode of Pd(0)/Pd(II) catalysis is the closest to the conventional 
cross-coupling reactions. A major challenge that still remains for this mode of cataly-
sis is to address its relatively limited substrate scope and versatility. 



















1.3.2 C-H Bond Functionalization via Pd(II)/Pd(IV) Catalysis 
Traditionally, Pd-catalyzed processes involve Pd(0)/Pd(II) complexes as inter-
mediates. In recent times, the involvement of Pd(IV) complexes have been implicated 
in many new synthetic methodologies, for which important advances have been made 
in the last decades.[40] The first case that involved the Pd(IV) complex as intermediate 
was reported by Tremont and Rhaman.[41] They described the first intriguing methyla-
tion of the ortho-C-H bond in anilides (Scheme 1.12). In this work, the reactivity of 
the cyclopalladated intermediate with MeI was established and a plausible Pd(IV) in-
termediate was proposed. 
Scheme 1.12 ortho-Methylation of anilide via Pd(II)/Pd(IV) catalytic cycle 




























The proposed oxidation of Pd(II) to Pd(IV) by MeI was unambiguously sup-
ported by X-ray crystallography. The first crystal structure was obtained by Canty in 
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1986 (Scheme 1.13a).[42a] Recently, additional corroborative physical evidence has 
been obtained by Sanford through X-ray crystallographic study of Pd(IV) intermedi-
ate generated in their acetoxylation reaction (Scheme 1.13b),[42b] which is also im-
portant evidence in support of the Pd(II)/Pd(IV) redox chemistry. A general mecha-
nism for this mode of Pd(II)/Pd(IV) catalysis is depicted in Scheme 1.14.  
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Based on the Pd(II)/Pd(IV) catalytic mechanism, Sanford[43a] and Daugulis[43b] 
respectively reported directed arylation of C-H bonds using [Ph2I]PF6 and [Ph2I]BF4 
in 2005 (Scheme 1.15). Sanford group designed a more general approach for the oxi-
dation and halogenation of unactivated C-H bonds via Pd(II)/Pd(IV) catalytic mode 
(Scheme 1.16).[44] Daugulis group discovered that the arylation of C-H bonds could be 
performed via cheap and practical ArI (Scheme 1.17).[43b, 45] This protocol represents 
the most efficient arylation process via Pd(II)/Pd(IV) catalysis to date.  
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Scheme 1.17 C-H bond arylation using ArI via Pd(II)/Pd(IV) catalytic cycle by Dau-










































































There are still some drawbacks that limit the use of this novel Pd(II)/Pd(IV) 
methodology. For example, the low stability of Pd(IV) intermediates means that poor 
selectivity is sometimes observed in C-C or C-heteroatom bond forming steps. 
Pd(II)/Pd(IV) catalysis commonly requires 2-20 mol % of a Pd(II) catalyst (usually 10 
mol %). Also, several equivalents of expensive additives, reagents and oxidants, such 
as silver or iodonium salts, are often required. However, it is clear that catalytic reac-
tions involving Pd(IV) intermediates offer new opportunities for the design of adven-
turous synthetic methodologies, which could complement or even in some cases su-
persede existing processes. 
1.3.3 C-H Bond Functionalization via Pd(0)/Pd(II)/Pd(IV) Catalysis 
The most famous reaction via Pd(0)/Pd(II)/Pd(IV) catalysis should be Catellani 
reaction, which was discovered by Catellani in 1997 (Scheme 1.18).[46] The overall 
process comprises the reaction of an iodoarene, a terminal olefin and two aliphatic 
iodides. The key feature of this reaction is the dialkylation of both ortho-C-H bonds 
of the aryl iodide substrate. Efforts from Lautens and others to make this transfor-
mation more amenable for synthesis have yielded substantial improvements.[47]  


































































The Pd(0)/Pd(II)/Pd(IV) ‘cascade catalysis’ is not limited to Catellani reaction. 
Before Catellani, Dyker reported an impressively intramolecular C(sp3)-H bond acti-
vation encompassing both Pd(0)/Pd(II) and Pd(II)/Pd(IV) redox chemistry without 
using norbornene as the mediator (Scheme 1.19).[48] 































































Although the lack of simplicity (because of the formation of multiple bonds, 
some of which may not be desired in a synthetic application) constitutes a limitation, 
the advantage of this catalytic cycle is that no external oxidant is needed. As a 
demonstration of the flexibility and power of Pd-redox chemistry, this complex and 
elegant catalytic cycle is unparalleled. 
1.3.4 C-H Bond Functionalization via Pd(II)/Pd(0) Catalysis 
Various approaches have been used in Pd-catalyzed C-H activation/C-C bond 
formation via Pd(II)/Pd(0) catalysis. A lot of mechanisms have been used to explain 
the process of these reactions, which could be summarized into three types: oxidative 
olefination, C-H activation/C-C coupling, oxidative arene-arene coupling (Scheme 
1.20). 































































Oxidative Olefination (Scheme 1.20a), also named as oxidative Heck coupling 
or modern Heck reaction, is in fact not modern at all. Oxidative olefination had suc-
cessfully moved into the catalytic realm even before the discovery of traditional 
Pd(0)-catalyzed Heck cross-coupling reaction. This is evidenced by the work of Fuji-
wara, who, in 1967, reported the oxidative olefination reaction before the initial dis-
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closures of Heck in 1968 (Scheme 1.21).[49] However, two major drawbacks largely 
hampered the application of this catalytic reaction: (i) A large excess of the arene was 
required (often used as solvent); (ii) There was a lack of control of the regioselectivity 
when monosubstituted benzene was used.  











In response to this regioselectivity problem, an early attempt of using directing 
groups to achieve ortho-selectivity represented an encouraging step forward, which 
was reported by Miura (Scheme 1.22a).[50] The use of a benzenesulfonamide substrate 
afforded high ortho-selectivity and allowed the arene to be used as the limiting rea-
gent. In this reaction, the acidity of substrates has a significant effect on the reaction 
efficiency and the mechanism of the C-H bond cleavage step for this reaction is pro-
posed to proceed by deprotonation, which seems to be enhanced by base. Another in-
strumental development using a directing group was reported by de Vries (Scheme 
1.22b).[51] The use of an anilide substrate afforded high ortho-selectivity and allowed 
the arene to be used as the limiting reagent. In this reaction, BQ is believed to be cru-
cial for the C-C bond forming step, and the use of TsOH is also found to be beneficial. 
Notably, the mechanism of the C-H cleavage step is likely to proceed by electrophilic 
palladation of the electron-rich arene and subsequent loss of the ortho-proton (SArE), 
which is different with Miura’s report.  
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In 2005, Gaunt developed a general method for the selective C-2 or C-3 inter-
molecular olefination of indoles through a Pd(II)-catalyzed C-H functionalization re-
action (scheme 1.23a).[52a] The nature of solvents determines the regioselectivity of 
the reaction, so the alkenylation could be directed to either the C-2- or the 
C-3-position of free indoles. In 2006, Gaunt reported a steric and electronic control 
strategy, which could be used to achieve regioselective olefination at either the C-2- 
or C-3-position of pyrroles through the use of different protecting groups (Scheme 
1.23b).[52b]  




































































































































In 2009, Pd(II)-catalyzed meta-olefination of highly electron-deficient unreactive 
arenes was achieved through the use of a rationally designed mutually repulsive lig-
and by Yu (Scheme 1.24).[53] A combination of C-H acidity and steric hinderance 
seems to govern the reactivity of different sites, suggesting a concerted mechanism 
whereby acetate serves as an internal base. In 2012, Yu utilized an end-on template 
strategy to realize the olefination of remote meta-C-H bonds (Scheme 1.7). 








































C-H Activation/C-C Coupling (Scheme 1.20b) has noticeable progress in the 
past several years. Currently, C-H bonds activation via Pd(II)/Pd(0) catalytic cycle has 
been successfully established. Yu reported that oxazoline as a directing group could 
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promote ortho-C-H activation during an unprecedented coupling process via 
Pd(II)/Pd(0) catalysis (Scheme 1.25).[54] Batch-wise addition of tetraalkyltin reagents 
is essential for the success of the reaction. BQ is believed to promote C-H activation 
step. 












































This potential generality of Pd(II)-catalyzed ortho-C-H activation by directing 
group via the Pd(II)/Pd(0) catalytic cycle has been further demonstrated by Yu and Shi 
(Scheme 1.26).[55] In 2006, Yu reported Pd(II)-catalyzed alkylation of aryl C-H bonds 
with sp3-organotin reagents using BQ as a crucial promoter (Scheme 1.26a).[55a] Shi 
reported ortho-arylation of anilides with organosilanes in 2006 (Scheme 1.26b) and 
with arylboronic acids in 2007 (Scheme 1.26c).[55b,c] The versatility and practicality of 
this model were further explored and improved by Yu, utilizing carboxylic acid as di-
recting group and potassium aryltrifluoroborate (ArBF3K) as coupling partner 
(Scheme 1.26d).[55d] O2 could be used as the oxidant and a wide range of functional 
groups were tolerated. Compared to the classic N-directed cyclopalladation reactions, 
the carboxylic O-directed Pd(II) insertion into C-H bond was proposed through the 
complex-induced proximity effect (CIPE).[56] 

































































































































It is encouraging to see that the coupling of electron-rich olefins, arenes and in-
doles with organoborons and organotins is feasible via Pd(II)/Pd(0) catalysis (Scheme 
1.27).[57]  





























































































































A key challenge to be addressed is regioselectivity. For example, Pd(II) generally 
reacts with monosubstituted benzene at the ortho, meta, para positions in an unselec-
tive fashion. One possible solution hinges on an innovative design of ligands that will 
impart an appropriate steric and electronic bias on Pd(II) so that selective C-H activa-
tion of monosubstituted arenes could be accomplished (Scheme 1.24). 
Oxidative Arene-Arene Coupling (Scheme 1.20c) is a far more efficient ap-
proach to aryl-aryl bonds, avoiding the use of organohalides or organometals as sub-
strates. Early work had been focused on the oxidative dimerization of arenes (homo-
coupling).[58] A recent report has shown that Pd(II) could catalyze the oxidative ho-
mocoupling of thiophenes under mild reaction conditions (Scheme 1.28).[59] 























Recently, a closely related coupling reaction involving two different arenes 
(cross-coupling) has attracted significant attention. Substantial progress towards this 
goal has been made by Lu (Scheme 1.29a).[60a] However, the yield and selectivity of 
cross-coupling product vs homocoupling product are not satisfactory. Directing 
groups have been successfully employed to suppress homocoupling. A highly efficient 
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cross-coupling process was developed by Sanford using a pyridyl moiety as the di-
recting group and BQ as the promoter (Scheme 1.29b).[60b] Another method to im-
prove selectivity for the cross-coupling reaction is to replace one of the arene partners 
by an electron-rich heterocycle. A highly efficient cross-coupling process of 
N-acetylindoles and benzenes with high yield and regioselectivity was developed by 
Fagnou (Scheme 1.29c).[60c] 
























































































Key challenge still remains in that the reaction requires a large excess of benzene. 
Additionally, Pd(II) generally reacts with monosubstituted benzene in an unselective 
fashion, limiting the potential for synthetic applications. One possible solution is the 
design of new ligands as mentioned above and indicated in Scheme 1.24. 
1.4 Pd-Catalyzed Alkyne Transformation via C-H Functionalization 
The C-C triple bond of alkynes is one of the basic functional groups. Its reactions 
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belong to the foundations of organic chemistry, due to not only its occurrence in mol-
ecules in the frontiers of organic chemistry such as biochemistry or material sciences, 
but also as building blocks or versatile intermediates for the synthesis of a vast array 
of (hetero)carbocycles. The traditional Pd-catalyzed inter or intramolecular reaction of 
alkynes usually involves an aryl or vinyl halide as coupling partner, which is not atom 
economic or step efficient. C-H functionalization reactions present an attractive and 
powerful alternative. However, Pd-catalyzed direct C-H alkynylation and cycloaro-
matization of alkynes to form alkynylated and (hetero)aromatic compounds are still at 
an early stage. This section will mainly present the recent progress of Pd-catalyzed 
alkyne reactions involving C-H functionalization, leading to different alkynylated and 
(hetero)aromatic compounds. 
1.4.1 Pd-Catalyzed Alkynylation Reactions  
1,3-Diynes: Different methodologies have been described for the preparation of 
1,3-diyne structures. The two common methods are Glaser-type reaction 
(Cu-catalysed oxidative homocoupling reaction of alkynes) and Cadiot-Chodkiewicz- 
type reaction (Cu-catalyzed cross-coupling of alkynes and 1-haloalkynes).[61] 
Pd-catalysis is also becoming an attractive method due to its usual efficiency and 
mildness. 
In 1975, Sonogashira reported the Glaser-type formation of 1,3-diynes as by-
products in the Pd/Cu-catalyzed Sonogashira coupling of aryl halides with terminal 
alkynes when an oxidant such as air was present in the reaction medium.[62] This 
finding inspired the use of this methodology for the preparation of conjugated 
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1,3-diynes. In 1985, Rossi optimized this process as a homocoupling method for ter-
minal acetylenes. Diaryl- and dialkyl 1,3-diynes were obtained in moderate to good 
yields using chloroacetone as oxidant and [Pd(PPh3)4]/CuI as catalyst together with 
triethylamine (Scheme 1.30a).[63] Whereas aryl-substituted alkynes react exclusively 
to give the corresponding 1,3-diynes, aliphatic acetylenes also form 
4-alkynylhexa-1,5-diyn-3-enes as byproducts under these conditions. The efficiency 
of this method has been underlined by Kim in 1999, who reported an oxidative ho-
mocoupling of alkynylpyrrole in a notable 92% yield (Scheme 1.30b).[64] A variety of 
other Pd-complexes have been developed and employed to achieve the symmetrical 
homocoupling of terminal alkynes.[65]  
























































































Direct oxidative cross-coupling of two different terminal alkynes to form un-
symmetrical 1,3-diynes seems a great challenge because of the oxidative homocou-
pling process mentioned above. The common procedure to form unsymmetrically 
substituted 1,3-diynes through Pd-catalysis is the coupling of terminal alkynes with 
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1-haloalkynes.[66] Recently, Lei developed an efficient highly selective Pd-catalyzed 
C(sp)-C(sp) cross-coupling reaction between terminal alkynes and 1-bromoacetylenes 
(Scheme 1.31).[66a] High selectivity and good to excellent yields could be attained 
with low catalyst loading. Preliminary kinetic studies indicate that this transformation 
might involve Pd-nanoparticles (Pd(NPs)). 



























1,3-Enynes: The Sonogashira cross-coupling reaction between a vinyl halide 
and a terminal alkyne or organometallic alkyne using Pd/Cu catalyst has become an 
indispensable and powerful tool for the synthesis of conjugated 1,3-enynes as shown 
in Scheme 1.32a, which also demonstrates that vinyl chlorides are less reactive than 
their corresponding bromides toward the coupling with terminal alkynes by means of 
Sonogashira reaction.[67a] In 2011, Jiang reported a ‘reverse’ Sonogashira reaction for 
regio- and stereoselective synthesis of 1,3-enynes by a simple Pd-catalyzed 
cross-coupling reaction of unactivated alkenes with ethynyl bromides (Scheme 
1.32b).[67b] 





























































Apart from Sonogashira coupling, other methodologies for the synthesis of 
1,3-enynes have also been reported. The direct Pd-catalyzed dimerization of alkynes 
is a more atom-economic approach toward conjugated 1,3-enynes. In 1987, A power-
ful method for selective construction of head-to-tail 1,3-enynes in the presence of 
Pd(OAc)2/TDMPP system was developed by Trost (Scheme 1.33a).[68a] Later in 1997, 
Trost further discovered that the C-H bond of terminal alkynes could be directly add-
ed to activated internal alkynes under the same reaction conditions (Scheme 
1.33b).[68b] In 2001, Gevorgyan developed a Pd2(dba)3/CHCl3/TDMPP system to re-
alize the head-to-head dimerization of terminal alkynes with high regio- and stereose-
lectivity.[69a] However, this method is limited to terminal aryl acetylenes bearing a 
requisite ortho-H atom, as agostic interactions are involved. Later, Gevorgyan devel-
oped an alternative IPr-Pd-IPr/TDMPP system to expand the substrate scope to a 
more general head-to-head self-coupling of terminal alkynes via a hydropalladation 
pathway (Scheme 1.33c).[69b]  















































































The direct Pd-catalyzed oxidative coupling of alkynes and alkenes is another ef-
ficient and atom-economical method to synthesize 1,3-enynes. In 2009, Jung devel-
oped a simple protocol to synthesize conjugated 1,3-enynones from alkynes and acry-
lates via an oxidative Pd-catalyzed Heck coupling reaction under mild reaction condi-
tions (Scheme 1.34a).[70] In 2012, Zhong reported a green and efficient method to 
prepare 1,3-enynes via Pd-catalyzed direct dehydrogenative olefination of terminal 
arylalkynes with unactived allylic (thio)ethers, stereoselectively affording the conju-
gated (Z)-1,3-enynes in moderate to good yields (Scheme 1.34b).[71] The aliphatic 
terminal alkynes such as 1-hexyne are intolerant to the catalytic system and olefins 
are limited to allylic (thio)ethers. Although limitations exist, these two oxidative cou-
pling methods do not require the pre-activation of alkenes and exemplify the ideals of 
atom and step economy. 
























































In 2003, Uemura reported a Pd-catalyzed oxidative alkynylation of olefins using 
tert-propargylic alcohols as alkynylation reagents via C-C bond cleavage under O2 
atmosphere, affording the corresponding 1,3-enyne compounds (Scheme 1.35a).[72a] In 
2011, Wang reported an elegant method to conjugated 1,3-enynes via Pd-catalyzed 
oxidative cross-coupling of N-tosylhydrazones with terminal alkynes (Scheme 
1.35b).[72b] Although these two systems need some pre-modified substrates, they with 
no doubt offer new synthetic methods for conjugated 1.3-enyne structures. 






































































Alkynylated Heterocylces are commonly prepared by Sonogashira 
cross-coupling reaction between halogenated heterocyclic systems and terminal al-
kynes.[73]  
The direct alkynylation of heteroarene C-H bonds has appeared as an alternative 
to Sonogashira reaction by using the alkynyl reagents prepared from terminal alkynes, 
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such as alkynyl halides,[74] benziodoxolone-based hypervalent iodine reagents,[75] or 
arylsulfonylacetylenes.[76] In 2007, Gevorgyan reported a direct Pd-catalyzed alkynyl-
ation reaction of electron-rich N-fused heterocycles with bromoalkynes through elec-
trophilic substitution pathway (Scheme 1.36a).[74a] However, this method is not com-
patible with non-fused heterocycles, such as indoles. Gu, in 2009, expanded the sub-
strate scope and reported a Pd-catalyzed direct coupling reaction of indoles and al-
kynyl bromides with high C-3 regioselectivity and good yields under mild reaction 
conditions (Scheme 1.36b).[74b] If a nitro group was introduced at the C-5-position of 
the indole ring, the reaction did not give any coupled product due to the decrease of 
the nucleophilicity of indole, so the reaction was proposed through electrophilic sub-
stitution pathway. In 2010, Chang further expanded the substrate scope to not only 
azoles but also partially saturated azolines, affording alkynylated heterocycles with 
high yields (Scheme 1.36c).[74c] This reaction is proposed through lithia-
tion/transmetalation motif, but electrophilic pathway is also possible. 





















































































Recently, the direct oxidative alkynylation of some five-membered heteroarenes 
with terminal alkynes has been achieved via Pd-catalysis. From the viewpoint of step 
efficiency and atom economy, the oxidative cross-coupling reactions between het-
eroarenes and terminal alkynes would be a straightforward and more promising 
method for installing alkynyl groups into heteroarenes, because the need for 
pre-functionalization of heteroarenes and/or alkynes would be eliminated. In 2010, Li 
reported a Pd-catalyzed oxidative Sonogashira-type cross-coupling reaction of 
1-methylindoles with alkynes under O2 atmosphere, affording C-2 alkynylated indoles 
when C-3 position was blocked (Scheme 1.37a).[77a] In order to suppress the oxidative 
homocoupling of alkynes, it is necessary to add the alkyne solution in DMSO slowly 
via a syringe pump. Besides indole rings, azoles could also be alkynylated via 
Pd-catalyzed direct oxidative cross-coupling reactions, as shown in Scheme 1.37b, 
which was reported by Chang in 2011.[77b] In this case, the choice of Pd-catalyst and 
external base was crucial for performing the reaction with efficiency and selectivity. 
These two established oxidative alkynylation methods mentioned above only work for 
specific heterocycles. In 2013, Su reported an elegant method that enables the al-
kynylation of versatile heterocycles, including thiophenes, furans, indoles and other 
heteroarenes, by applying a low loading of Pd-catalyst (Scheme 1.37c).[77c]  







































































































A major problem of the Pd-catalyzed direct oxidative cross-coupling reactions 
between heteroarenes and terminal alkynes is the undesired alkyne homocoupling 
process under oxidative reaction conditions. The slow addition of terminal alkynes to 
the reaction system partially overcomes the alkyne homocoupling problem, but 
meanwhile brings about the operational inconvenience. The use of a large excess of 
the other coupling partner is capable of suppressing alkyne homocoupling, but sacri-
fices those reagents. Therefore more efficient and general method for the oxidative 
cross-coupling of heterocycles with terminal alkynes would be desirable. 
Alkynylated Arenes: the Pd-catalyzed Sonogashira cross-coupling reaction be-
tween a terminal alkyne and an aryl halide (pseudohalide) is the main and principal 
way of obtaining this kind of compounds.[78] 
On the other hand, catalytic aromatic C-H bond alkynylation using a readily 
available alkynyl source should offer a complementary and powerful approach. Re-
cently, there are some pioneering studies of the direct Pd-catalyzed alkynylation of 
aromatic C-H bonds through chelation-assisted strategies.[79] In 2009, Chatani devel-
oped a method of direct alkynylation of ortho-C-H bonds of anilides with bromoal-
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kynes via electrophilic palladation pathway (Scheme 1.38a).[79a] Silver salt is neces-
sary by sequestering the bromide ligand to increase the electrophilicity of the 
Pd-species. In 2010, Chatani further developed a protocol for Pd-catalyzed direct al-
kynylation of benzoic acid derivatives by utilizing 8-aminoquinoline as directing 
group without the need of any silver salts (Scheme 1.38b).[79b] Interestingly, the C-H 
bond cleavage process in this system has an opposite electronic demand to the SEAr 
pathway, thus a concerted metalation/deprotonation mechanism is proposed. 







































































In 2012, Chang presented the first example of Pd-catalyzed oxidative alkynyla-
tion of aromatic C-H bonds with alkynes, employing 2-aminopyridine as directing 
group (Scheme 1.39).[79c] Although the substrate scope is rather narrow and product 
yields are not very high, this study is an important clue for the subsequent progress 
toward the development of highly efficient and more general Pd-catalyzed oxidative 
alkynylation reactions. 



















Alkynylated Alkanes: C(sp)-C(sp3) bond formation reactions are less reported 
even by traditional Pd-catalyzed Sonogashira coupling reactions, due to a generally 
more difficult oxidative addition step and possible side reactions like β-hydride elim-
ination.[80] 
In 2010, Lei first reported a Pd-catalyzed aerobic oxidative C(sp)-C(sp3) 
cross-coupling reaction, employing terminal alkynes as one nucleophile and alkylzinc 
reagents as the other nucleophile (Scheme 1.40a).[81] In this oxidative coupling reac-
tion, CO acts as a π-acidic ligand to promote the C(sp)-C(sp3) reductive elimination. 
In 2011, Chatani developed an elegant Pd-catalyzed alkynylation reaction of aliphatic 
C-H bonds in carboxylic acids by attaching an 8-aminoquinoline directing group 
(Scheme 1.40b).[82] 





























































1.4.2 Pd-Catalyzed Alkyne Cycloaromatization Reactions  
Carbocycles: The Pd(0)-catalyzed intermolecular annulation of alkynes with 
halogenated arenes is a traditional method to carbocycles. After observing formation 
of naphthalene derivatives between alkynes and organopalladium derivatives,[83] Heck 
reported a Pd-catalyzed annulation reaction of aryl iodides with diphenylacetylenes to 
afford tetraphenylnaphthalene products in 1987 (Scheme 1.41a).[84] Although the 
yield is only moderate and the substrate scope is limited, this early study makes it 
possible to synthesize carbocycles via Pd-catalyzed alkyne annulation/C-H activation 
process. Intriguingly, a minor change in the reaction conditions strongly influences 
the product formation (Scheme 1.41b). Replacing PPh3/MeNO2 system by the coor-
dinating solvent DMF led to the formation of substituted phenanthrenes as major 
products, which was reported by Dyker in 1994.[85]  
Scheme 1.41 Naphthalene and phenanthrene formation via Pd(0)-catalyzed cy-
































































Phenanthrene formation was also reported by Heck through Pd-catalyzed reac-
tion of 2-iodobiphenyl and diphenylacetylene, but only in 14% yield (Scheme 
1.42a).[84] This process was improved by Larock, extending the Heck annulation pro-
cess fairly general (including a wide variety of internal alkynes, 2-iodobiaryls, cyclic 
and acyclic vinylic iodides and triflates bearing a neighboring aromatic ring) and 
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highly regioselective in moderate to excellent yields (Scheme 1.42b).[86a,b] The reac-
tion was proposed to proceed through a seven-membered Pd-complex, in which the 
regiochemistry of the reaction was controlled by steric factors.  
























































Later in 1999, benz[a]anthracene scaffold was also obtained through a double 
annulation process of dihalo-substituted ester and diphenylacetylene with two C-H 
bond cleavage and four C-C bond formation, but only in 19% yield, which was re-
ported by Larock (Scheme 1.43).[86c]  











































Pd(II)-catalyzed oxidative carbocyclization of alkynes with arenes/alkenes is a 
more efficient route for the preparation of carbocycles. The Pd-catalyzed conversion 
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of internal and terminal alkynes to substituted benzene derivatives by a cyclotrimeri-
zation process is an old procedure.[87] Recently, a series of 1,2,4,5-tetrasubstituted 
benzenes were obtained via Pd(II)-catalyzed oxidative 1:2 cyclic cross-trimerization 
of alkynes and alkenes using O2 as the sole oxidant, which was reported by Jiang 
(Scheme 1.44).[88] A minor change in the reaction conditions could chemoselectively 
form the 1:2 linear cross-coupling 1,3,5-triene products.[88] 
Scheme 1.44 Benzene formation via Pd(II)-catalyzed oxidative cycloarmatization of 






































In 2008, several highly substituted naphthalenes have been synthesized by Wu 
via treatment of electron-rich arenes with alkynes using Pd(OAc)2 as catalyst and 
AgOAc as oxidant (Scheme 1.45a).[89a] This transformation was proposed through a 
tetraphenylcyclopentadiened Pd(IV)-complex, which undergoes a series of transfor-
mations, including C-H activation and reductive elimination, to produce naphthalene 
products. When amide was employed as the arene partner, a similar Pd(II)-catalyzed 
oxidative cycloaromatization was realized for the chemo- and regioselective synthesis 
of highly substituted naphthalenes, which was reported by Wu in 2010 (Scheme 
1.45b).[89b] In addition to the switch of oxidant from AgOAc to K2S2O8, TsOH was 
found to promote the reaction. The authors traced this acid effect to the formation of 
cationic [PdOAc]+ species, which was believed to be the active catalyst. Meanwhile, 
Loh developed an elegant Pd(II)-catalyzed bisolefination of C-C triple bond for the 
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synthesis of naphthalene derivatives utilizing O2 as the sole oxidant (Scheme 
1.45c).[89c] The success of the reaction was believed due to the Lewis acidity and 
late-transition-metal character of Pd. An investigation of the substrate scope revealed 
that the α-methyl group on the styrene moiety is an absolute necessity for this catalyt-
ic process to be efficient, which could stabilize the benzylic cation intermediate. 
Scheme 1.45 Naphthalene formation via Pd(II)-catalyzed oxidative cycloarmatization 




























































































Besides naphthalene derivatives, some polycyclic aromatic hydrocarbons (PAHs), 
such as fluorenes, phenanthrenes and dibenzo[a,e]pentalenes, have been reported uti-
lizing Pd(II)-catalyzed oxidative carbocyclization of alkynes. In 2008, Gevorgyan 
demonstrated the first example of Pd(II)-catalyzed exclusive 5-exo-dig hydroarylation 
of electron-neutral and electron-deficient o-alkynyl biaryls to produce fluorenes 
(Scheme 1.46a).[90a] A mechanism involving the C-H activation has been proposed for 
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this transformation. One thing to be mentioned is that Fürstner reported electron-rich 
o-alkynyl biaryls in the presence of transition metals underwent an exclusive or pre-
dominant 6-endo-dig carbocyclization, leading to the phenanthrene frameworks via 
Friedel–Crafts-type electrophilic aromatic substitution pathway.[90b] In 2010, Glorius 
developed a ligand promoted Pd(II)-catalyzed intermolecular [4+2] annulation of al-
kynes and 2-phenylbenzoic acids, which act as 2- iodobiaryl surrogates (Scheme 1.46b 
vs Scheme 1.42a).[90c] Ag2CO3 is the most effective oxidant along with acridine as the 
ligand, affording moderate to high yields. However, the choice of alkyne is limited to 
internal alkynes bearing at least one phenyl group. Mechanistically this transfor-
mation seems rather complex and it is difficult to determine whether decarboxylation 
occurs at an early stage or at the end of the catalytic cycle. More recently, A novel 
catalytic C-H activation route to privileged dibenzo[a,e]pentalene structures has been 
established by Itami (Scheme 1.46c).[90d] This transformation was proposed through 
alkyne-directed, ortho-selective, electrophilic aromatic C-H palladation pathway. 


















































































Heterocarbocycles: The Pd(0)-catalyzed intermolecular annulation of  an al-
kyne with an aryl or vinyl halide bearing a neighboring nucleophile is a traditional 
method for the synthesis of a variety of heterocarbocycles (Scheme 1.47a).[91] One 
example is the ‘Larock indole synthesis’, a Pd(0)-catalyzed heteroannulation reaction 
to synthesize indoles from ortho- iodoanilines and internal alkynes.[92a] In 2001, 
Larock reported an efficient Pd(0)-catalyzed heteroannulation reaction of internal al-
kynes with imines derived from o- iodoanilines to afford a variety of substituted iso-
indolo[2,1-a]indoles via 5-exo addition and C-H activation process (Scheme 
1.47b).[92b] 

























































Compared with the traditional method for indole synthesis, modern C-H func-
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tionalization approach avoids pre-functionalization of anilines. In 2009, Jiao demon-
strated an efficient approach to indoles through direct dehydrogenative annulations 
via Pd(OAc)2/O2 system (Scheme 1.48a).[93a] All para-, meta- and ortho-substituted 
anilines could be smoothly transformed to the desired indole products, which indi-
cates that the steric effects do not significantly affect the reactivity. However, only 
electron-deficient alkynes are tolerated for this transformation. Later in 2011, another 
approach to indoles compatible with a wider scope of alkynes was developed by Li 
via a directing group assisted strategy (Scheme 1.48b).[93b] indole derivatives were 
readily available via Pd(II)-catalyzed oxidative coupling of N-aryl-2-aminopyridines 
and internal alkynes involving ortho-C-H activation. O2 could be used as the oxidant, 
but less effective than CuCl2. 


























































Indole-fused carbocycles have also been developed by Pd(II)-catalyzed oxidative 
carbocyclization of alkynes with indoles. Jiao and co-wokers have made a great con-
tribution to this area (Scheme 1.49).[94] In 2009, Jiao developed the first 
Pd(II)-catalyzed cycloaromatization of biaryls with alkynes through dual activation of 
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C-H bonds using O2 as the sole oxidant (Scheme 1.49a).[94a] As with many other simi-
lar aryl-aryl bond-forming carbocyclizations, electron-rich substrates are more effi-
cient for this transformation. With addition of TBAB, there is a notable improvement 
of the yield. However, the authors did not comment on this phenomenon in any details. 
This process is believed to involve electrophilic aromatic palladation, followed by al-
kyne insertion and subsequent second electrophilic aromatic palladation to form the 
final polycyclic carbazole products. Following this report, Jiao broadened the research 
to obtain the β-carbolines (Scheme 1.49b)[94b] and β-carbolinones (Scheme 1.49c)[94c] 
using a similar Pd(II)-catalyzed direct dehydrogenative annulation strategy. In 2010, 
Jiao discovered an unprecedented Pd(II)-catalyzed ring expansion of indoles with al-
kynes leading to tetrahydroquinoline derivatives with highly substituted cyclopenta-
dienyl cores (Scheme 1.49d).[94d] Dual C-H bond activation, one C-C bond cleavage, 
five new C-C bond formation, and unique ring-expansion of indoles via rearrange-
ment are involved in this kind of transformation under mild reaction conditions.  
Scheme 1.49 Indole-fused carbocycles via Pd(II)-catalyzed oxidative cycloaromatiza-































































































































































Meanwhile, Miura in 2009 also developed an approach for the synthesis of 
1,2,3,4-tetrasubstitued carbazoles through Pd(II)-catalyzed oxidative carbocyclization 
of indoles and their carboxylic acid derivatives with alkynes (Scheme 1.50a).[95] Fur-
thermore, unsymmetrically octasubstituted carbazoles were obtained from the step-
wise coupling of 1-methylpyrrole-2-carboxylic acid with two different alkynes 
(Scheme 1.50b).[95a] 
Scheme 1.50 Carbazole formation via Pd(II)-catalyzed oxidative cycloarmatization of 























































































































 Besides indole derivatives, other heteroaromatic hydrocarbons, such as iso-
quinolinones and benzo[b]furans, have also been reported utilizing Pd(II)-catalyzed 
direct oxidative alkyne cycloaromatization reactions. In 2012, Huang reported an at-
om economic and cost-effective (compared to Rh or Ru catalysts) synthesis of iso-
quinolinones via Pd(II)-catalyzed C-H and N-H double functionalization (Scheme 
1.51a).[96a] A wide range of isoquinolinones were successfully constructed with mod-
erate to good yields and good regioselectivity for unsymmetrical alkynes. More re-
cently, Sahoo developed an unprecedented one-step synthesis of benzo[b]furans via 
Pd(II)-catalyzed oxidative annulation of readily accessible phenols and unactivated 
internal alkynes (Scheme 1.51b).[96b] The procedure used for these reactions is de-
pendent upon the electronic property of phenols. In general, electron-poor phenols 
afford better yields when Bathophen/AgOAc system is employed and electron-rich 
phenols perform well when 1,10-Phen/NaOAc system is used. 
Scheme 1.51 Heteroaromatic hydrocarbon formation via Pd(II)-catalyzed oxidative 


















































































































1.5 Project Objectives 
Huge advances have been made in the field of Pd-catalyzed C-H functionaliza-
tion/C-C coupling reactions over the past decades. Both the development of novel re-
actions and the mechanistic studies of the transformation of C-H bonds to C-C and 
C-heteroatom bonds have been greatly explored. A number of novel transformations, 
as described above, have been discovered, providing access to many important mole-
cules. 
Despite great advances in the development of Pd-chemistry (both traditional 
cross-coupling reactions and modern C-H functionalization reactions), the 
Pd-catalyzed alkyne reactions involving C-H functionalization to form alkynylated 
and (hetero)aromatic complexes are still at an early stage and remain a key future ob-
jective, as described in section 1.4. 
The main purpose of my projects is to explore Pd-catalyzed alkyne transfor-
mations via direct C-H functionalization to form polyarylated (hetero)aromatic com-
pounds utilizing readily available starting materials, providing a concise way to syn-
thesize different types of important molecules.  
Three types of reactions to form different polyarylated (hetero)aromatic com-
pounds are explored. In chapter 2, we present our results regarding a Pd-catalyzed 
[2+2+1] oxidative annulation of 4-hydroxycoumarins with unactivated internal al-
kynes, affording a new class of compounds: the spiro-cyclopentadiene chro-
man-2,4-diones (Scheme 1.52a).[97a] In chapter 3, pyrroles, ubiquitous bioactive het-
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erocycles in nature, are readily prepared via a Pd-catalyzed oxidative annulation reac-
tion of cyclic trans-enamines with various internal alkynes in the absence of a direct-
ing group (Scheme 1.52b).[97b] In chapter 4, we have developed an efficient 
Pd-catalyzed synthesis of highly substituted 1-naphthols utilizing simple and readily 
available benzoylacetates and unactivated internal alkynes (Scheme 1.52c).[97c] 
Scheme 1.52 Polyarylated (hetero)aromatic compounds formation via 
























































































In chapter 5, we have a initial try to utilize a much cheaper Fe-catalyst to realize 
an unprecedented FeCl3-catalyzed ene-type reaction of propargylic alcohols with 
1,1-diaryl alkenes, which affords a 1,4-enyne framework in moderate to high yields 
(Scheme 1.53a).[97d] Next, we have further expanded our research to metal- free reac-
tions and in chapter 6, we have documented an efficient and convenient double de-
carboxylation process for the synthesis of 4-substituted 3,4-dihydrocoumarins in 
moderate to excellent yields under metal-free reaction conditions (Scheme 1.53b).[97e] 


























































Palladium-Catalyzed [2+2+1] Oxidative Annulation of 
4-Hydroxycoumarins with Unactivated Internal Alkynes: 


































The annulation coupling of 4-hydroxycoumarins with alkynes is described, 
which proceeds through a Pd-catalyzed [2+2+1] oxidative cyclization. This 







The realm of transition-metal-catalyzed cross-coupling reactions has traditionally 
depended on pre-functionalized substrates for both reactivity and selectivity.[98] The 
quest for improved atom economy and efficiency has brought forward revolutionary 
changes and important advances especially in the Pd-catalyzed direct C-H 
functionalization, efficiently leading to a diversity-oriented synthesis of various 
functional molecules.[99] Although these strategies offer numerous advantages (e.g. 
mild conditions, readily accessible starting materials and environmental benign 
procedures), the development of general and flexible routes to a vast number of 
heterocycles still remains an important goal. 
Internal alkynes are important building blocks extensively utilized in 
Pd-catalyzed direct C-H functionalization for preparation of a wide range of pharma-
ceuticals, agrochemicals, and heterocycles (section 1.4). In recent reports, Ellman 
group described a synthesis of dihydropyridine and pyridine from imines and internal 
alkynes through a Pd-catalyzed direct C-H functionalization.[100] Jiao and co-workers 
reported an elegant Pd-catalyzed oxidative annulation of activated internal alkynes 
with anilines via a C-H functionalization to construct indoles.[93a] The group of Wu 
used a similar strategy to successfully facilitate substituted naphthalenes using inter-
nal alkynes as building blocks.[89] Most recently, Sahoo disclosed an example of ben-
zofuran synthesis through a Pd-catalyzed oxidative annulation of phenols and internal 
alkynes.[96b] Our group recently disclosed a Pd-catalyzed oxidative annulation of 
4-hydroxycoumarins and internal alkynes to access highly substituted cyclopentadiene 
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fused chromones (Scheme 2.1a).[101b] As part of our continued interest in transi-
tion-metal-catalyzed oxidative coupling processes,[101] we have developed a 
Pd-catalyzed [2+2+1] oxidative annulation of 4-hydroxycoumarins with unactivated 
internal alkynes, which offers a new class of compounds: spiro cyclopentadi-
ene-chroman-2,4-diones (Scheme 2.1b). 








































2.2 Results and Discussion 
Initially, we investigated the influence of various catalysts for the annulation of 
4-hydroxylcoumarin 2-1a with diphenylacetylene 2-2a in DMSO under 80 oC by 10 
mol % of catalysts and 2.0 equivalents of oxidant Cu(OAc)2 for 48 h (Table 2.1, 
entries 1-4). It was found that reaction occurred and formed the desired product 2-3aa 
only in the presence of Pd(PPh3)2Cl2 and Pd(OAc)2 catalysts (Table 2.1, entries 2 and 
4). Next, we examined a series of solvents (Table 2.1, entries 4-8). As a result, DMSO 
supported a high chemical yield. To further improve the efficiency of the reaction, we 
tested the ratio of 2-2a/2-1a. Notably, changing the ratio of 2-2a/2-1a from 2.5 to 4.0 
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equivalents increased the chemical yield to 79% (Table 2.1,entry 9). Further lowering 
or increasing temperature led to a slow reaction conversion (Table 2.1, entries 10-11). 
Variation of oxidants led to no reaction or a decrease in chemical yield (Table 2.1, 
entries 12-17). Moreover, the lowering of catalyst loading decreased the chemical 
yields dramatically (Table 2.1, entries 18-19). 




















2-2a2-1a 2-3aa  
Entry Cat. Oxidant Solvent 2-3aa [%][b] 
 1[c] PdCl2 Cu(OAc)2 DMSO -- 
2 Pd(PPh3)2Cl2 Cu(OAc)2 DMSO 58 
 3[c] Pd(TFA)2 Cu(OAc)2 DMSO -- 
4 Pd(OAc)2 Cu(OAc)2 DMSO 69 
5 Pd(OAc)2 Cu(OAc)2 DMF 23 
6 Pd(OAc)2 Cu(OAc)2 1,4-Dioxane 27 
7 Pd(OAc)2 Cu(OAc)2 THF 27 
8 Pd(OAc)2 Cu(OAc)2 MeCN 8 
 9[d] Pd(OAc)2 Cu(OAc)2 DMSO 79 
 10[e] Pd(OAc)2 Cu(OAc)2 DMSO 66 
 11[f] Pd(OAc)2 Cu(OAc)2 DMSO 57 
12 Pd(OAc)2 O2 DMSO 24 
13 Pd(OAc)2 AgOAc DMSO 64 
 14[c] Pd(OAc)2 PhI(OAc)2 DMSO -- 
 15[c] Pd(OAc)2 BQ DMSO -- 
 16[c] Pd(OAc)2 Oxones DMSO -- 
 17[c] Pd(OAc)2 DDQ DMSO -- 
 18[g] Pd(OAc)2 Cu(OAc)2 DMSO 52 
 19[h] Pd(OAc)2 Cu(OAc)2 DMSO 33 
[a] Reaction conditions: 2-1a (0.2 mmol, 1.0 equiv.), 2-2a (0.5 mmol, 2.5 equiv. ), Cat. (10 mol%), Oxidant (2.0 
equiv.), Solvent (2 mL), 80 oC, 48 h, otherwise indicated. [b] Isolated yield of 2-3aa. [c] No desired product 
detected. [d] 2-2a (0.8 mmol, 4.0 equiv.). [e] 60 oC. [f] 100 oC. [g] Cat.(5 mol%), 48 h. [h] Cat. (1 mol%), 96 h. 
With the optimized reaction condition in hand, we next surveyed the scope of 
4-hydroxylcoumarins 2-1 (Table 2.2). Electron-withdrawing, neutral and 
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electron-donating substituents on C-4 position were tolerated and gave high yields 
(Table 2.2, 2-3aa to 2-3da, 2-3fa). Substrates with electron-withdrawing or 
electron-donating substituents at the C-3, C-5 or C-6 position also showed moderate 
to high reactivity and afforded the corresponding products (Table 2.2, 2-3ea, 2-3ga to 
2-3ja). In addition, naphthalene ring based 4-hydroxylcoumarins were also tolerated 
and gave the corresponding spiro-products in good yields (Table 2.2, 2-3ka and 
2-3la). 




























































































































































Given the great value of alkynes, we then examined various internal alkynes 2-2 
that could potentially react with 2-1a to construct a diversity of spiro-complexes 
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(Table 2.3). The reaction presented a broad substrate tolerance of internal alkynes. 
Electron-rich internal alkynes reacted smoothly to give good reaction yields (Table 
2.3, 2-3ab to 2-3ad, 2-3af to 2-3ag), while electron-deficient alkynes were less facile 
(Table 2.3, 2-3ae). When asymmetrical internal alkynes were employed, a mixture of 
regioisomers was usually observed (2-3ah, 2-3ai and 2-3aj). Heteroaryl-containing 
alkyne was also tolerated (2-3aj). 












































































































































































 regioisomers.  
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It was found that cyclic ketone 2-1m efficiently reacted with diphenylacetylene 
2-2a to form the corresponding spiro-structure 2-3ma in 85% yield under the standard 
reaction conditions (Scheme 2.2). 




















The plausible mechanism for the synthesis of spiro-products 2-3 is illustrated in 
Scheme 2.3. The catalytic cycle starts from the palladation of 4-hydroxycoumarin 
2-1a to yield the palladium intermediate 2-8. Then the syn-addition of intermediate 
2-8 to diphenylacetylene 2-2a generates the vinylpalladium intermediate 2-9. The 
following second insertion of 2-2a affords the butadienylpalladium intermediate 2-10. 
Finally, the intramolecular palladation of 2-10 leads to the formation of pal-
ladabenzocyclodiene 2-11, which subsequently undergoes reductive elimination to 
yield the spiro-product 2-3aa. 












































In the survey of oxidants, an exception was observed using oxidant K2S2O8 (Ta-
ble 2.4). 4-Hydroxylcoumarins reacted with various alkynes in the presence of 
K2S2O8 to directly generate a variety of valuable furo[3,2-c]coumarins 2-4 in 
moderate yields. We envisioned that the reaction might undergo a Pd(II)/Pd(IV) 
mechanism to afford 2-4.[102] As indicated in Scheme 2.4, a plausible key intermediate 
2-7 could be generated in the presence of oxidant K2S2O8. Further optimization to 
improve the reaction efficiency is underway in our laboratory.  































































































































































Due to various bioactivities of heterocycles, we turned our attention to late-stage 
diversification of functional molecules. Upon treatment of product 2-4aa with KOH 
and MeI in DMSO at 80 oC for 2 h, tetrasubstituted furan 2-5 was obtained in 80% 
yield (Scheme 2.5a). The photolysis of 2-4aa was accomplished in the presence of 
iodobenzene diacetate and UV light, smoothly affording the functionalized coumarin 
2-6 (Scheme 2.5b).  










































In summary, we have developed an efficient synthesis of spiro 
cyclopentadiene-chroman-2,4-dione heterocycles. The method employs a direct 
Pd(II)-catalyzed oxidative [2+2+1] cycloaddition of readily available 4-hydroxyl 
coumarins and unactivated internal alkynes. Various substrates are well tolerated in 
the reaction, leading to a number of unique molecular structures. Further extension of 
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this synthetic strategy to other types of substrates is underway in our laboratory and 
will be presented in due course. 
2.4 Experimental Section 
2.4.1 General Information 
Chemicals and solvents were purchased from commercial suppliers and used as 
received. 1H and 13C NMR spectra were recorded on a Bruker ACF300 (300 MHz) or 
AMX500 (500 MHz) spectrometer in CDCl3 at 298K otherwise indicated.Chemical 
shifts were reported in parts per million (ppm), and the residual solvent peak was used 
as an internal reference. Multiplicity was indicated as follows: s (singlet), d (doublet), 
t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), bs (broad singlet). 
Coupling constants were reported in Hertz (Hz). Low resolution mass spectra were 
obtained on a Finnigan/MAT LCQ spectrometer in ESI mode or a Finnigan/MAT 
95XL-T mass spectrometer in EI mode. All high resolution mass spectra were 
obtained on a Finnigan/MAT 95XL-T mass spectrometer. For thin layer 
chromatography (TLC), Merck pre-coated TLC plates (Merck 60 F254) were used 
and compounds were visualized with a UV light at 254 nm. Flash chromatography 
separations were performed on Merck 60 (0.040-0.063 mm) mesh silica gel.  
2-1a and 2-1m were commercially available. 2-1b to 2-1l were synthesized 
according to related procedures. [103] 2-2a and 2-2i were commercially available. 2-2b 
to 2-2h and 2-2j were synthesized according to related procedures. [104] 
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2-2a2-1a 2-3aa  
2',3',4',5'-Tetraphenylspiro[chroman-3,1'-cyclopenta[2,4]diene]-2,4-dione (2-3aa): 
4-hydroxycoumarin 2-1a (0.2 mmol), diphenylacetylene 2-2a (0.8 mmol), Pd(OAc)2 
(0.02 mmol) and Cu(OAc)2 (0.4 mmol) were added into DMSO (2 mL). The mixture 
was stirred at 80 oC under N2 atmosphere for 2 d. Work-up: The crude mixture was 
cooled down to room temperature and then poured into ethyl acetate (20 mL), which 
was washed with brine (10 mL*4), dried with MgSO4 and filtered. The solvent was 
removed to obtain crude product, which was purified by column chromatography on 
silica gel (eluent: ethyl acetate/hexane = 1/30) to afford the desired product 2-3aa as 
yellow solid (81.6 mg, 79%). 1H NMR (500 MHz, CDCl3): δ 7.84 (d, J = 7.6 Hz, 1H), 
7.50 (t, J = 7.7 Hz 1H), 7.16–6.98 (m, 22H). 13C NMR (125 MHz, CDCl3): δ 188.3, 
164.9, 154.8, 149.1, 142.7, 137.4, 134.2, 133.5, 130.1, 129.4, 128.4, 127.9, 127.8, 
127.6, 127.4, 125.0, 119.9, 117.6, 80.2, 77.4, 77.2, 76.9. HRMS (EI) calcd for 









e (2-3ba): Isolated by column chromatography (eluent: ethyl acetate/hexane = 1/20) 
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as yellow solid in 84% yield (89.8 mg) following the general procedure. 1H NMR 
(500 MHz, CDCl3): δ 7.88 (dd, J = 8.7, 6.3 Hz, 1H), 7.18–7.03 (m, 12H), 7.02–6.96 
(m, 8H), 6.86 (td, J = 8.5, 2.3 Hz, 1H), 6.69 (dd, J = 8.8, 2.3 Hz, 1H). 13C NMR (125 
MHz, CDCl3): δ 186.8, 168.8, 166.7, 164.4, 156.4, 156.3, 149.2, 142.5, 134.1, 133.4, 
130.1, 130.1, 130.0, 129.3, 128.4, 127.9, 127.6, 116.8, 116.8, 113.2, 113.1, 105.2, 









ne (2-3ca): Isolated by column chromatography (eluent: ethyl acetate/hexane = 1/40 
to 1/20) as yellow solid in 60% yield (66.1 mg) following the general procedure. 1H 
NMR (500 MHz, CDCl3): δ 7.79 (d, J = 2.6 Hz, 1H), 7.45 (dd, J = 8.8, 2.6 Hz, 1H), 
7.16–7.04 (m, 12H), 7.00–6.94 (m, 9H). 13C NMR (125 MHz, CDCl3): δ 187.5, 164.4, 
153.2, 149.4, 142.5, 137.2, 134.1, 133.4, 130.7, 130.1, 129.3, 128.5, 128.0, 127.9, 
127.6, 126.6, 120.7, 119.3, 79.9, 77.4, 77.1, 76.9. HRMS (EI) calcd for [C37H27ClO3]+ 








ne (2-3da): Isolated by column chromatography (eluent: ethyl acetate/hexane = 1/20) 
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as yellow solid in 79% yield (83.8 mg) following the general procedure. 1H NMR 
(500 MHz, CDCl3): δ 7.62 (d, J = 1.3 Hz, 1H), 7.32 (dd, J = 8.4, 1.9 Hz, 1H), 
7.15–6.98 (m, 20H), 6.89 (d, J = 8.4 Hz, 1H), 2.31 (s, 3H). 13C NMR (125 MHz, 
CDCl3): δ 188.3, 165.1, 152.9, 149.0, 142.9, 138.3, 134.8, 134.2, 133.5, 130.1, 129.3, 
128.3, 127.9, 127.7, 127.5, 127.0, 119.4, 117.4, 79.9, 77.4, 77.1, 76.9, 20.6. HRMS 








one (2-3ea): Isolated by column chromatography (eluent: ethyl acetate/hexane = 1/5) 
as yellow solid in 79% yield (83.8 mg) following the general procedure. 1H NMR 
(500 MHz, CDCl3): δ 7.33 (t, J = 8.4 Hz, 1H), 7.13–6.97 (m, 20H), 6.58 (d, J = 8.5 
Hz, 1H), 6.52 (d, J = 8.2 Hz, 1H), 3.87 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 185.5, 
164.7, 159.9, 155.7, 148.6, 142.4, 136.9, 134.3, 133.8, 130.0, 129.4, 128.1, 127.8, 
127.6, 127.3, 110.7, 109.3, 107.5, 80.9, 77.4, 77.1, 76.9, 56.5. HRMS (EI) calcd for 








one (2-3fa): Isolated by column chromatography (eluent: ethyl acetate/hexane = 1/10) 
as yellow solid in 86% yield (94.0 mg) following the general procedure. 1H NMR 
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(500 MHz, CDCl3): δ 7.26 (s, 1H), 7.16–7.00 (m, 21H), 6.93 (d, J = 9.0 Hz, 1H), 3.78 
(s, 3H). 13C NMR (125 MHz, CDCl3): δ 188.4, 165.1, 156.5, 149.3, 149.1, 142.9, 
134.3, 133.5, 130.1, 129.3, 128.4, 127.9, 127.8, 127.5, 125.8, 120.1, 119.0, 108.1, 









one (2-3ga): Isolated by column chromatography (eluent: ethyl acetate/hexane = 
1/10) as white solid in 78% yield (85.3 mg) following the general procedure. 1H NMR 
(500 MHz, CDCl3): δ 7.80 (d, J = 8.8 Hz, 1H), 7.15–6.99 (m, 20H), 6.69 (dd, J = 8.8, 
2.1 Hz, 1H), 6.44 (d, J = 2.0 Hz, 1H), 3.81 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 
186.4, 167.0, 165.3, 156.8, 149.0, 143.0, 134.4, 133.7, 130.1, 129.3, 129.3, 128.3, 
127.9, 127.7, 127.5, 113.6, 112.7, 101.3, 79.6, 77.4, 77.2, 76.9, 56.1. HRMS (EI) 








ne (2-3ha): Isolated by column chromatography (eluent: ethyl acetate/hexane = 1/20) 
as white solid in 80% yield (84.9 mg) following the general procedure. 1H NMR (500 
MHz, CDCl3): δ 7.68 (d, J = 7.6 Hz, 1H), 7.32 (d, J = 7.3 Hz, 1H), 7.15–7.00 (m, 
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21H), 2.21 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 188.5, 164.7, 153.1, 148.8, 142.5, 
138.5, 134.3, 133.6, 130.1, 129.4, 128.2, 127.9, 127.7, 127.5, 127.0, 124.9, 124.4, 










dione (2-3ia): Isolated by column chromatography (eluent: ethyl acetate/hexane = 
1/30) as white solid in 81% yield (88.2 mg) following the general procedure. 1H NMR 
(500 MHz, CDCl3): δ 7.59 (s, 1H), 7.14–6.99 (m, 20H), 6.79 (s, 1H), 2.25 (s, 3H), 
2.21 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 187.9, 165.5, 153.2, 149.5, 148.4, 143.2, 
134.4, 133.9, 133.7, 130.2, 129.3, 128.3, 127.9, 127.7, 127.5, 127.4, 118.2, 117.5, 










dione (2-3ja): Isolated by column chromatography (eluent: ethyl acetate/hexane = 
1/30) as white solid in 10% yield (13.5 mg) following the general procedure. 1H NMR 
(500 MHz, CDCl3): δ 7.93 (d, J = 2.5 Hz, 1H), 7.59 (dd, J = 8.8, 2.5 Hz, 1H), 
7.19–7.02 (m, 12H), 7.01–6.91 (m, 7H), 6.88 (d, J = 8.7 Hz, 1H). 13C NMR (125 MHz, 
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CDCl3): δ 187.4, 164.3, 153.8, 149.4, 142.5, 140.0, 134.1, 133.4, 130.1, 129.8, 129.3, 
128.5, 128.0, 128.0, 127.7, 121.1, 119.6, 117.9, 79.9, 77.4, 77.1, 76.9. HRMS (EI) 







ne (2-3ka): Isolated by column chromatography (eluent: ethyl acetate/hexane = 1/20) 
as yellow solid in 80% yield (90.7 mg) following the general procedure. 1H NMR 
(500 MHz, CDCl3): δ 8.34 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.7 Hz, 2H), 7.68–7.64 (m, 
1H), 7.60–7.56 (m, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.15–7.09 (m, 6H), 7.03–6.96 (m, 
14H). 13C NMR (125 MHz, CDCl3): δ 188.2, 164.9, 153.1, 149.1, 142.9, 138.1, 134.3, 
133.6, 130.6, 130.2, 129.3, 128.3, 128.0, 127.9, 127.7, 127.5, 127.4, 124.7, 123.6, 
122.9, 121.2, 115.3, 80.0, 77.4, 77.1, 76.9. HRMS (EI) calcd for [C41H26O3] + 








ne (2-3la): Isolated by column chromatography (eluent: ethyl acetate/hexane = 1/20) 
as yellow solid in 63% yield (71.4 mg) following the general procedure. 1H NMR 
(500 MHz, CDCl3): δ 9.35 (d, J = 7.1 Hz, 1H), 7.93 (d, J = 8.9 Hz, 1H), 7.76 (d, J = 
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7.9 Hz, 1H), 7.68 (t, J = 7.6 Hz, 1H), 7.51 (t, J = 7.4 Hz, 1H), 7.16–6.96 (m, 21H). 13C 
NMR (125 MHz, CDCl3): δ 189.0, 165.0, 156.7, 148.9, 142.8, 138.8, 134.4, 133.7, 
130.8, 130.7, 130.1, 130.1, 129.4, 128.7, 128.3, 127.9, 127.7, 127.5, 126.5, 125.7, 
117.1, 113.3, 81.1, 77.4, 77.2, 76.9. HRMS (EI) calcd for [C41H26O3] + 566.1882, 








Isolated by column chromatography (eluent: ethyl acetate/hexane = 1/30) as white 
solid in 85% yield (84.1 mg) following the general procedure. 1H NMR (500 MHz, 
CDCl3): δ 7.25–7.18 (m, 6H), 7.16–7.11 (m, 4H), 7.06–6.96 (m, 6H), 6.88 (d, J = 7.1 
Hz, 4H), 2.25 (s, 4H), 0.66 (s, 6H). 13C NMR (125 MHz, CDCl3): δ 205.5, 148.4, 
143.5, 135.9, 134.4, 130.8, 130.1, 128.2, 127.8, 127.4, 126.9, 90.7, 77.4, 77.2, 76.9, 









(2-3ab): Isolated by column chromatography (eluent: ethyl acetate/hexane = 1/30) as 
yellow solid in 76% yield (87.0 mg) following the general procedure. 1H NMR (500 
MHz, CDCl3): δ 7.84 (dd, J = 8.0, 0.9 Hz, 1H), 7.50 (t, J = 7.7 Hz, 1H), 7.14 (t, J = 
 69 
 
7.5 Hz, 1H), 6.99 (d, J = 8.3 Hz, 1H), 6.92–6.82 (m, 16H), 2.25 (s, 6H), 2.16 (s, 6H). 
13C NMR (125 MHz, CDCl3): δ 188.7, 165.3, 154.9, 148.8, 142.2, 137.3, 137.1, 137.0, 
131.6, 130.9, 130.0, 129.2, 129.0, 128.6, 127.3, 124.9, 120.0, 117.6, 80.0, 77.4, 77.2, 









4-dione (2-3ac): Isolated by column chromatography (eluent: ethyl acetate/hexane = 
1/4) as yellow solid in 82% yield (104.4 mg) following the general procedure. 1H 
NMR (500 MHz, CDCl3): δ 7.83 (dd, J = 7.8, 1.4 Hz, 1H), 7.57–7.45 (m, 1H), 7.15 (t, 
J = 7.5 Hz, 1H), 7.00 (d, J = 8.2 Hz, 1H), 6.89 (d, J = 8.7 Hz, 8H), 6.64 (d, J = 8.7 Hz, 
4H), 6.57 (d, J = 8.8 Hz, 4H), 3.73 (s, 6H), 3.65 (s, 6H). 13C NMR (125 MHz, 
CDCl3): δ 188.9, 165.4, 158.9, 158.8, 154.9, 148.0, 141.4, 137.3, 131.5, 130.6, 127.3, 
126.9, 126.3, 125.0, 120.0, 117.6, 113.8, 113.4, 80.0, 77.4, 77.2, 76.9, 55.2, 55.1. 











-2,4-dione (2-3ad): Isolated by column chromatography (eluent: ethyl acetate/hexane 
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= 1/50) as yellow solid in 75% yield (111.2 mg) following the general procedure. 1H 
NMR (500 MHz, CDCl3): δ 7.80 (d, J = 7.6 Hz, 1H), 7.48–7.40 (m, 1H), 7.15–7.06 
(m, 5H), 7.05–6.99 (m, 4H), 6.96–6.85 (m, 9H), 1.24 (s, 18H), 1.16 (s, 18H). 13C 
NMR (125 MHz, CDCl3): δ 188.8, 165.2, 154.9, 150.3, 150.1, 148.9, 141.4, 136.8, 
131.8, 130.6, 129.7, 128.9, 127.4, 125.1, 124.7, 124.6, 120.3, 117.5, 80.2, 77.4, 77.2, 











dione (2-3ae): Isolated by column chromatography (eluent: ethyl acetate/hexane = 
1/30) as yellow solid in 50% yield (58.9 mg) following the general procedure. 1H 
NMR (500 MHz, CDCl3): δ 7.82 (dd, J = 7.8, 1.5 Hz, 1H), 7.61–7.48 (m, 1H), 
7.21–7.16 (m, 1H), 7.00–6.90 (m, 9H), 6.85–6.75 (m, 8H). 13C NMR (125 MHz, 
CDCl3): δ 188.0, 164.5, 163.4, 163.3, 161.4, 161.3, 154.8, 148.0, 141.9, 137.9, 131.8, 
131.8, 131.3, 131.2, 129.7, 129.6, 129.3, 129.3, 127.4, 125.4, 119.8, 117.7, 115.8, 
115.6, 115.5, 115.3, 80.5, 77.4, 77.2, 76.9. HRMS (EI) calcd for [C37H20F4O3] + 












(2-3af): Isolated by column chromatography (eluent: ethyl acetate/hexane = 1/30) as 
yellow solid in 67% yield (76.7 mg) following the general procedure. 1H NMR (500 
MHz, CDCl3): δ 7.85 (dd, J = 7.8, 1.6 Hz, 1H), 7.57–7.46 (m, 1H), 7.16 (t, J = 7.2 Hz, 
1H), 7.04–6.72 (m, 17H), 2.11 (s, 6H), 2.05 (s, 6H). 13C NMR (125 MHz, CDCl3): δ 
188.6, 165.1, 154.9, 149.2, 142.4, 137.7, 137.2, 137.2, 134.4, 133.5, 130.8, 129.9, 
128.4, 128.2, 128.1, 127.7, 127.3, 127.2, 126.6, 124.9, 120.2, 117.5, 80.0, 77.4, 77.2, 














-2,4-dione (2-3ag): Isolated by column chromatography (eluent: ethyl acetate/hexane 
= 1/30) as yellow solid in 82% yield (103.1 mg) following the general procedure. 1H 
NMR (500 MHz, CDCl3): δ 7.91–7.81 (m, 1H), 7.55–7.45 (m, 1H), 7.15 (t, J = 7.5 Hz, 
1H), 7.00 (d, J = 8.3 Hz, 1H), 6.75 (s, 2H), 6.64 (s, 6H), 6.59 (s, 4H), 2.08 (s, 12H), 
2.00 (s, 12H). 13C NMR (125 MHz, CDCl3): δ 188.8, 165.3, 154.9, 149.3, 142.0, 
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137.4, 137.0, 136.8, 134.5, 133.4, 129.2, 128.8, 127.9, 127.3, 127.1, 124.7, 120.4, 
117.4, 79.7, 77.4, 77.2, 76.9, 21.3, 21.2. HRMS (EI) calcd for [C45H40O3] + 628.2977, 







2-3ah was isolated by column chromatography (eluent: ethyl acetate/hexane = 1/30) 
as white solid of 3 inseperable regioisomers in 65% total yield (71.8 mg, the ratio of 3 
regioisomers is unclear based on 1H NMR) following the general procedure. 1H NMR 
(500 MHz, CDCl3): δ 7.96–7.80 (m, 1H), 7.59–7.49 (m, 1H), 7.21–7.03 (m, 7H), 
7.02–6.91 (m, 9H), 6.85–6.71 (m, 4H). 13C NMR (125 MHz, CDCl3): δ 188.1, 188.1, 
188.0, 164.7, 163.2, 163.2, 161.3, 161.2, 154.8, 154.7, 154.7, 149.3, 149.2, 147.8, 
147.7, 143.0, 142.9, 141.6, 141.5, 137.7, 137.6, 137.5, 133.8, 133.2, 133.2, 131.9, 
131.8, 131.7, 131.3, 131.2, 131.1, 130.0, 129.6, 129.5, 129.3, 128.5, 128.1, 128.0, 
127.8, 127.7, 127.4, 127.3, 127.3, 125.2, 125.2, 125.1, 119.8, 117.7, 115.6, 115.4, 
115.3, 115.2, 115.1, 115.0, 80.5, 80.3, 80.2, 77.4, 77.2, 76.9. HRMS (EI) calcd for 









2-3ai was isolated by column chromatography (eluent: ethyl acetate/hexane = 1/40) as 
3 regioisomers in 80% total yield (105.7 mg) following the general procedure. 
2-3ai-P1 (yellow solid, 35.0 mg, 27%); 1H NMR (500 MHz, CDCl3): δ 7.80 (dd, J = 
7.8, 1.6 Hz, 1H), 7.53–7.41 (m, 1H), 7.21–7.06 (m, 11H), 7.05–6.98 (m, 4H), 
6.97–6.88 (m, 5H), 0.13 (s, 18H). 13C NMR (125 MHz, CDCl3): δ 188.3, 164.9, 154.9, 
149.0, 142.6, 140.0, 137.1, 134.5, 133.6, 133.2, 130.1, 128.4, 128.0, 127.5, 127.5, 
124.9, 120.1, 117.6, 80.1, 77.4, 77.2, 76.9, -1.2. HRMS (EI) calcd for [C43H40O3Si2] + 
660.2516, found 660.2545. 
2-3ai-P2 (yellow solid, 35.2 mg, 27%); 1H NMR (500 MHz, CDCl3): δ 7.82 (dd, J = 
7.6, 1.0 Hz, 1H), 7.52–7.45 (m, 1H), 7.23–7.10 (m, 8H), 7.08–6.87 (m, 12H), 0.17 (s, 
9H), 0.13 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 188.3, 164.9, 154.8, 149.2, 149.0, 
142.6, 142.6, 139.9, 139.6, 137.2, 134.6, 134.3, 133.7, 133.5, 133.3, 132.7, 130.1, 
129.6, 129.2, 128.3, 128.1, 127.8, 127.6, 127.4, 124.9, 120.0, 117.6, 80.2, 77.4, 77.2, 
76.9, -1.0, -1.1. HRMS (EI) calcd for [C43H40O3Si2] + 660.2516, found 660.2545. 
2-3ai-P3 (white solid, 35.5 mg, 27%); 1H NMR (500 MHz, CDCl3): δ 7.83 (dd, J = 
7.7, 1.5 Hz, 1H), 7.53–7.46 (m, 1H), 7.23–7.18 (m, 4H), 7.17–7.12 (m, 1H), 
7.08–6.86 (m, 15H), 0.19 (s, 18H). 13C NMR (125 MHz, CDCl3): δ 188.4, 165.0, 
154.8, 149.2, 142.5, 139.6, 137.3, 134.5, 133.7, 132.7, 129.4, 129.2, 128.3, 127.7, 
127.4, 125.0, 120.0, 117.6, 80.4, 77.4, 77.2, 76.9, -1.0. HRMS (EI) calcd for 









2-3aj was isolated by column chromatography (eluent: ethyl acetate/hexane = 1/20) as 
dark solid of 2 inseperable regioisomers in 40% total yield (42.3 mg, the ratio of 2 
regioisomers is 1:1 based on 1H NMR) following the general procedure. 1H NMR 
(500 MHz, CDCl3): δ 8.01–7.84 (m, 1H), 7.75–7.50 (m, 1H), 7.46 (s, 2H), 7.35–6.96 
(m, 12H), 6.79–6.56 (m, 3H), 6.50–6.36 (m, 1H). 13C NMR (125 MHz, CDCl3): δ 
187.7, 187.5, 164.8, 164.5, 155.1, 154.8, 149.4, 147.1, 141.3, 140.3, 137.9, 137.5, 
137.2, 137.0, 136.3, 135.4, 135.0, 134.9, 134.1, 133.0, 130.5, 130.0, 129.9, 129.1, 
129.0, 128.9, 128.7, 128.5, 128.4, 128.2, 128.0, 127.4, 127.0, 126.9, 126.8, 126.7, 
126.6, 126.4, 126.3, 126.2, 125.6, 125.2, 119.8, 119.5, 118.1, 117.7, 79.6, 77.6, 77.4, 
77.2, 76.9. HRMS (EI) calcd for [C33H20S2O3] + 528.0854, found 528.0853. 




















2,3-Diphenyl-4H-furo[3,2-c]chromen-4-one (2-4aa): 4-Hydroxycoumarin 2-1a (0.2 
mmol), diphenylacetylene 2-2a (0.4 mmol), Pd(OAc)2 (0.02 mmol), and K2S2O8 (0.4 
mmol) were added into DMSO (2 mL). The mixture was stirred at 80 oC under N2 
atmosphere for 2 d. Work-up: The crude mixture was cooled down to room 
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temperature and then poured into ethyl acetate (20 mL), which was washed with brine 
(10 mL*4), dried with MgSO4 and filtered. The solvent was removed to obtain crude 
product, which was purified by column chromatography on silica gel (eluent: ethyl 
acetate/hexane = 1/30) to afford the desired product 2-4aa as yellow solid (35.9 mg, 
53%). 1H NMR (500 MHz, CDCl3): δ 7.99 (d, J = 7.7 Hz, 1H), 7.59–7.49 (m, 5H), 
7.48–7.42 (m, 4H), 7.38 (t, J = 7.5 Hz, 1H), 7.35–7.29 (m, 3H). 13C NMR (125 MHz, 
CDCl3): δ 157.6, 156.6, 152.8, 151.5, 130.8, 130.4, 130.3, 129.4, 128.9, 128.7, 128.7, 
128.5, 126.8, 124.6, 121.0, 120.9, 117.4, 112.9, 111.4, 77.4, 77.2, 76.9. HRMS (EI) 





8-Chloro-2,3-diphenyl-4H-furo[3,2-c]chromen-4-one (2-4ca): Isolated by column 
chromatography (eluent: ethyl acetate/hexane = 1/30) as yellow solid in 33% yield 
(26.1 mg) following the general procedure. 1H NMR (500 MHz, CDCl3): δ 7.95 (d, J 
= 2.4 Hz, 1H), 7.58–7.52 (m, 2H), 7.52–7.41 (m, 6H), 7.40–7.37 (m, 1H), 7.35–7.30 
(m, 3H). 13C NMR (125 MHz, CDCl3): δ 157.0, 155.2, 152.17, 151.1, 130.7, 130.3, 
130.1, 130.0, 129.2, 129.1, 128.8, 128.8, 128.7, 126.9, 121.1, 120.5, 118.8, 113.9, 








8-Methyl-2,3-diphenyl-4H-furo[3,2-c]chromen-4-one (2-4da): Isolated by column 
chromatography (eluent: ethyl acetate/hexane = 1/30) as yellow solid in 38% yield 
(26.8 mg) following the general procedure. 1H NMR (500 MHz, CDCl3): δ 7.77 (s, 
1H), 7.58–7.53 (m, 2H), 7.53–7.48 (m, 2H), 7.48–7.40 (m, 3H), 7.36–7.29 (m, 5H), 
2.49 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 157.8, 156.6, 151.3, 151.1, 134.4, 131.9, 
130.4, 129.5, 128.9, 128.7, 128.7, 128.5, 126.8, 121.0, 120.7, 117.1, 112.5, 111.3, 




6-Methyl-2,3-diphenyl-4H-furo[3,2-c]chromen-4-one (2-4ha): Isolated by column 
chromatography (eluent: ethyl acetate/hexane = 1/30) as yellow solid in 33% yield 
(23.3 mg) following the general procedure. 1H NMR (500 MHz, CDCl3): δ 7.83 (d, J 
= 7.7 Hz, 1H), 7.58–7.49 (m, 4H), 7.49–7.42 (m, 3H), 7.38 (d, J = 7.3 Hz, 1H), 
7.35–7.30 (m, 3H), 7.29–7.24 (m, 1H), 2.52 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 
157.6, 157.0, 151.4, 151.3, 132.2, 130.4, 129.6, 128.9, 128.7, 128.7, 128.5, 126.9, 
126.8, 124.1, 121.0, 118.7, 112.6, 111.2, 77.4, 77.2, 76.9, 16.3. HRMS (EI) calcd for 








2,3-Di-p-tolyl-4H-furo[3,2-c]chromen-4-one (2-4ab): Isolated by column 
chromatography (eluent: ethyl acetate/hexane = 1/30) as white solid in 43% yield 
(31.5 mg) following the general procedure. 1H NMR (500 MHz, CDCl3): δ 7.97 (dd, J 
= 7.7, 1.1 Hz, 1H), 7.55–7.48 (m, 1H), 7.48–7.42 (m, 3H), 7.42–7.33 (m, 3H), 7.25 (d, 
J = 8.3 Hz, 2H), 7.13 (d, J = 8.1 Hz, 2H), 2.43 (s, 3H), 2.36 (s, 3H). 13C NMR (125 
MHz, CDCl3): δ 157.7, 156.3, 152.7, 151.6, 139.0, 138.2, 130.6, 130.2, 129.4, 129.4, 
127.3, 126.8, 126.7, 124.5, 120.9, 120.3, 117.3, 112.9, 111.5, 77.4, 77.2, 76.9, 21.6, 






2,3-Bis(4-chlorophenyl)-4H-furo[3,2-c]chromen-4-one (2-4ak): Isolated by column 
chromatography (eluent: ethyl acetate/hexane = 1/30) as yellow solid in 37% yield 
(30.1 mg) following the general procedure. 1H NMR (500 MHz, CDCl3): δ 7.96 (d, J 
= 7.7 Hz, 1H), 7.58–7.51 (m, 1H), 7.48–7.41 (m, 7H), 7.39 (t, J = 7.6 Hz, 1H), 7.32 (d, 
J = 8.5 Hz, 2H). 13C NMR (125 MHz, CDCl3): δ 157.4, 156.9, 152.9, 150.6, 135.2, 
134.8, 131.7, 131.2, 129.2, 129.1, 128.4, 128.1, 127.6, 124.7, 121.1, 120.3, 117.4, 








2,3-Di-m-tolyl-4H-furo[3,2-c]chromen-4-one (2-4af): Isolated by column 
chromatography (eluent: ethyl acetate/hexane = 1/30) as white solid in 48% yield 
(35.2 mg) following the general procedure. 1H NMR (500 MHz, CDCl3): δ 8.00 (d, J 
= 7.7 Hz, 1H), 7.56–7.49 (m, 1H), 7.45 (d, J = 8.7 Hz, 2H), 7.37 (t, J = 7.6 Hz, 1H), 
7.33 (d, J = 7.6 Hz, 2H), 7.29 (d, J = 9.3 Hz, 2H), 7.24 (d, J = 7.5 Hz, 1H), 7.18 (t, J = 
7.6 Hz, 1H), 7.13 (d, J = 7.5 Hz, 1H), 2.39 (s, 3H), 2.33 (s, 3H). 13C NMR (125 MHz, 
CDCl3): δ 157.6, 156.4, 152.8, 151.6, 138.4, 138.2, 130.9, 130.7, 130.2, 129.7, 129.4, 
129.3, 128.5, 128.5, 127.4, 127.2, 124.5, 123.9, 121.0, 120.9, 117.3, 112.9, 111.5, 





2-4ah was isolated by column chromatography (eluent: ethyl acetate/hexane = 1/30) 
as white solid of 2 inseperable regioisomers in 46% total yield (32.8 mg, the ratio of 2 
regioisomers is 1:1 based on 1H NMR) following the general procedure. 1H NMR 
(500 MHz, CDCl3): δ 8.12–7.84 (m, 1H), 7.58–7.41 (m, 7H), 7.41–7.28 (m, 3H), 7.14 
(t, J = 8.7 Hz, 1H), 7.02 (t, J = 8.7 Hz, 1H). 13C NMR (125 MHz, CDCl3): δ 163.9, 
162.0, 161.9, 157.7, 157.5, 156.6, 156.5, 152.8, 151.6, 150.6, 132.2, 132.2, 131.0, 
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130.9, 130.3, 130.1, 129.2, 129.1, 128.8, 128.8, 128.8, 128.6, 126.9, 126.2, 125.7, 
124.6, 121.0, 120.8, 119.9, 117.4, 116.0, 115.9, 115.8, 115.8, 112.8, 111.4, 111.3, 
77.4, 77.2, 76.9. HRMS (EI) calcd for [C23H13FO3] + 356.0849, found 356.0833. 























Methyl 2-(2-methoxyphenyl)-4,5-diphenylfuran-3-carboxylate (2-5): A mixture of 
2-4aa (0.2 mmol) and KOH (1.0 mmol) in DMSO (2 mL) was stirred at 80 oC for 1 h. 
Then MeI (1.0 mmol) was added. The resulting mixture was stirred at 80 oC for 
another 1 h. Work-up: The crude mixture was cooled down to room temperature and 
then poured into ethyl acetate (20 mL), which was washed with brine (10 mL*4), 
dried with MgSO4 and filtered. The solvent was removed to obtain crude product, 
which was purified by column chromatography on silica gel (eluent: ethyl 
acetate/hexane = 1/6) to afford the desired product 2-5 as white solid (61.5 mg, 80%). 
1H NMR (500 MHz, CDCl3): δ 7.71 (d, J = 7.6 Hz, 1H), 7.47–7.36 (m, 8H), 
7.28–7.19 (m, 3H), 7.10 (t, J = 7.5 Hz, 1H), 6.99 (d, J = 8.3 Hz, 1H), 3.84 (s, 3H), 
3.59 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 164.9, 156.7, 151.0, 148.6, 132.9, 130.7, 
130.4, 130.3, 130.1, 128.5, 128.4, 127.8, 127.7, 126.0, 123.1, 120.7, 119.6, 118.9, 


























3-Benzoyl-2-oxo-2H-chromen-4-yl benzoate (2-6): A mixture of 2-4aa (0.2 mmol) 
and iodobenzene diacetate (0.6 mmol) in 1,4-dioxane (2 mL) was stirred at room 
temperature in air and simultaneously exposed to UV light (Rayonet UV reactor, 366 
nm) for 12 h. Work-up: The solvent was removed to obtain crude product, which was 
purified by column chromatography on silica gel (eluent: ethyl acetate/hexane = 1/20) 
to afford the desired product 2-6 as yellow solid (70.4 mg, 95%). 1H NMR (500 MHz, 
CDCl3): δ 8.02 (d, J = 7.5 Hz, 2H), 7.93 (d, J = 7.6 Hz, 2H), 7.71–7.60 (m, 3H), 7.56 
(t, J = 7.5 Hz, 1H), 7.50–7.40 (m, 5H), 7.34 (t, J = 7.7 Hz, 1H). 13C NMR (125 MHz, 
CDCl3): δ 189.3, 162.7, 159.4, 158.5, 153.8, 136.2, 134.9, 134.1, 134.0, 130.7, 129.6, 
129.0, 128.8, 127.2, 125.0, 124.2, 118.3, 117.4, 115.9, 77.4, 77.2, 76.9. HRMS (EI) 
calcd for [C23H14O5] + 370.0841, found 370.0840. 
2.4.6 X-ray Crystallographic Analysis 
The configuration of product 2-3aa was assigned by X-ray crystallographic analysis 
(Figure 2.1). The other products of 2-3 were assigned by analogy. 




Table 2.5 Crystal data and structure refinement for 2-3aa 
Empirical formula  C37 H24 O3 
Formula weight  516.56 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.3266(6) Å α = 94.305(2)°. 
 b = 11.3868(11) Å β = 99.144(2)°. 
 c = 18.6894(19) Å γ = 100.166(2)°. 
Volume 1301.0(2) Å3 
Z 2 
Density (calculated) 1.319 Mg/m3 




Crystal size 0.60 x 0.40 x 0.20 mm3 
Theta range for data collection 1.11 to 27.50°. 
Index ranges -8<=h<=8, -14<=k<=14, -24<=l<=24 
Reflections collected 17120 
Independent reflections 5964 [R(int) = 0.0241] 
Completeness to theta = 27.50° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9836 and 0.9521 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5964 / 0 / 361 
Goodness-of-fit on F2 1.062 
Final R indices [I>2sigma(I)] R1 = 0.0470, wR2 = 0.1316 
R indices (all data) R1 = 0.0539, wR2 = 0.1432 
Largest diff. peak and hole 0.541 and -0.308 e.Å-3 
The configuration of product 2-4aa was assigned by X-ray crystallographic analysis 
(Figure 2.2). The other products of 2-4 were assigned by analogy. 




Table 2.6 Crystal data and structure refinement for 2-4aa 
Empirical formula  C23 H14 O3 
Formula weight  338.34 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 6.3989(5) Å a= 90°. 
 b = 9.6133(7) Å b= 90.763(2)°. 
 c = 26.4302(19) Å g = 90°. 
Volume 1625.7(2) Å3 
Z 4 
Density (calculated) 1.382 Mg/m3 
Absorption coefficient 0.091 mm-1 
F(000) 704 
Crystal size 0.60 x 0.24 x 0.18 mm3 
Theta range for data collection  2.25 to 27.48°. 
Index ranges -8<=h<=8, -12<=k<=10, -31<=l<=34 
Reflections collected 11089 
Independent reflections 3720 [R(int) = 0.0317] 
Completeness to theta = 27.48° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9838 and 0.9473 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3720 / 0 / 235 
Goodness-of-fit on F2 1.091 
Final R indices [I>2sigma(I)] R1 = 0.0491, wR2 = 0.1146 
R indices (all data) R1 = 0.0570, wR2 = 0.1192 






Palladium-Catalyzed Oxidative Annulation via C–H/N–H 


































The coupling of 4-aminocoumarins with alkynes is described, which proceeds 
through a Pd-catalyzed oxidative annulations process, providing a concise route 








The synthesis of N-heterocycles is an important field of research because of their 
prevalence in natural products and drugs.[103] Of the N-heterocycles, pyrroles are 
well-known five-membered N-containing heterocycles that form the structural 
scaffold of many pharmaceuticals.[104]  Therefore, they are often used as structural 
elements in medicinal chemistry. For example, Atorvastatin (Figure 3.1A), marketed 
by Pfizer under the trade name Lipitor, is a member of the drug class known as stains, 
used for lowering blood cholesterol.[105] Lamellarin D (Figure 3.1B) has been found to 
be cytotoxic to a wide range of cancer cell lines and is also a potent inhibitor of 
human topisomerase I60.[106] Zomepirac (Figure 3.1C) is an orally effective non- 
steroidal anti- inflammatory drug that has anti-pyretic actions.[107] Compound D is 
identified as an anti-cancer drug candidate.[108]  











































-cancer activity)  
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A number of methods have been reported for the synthesis of pyrroles. The 
traditional methods are Knorr,[109] Paal-Knorr[110] and Hantzsch[111] reactions. 
Although these methods are very helpful in assembling pyrrole molecules, they 
exhibit some significant drawbacks, such as low availability of starting materials, low 
compatibility of functional groups, multiple synthetic steps and harsh reaction condi-
tions, which largely limit their applications. However, the high value of pyrrole scaf-
fold in medicinal chemistry has still driven organic chemists to continue developing 
novel synthetic methods to prepare differentially substituted pyrroles. Aside from tra-
ditional methods, one of the most attractive modern approaches for the direct synthe-
sis of substituted pyrroles is the transition-metal-catalyzed annulation reaction. Spe-
cifically, the groups of Glorius,[112] Fagnou,[113] and Ackermann[114] have inde-
pendently reported Rh(III)- or Ru(II)-catalyzed oxidative couplings using a directing 
group (DG) for aryl C-H bond activation followed by insertion of an internal alkyne, 
leading to various substituted pyrroles (Scheme 3.1a). In this article, we wish to dis-
close a new synthetic approach through a direct Pd(II)-catalyzed oxidative coupling of 
4-aminocoumarins with internal alkynes in the absence of DG (Scheme 3.1b). 










































3.2 Results and Discussion 
In connection to our group’s continued interest in developing efficient and direct 
Pd-catalyzed alkyne transformations via C-H functionalization,[101] we decided to 
choose Pd(OAc)2 as the catalyst to explore the direct annulation of enamines with al-
kynes. As shown in Scheme 3.2, no reaction happened for either less bulky enamines 
or active β-enaminoesters. We deduced that the substrate reactivity is largely affected 
by both the geometry and the steric hindrance of nucleophiles.  







































































To test our hypothesis, a trans- and less steric hindered 4-aminocoumarin 3-1a 
was synthesized and applied to the annulation reaction. Initially, a number of oxidants 
were screened and identified to be a critical factor in the process (Table 3.1, entries 
2-8). Reaction only occurred in the presence of a stoichiometric amount of oxidant 
AgOAc or Cu(OAc)2 at 100 oC. To further improve the efficiency of this reaction, 
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various solvents were examined and DMSO afforded a good yield in 12 h (Table 3.1, 
entries 9-11). Having the optimized oxidant Cu(OAc)2 and solvent DMSO in hand, we 
then investigated the effect of temperature. Pleasingly, a satisfactory yield was af-
forded at room temperature for a longer reaction time (Table 3.1, entry 12). However, 
a stoichiometric amount of Cu(OAc)2 as oxidant was still used. When O2 was em-
ployed as the sole oxidant, a much decrease result was obtained (Table 3.1, entry 13). 
Gratifyingly, a satisfactory yield was afforded by using a catalytic amount of 
Cu(OAc)2 (20 mol%) and O2 at room temperature for 72 h (Table 3.1, entry 14). We 
speculate that O2 plays a very important role here. Firstly, O2 could itself work as an 
oxidant to directly recycle Pd-catalyst by oxidizing Pd(0) to Pd(II). Secondly, O2 
could regenerate the oxidant Cu(OAc)2 by oxidizing the Cu(I) specie to Cu(II). 


















Entry Oxidant Solvent Temp. [oC] t [h] Yield [%][b] 
  1[c, d] -- DMA 100 12 -- 
2 AgOAc DMA 100 12 24 
 3[d] CuCl2 DMA 100 12 -- 
 4[d] PhI(OAc)2 DMA 100 12 -- 
 5[d] Oxones DMA 100 12 -- 
 6[d] BQ DMA 100 12 -- 
 7[d] DDQ DMA 100 12 -- 
8 Cu(OAc)2 DMA 100 12 23 
9 Cu(OAc)2 DMSO 100 12 71 
10 Cu(OAc)2 NMP 100 12 32 
11 Cu(OAc)2 MeCN 100 12 17 
12 Cu(OAc)2 DMSO 25 72 91 
13 O2 DMSO 25 72 45 
14[e] Cu(OAc)2/O2 DMSO 25 72 90 
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[a] Reaction conditions: 3-1a (0.2 mmol, 1.0 equiv.), 3-2a (0.6 mmol, 3.0 equiv.), Pd(OAc)2 (10 mol%), oxidant 
(2.0 equiv.), DMSO (1 mL), 100 oC, 12 h. [b] Isolated yield. [c] No oxidant. [d] No desired product was detected. 
[e] Cu(OAc)2 (20 mol%) and O2 balloon.  
Under the optimal reaction conditions, various 4-aminocoumarins 3-1 were 
surveyed (Table 3.2). Reactions of 4-aminocoumarins 3-1a to 3-1l with 
electron-withdrawing or electron-donating groups proceeded efficiently with 
moderate to excellent yields.  

































































































































































To further indicate the generality and potential of our approach, we then 
investigated different alkynes 3-2. Table 3.3 showed a broad substrate scope of 
internal alkynes. In general, electron-rich symmetric alkynes gave high reaction yields 
(Table 3.3, 3-3ab to 3-3ac, 3-3af to 3-3ah, r.t.), while electron-deficient systems were 
less facile (Table 3.3, 3-3ad and 3-3ae, 80 oC). Heteroaryl and aliphatic alkynes were 
also tolerated (3-3aj and 3-3ak). 






































































































































When asymmetrical internal alkynes were employed, two regioisomers were 
usually observed (Table 3.4, 3-3al to 3-3aq, r.r. ~ 1:1 to 2:1). When alkyne 3-2r or 
3-2s was employed, only one regioisomer was formed following a Markovnikov’s 
rule in the alkyne addition step (Table 3.4, 3-3ar and 3-3as). However, when highly 
electron deficient substate dimethyl acetylenedicarboxylate (DMAD, 3-2t) was used, 
reaction failed (3-3at). 




































































[a] Reaction conditions: 3-1a
 
(0.2 mmol, 1.0 equiv.), 3-2
 





balloon,DMSO (1.0 mL), r.t., 72 h. [b] 80 
oC, 24 h. [c] Ratio of regioisomers (r.r.), determined by 1H NMR.
 
To our delight, both N-protected 4-aminocoumarin (3-1m) and β-enaminones 
(3-1n and 3-1o) underwent the Pd-catalyzed oxidative annulation reaction with good 
reactivity (Scheme 3.3).  

























































































As heterocyclic molecules show different bioactive and electronic properties, we 
further tried to expand our reaction to construct some other useful frameworks. Upon 
treatment of product 3-3aa with KOH and MeI in DMSO at 80 oC for 1 h, highly 
functionalized pyrrole 3-4 was obtained in 86% yield (Scheme 3.4a). Photolysis of 
3-3aa was also accomplished in the presence of iodobenzene diacetate under UV light, 
smoothly affording functionalized coumarin 3-5 (Scheme 3.4b).  














































On the basis of known transition-metal-catalyzed C-H activation/oxidative 
annulation reactions, we proposed two possible pathways (Scheme 3.5). For path a, 
the formation of pyrrole 3-3aa presumably commences with the palladation of 
4-aminocoumarin 3-1a to yield the palladium intermediate 3-6. This is followed by 
syn-addition of the intermediate 3-6 to an internal alkyne 3-2a to generate the 
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vinylpalladium intermediate 3-7. Finally, intramolecular palladation of 3-7 leads to 
the formation of the palladacyclohexene intermediate 3-8, which subsequently 
undergoes reductive elimination to yield the coumarin-fused pyrrole 3-3aa. 
Alternatively, for path b, alkyne 3-2a is initially activated by Pd(II), which acts as a 
Lewis acid.[115] Subsequent aminopalladation[116] of alkyne 3-2a could occur to form 
the intermediate 3-9, which generates the intermediate 3-10 via electrophilic aromatic 
palladation and subsequent proton abstraction.[117] The intermediate 3-10 then 
undergoes reductive elimination to give the expected product 3-3aa. The resulting 
Pd(0) is additionally oxidized to Pd(II) by Cu(OAc)2/O2 system to complete the 
catalytic cycle. 
























































In summary, we have developed an efficient method for the synthesis of highly 
substituted pyrroles. The method employs a direct Pd(II)-catalyzed oxidative 
annulation of simple and readily available enamines and alkynes. The mild nature, 
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broad functional group compatibility and the significance of pyrrole scaffold should 
render this method attractive for both synthetic and medicinal chemistry. 
3.4 Experimental Section 
3.4.1 General Information 
Chemicals and solvents were purchased from commercial suppliers and used as 
received. NMR spectra were recorded on a Bruker ACF-300 or ACF-500 spectrome-
ter in d6-DMSO or CDCl3 at 298K, otherwise indicated. Chemical shifts were 
reported in parts per million (ppm), and the residual solvent peak was used as an 
internal reference. Multiplicity was indicated as follows: s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet), dd (doublet of doublet), bs (broad singlet). 
Coupling constants were reported in Hertz (Hz). Low resolution mass spectra were 
obtained on a Finnigan/MAT LCQ spectrometer in ESI mode, or a Finnigan/MAT 
95XL-T mass spectrometer in EI mode. All high resolution mass spectra were 
obtained on a Finnigan/MAT 95XL-T mass spectrometer. For thin layer 
chromatography (TLC), Merck pre-coated TLC plates (Merck 60 F254) were used, 
and compounds were visualized with a UV light at 254 nm. Flash chromatography 
separations were performed on Merck 60 (0.040-0.063 mm) mesh silica gel.  
3-1 were synthesized according to related procedures. [103, 118] 3-2a, 3-2k, 3-2l, 
3-2s and 3-2t were commercially available. The other starting materials of 3-2 were 




















-2a 3-3aa  
2,3-Diphenylchromeno[4,3-b]pyrrol-4(1H)-one (3-3aa, 90%): 4-Aminocoumarin 
3-1a (0.2 mmol), diphenylacetylene 3-2a (0.6 mmol), Pd(OAc)2 (0.02 mmol) and 
Cu(OAc)2 (0.04 mmol) were added into DMSO (1.0 mL). The mixture was stirred at 
r.t. under O2 atmosphere for 72 h. The crude product was purified by column 
chromatography on silica gel (eluent: EtOAc/Hexane = 1/4) to afford the desired 
product. 1H NMR (500 MHz, d6-DMSO): δ 12.80 (s, 1H), 8.37–8.17 (m, 1H), 
7.56–7.20 (m, 13H). 13C NMR (125 MHz, d6-DMSO): δ 157.7, 151.6, 135.8, 133.9, 
133.6, 131.5, 131.1, 129.2, 128.8, 128.2, 128.1, 127.1, 124.4, 122.1, 121.1, 117.0, 
113.9, 107.3, 40.7, 40.5, 40.2, 39.9, 39.6, 39.4, 39.1. HRMS (ESI) Calcd for 








8-Methyl-2,3-diphenylchromeno[4,3-b]pyrrol-4(1H)-one (3-3ba, 89%): 1H NMR 
(500 MHz, d6-DMSO): δ 12.72 (s, 1H), 8.11 (s, 1H), 7.65–7.08 (m, 12H), 2.43 (s, 3H). 
13C NMR (125 MHz, d6-DMSO): δ 157.9, 149.8, 135.8, 133.7, 133.6, 133.5, 131.5, 
131.1, 130.1, 128.8, 128.7, 128.1, 127.1, 121.9, 121.1, 116.8, 113.5, 107.3, 40.7, 40.5, 
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8-Ethyl-2,3-diphenylchromeno[4,3-b]pyrrol-4(1H)-one (3-3ca, 99%): 1H NMR 
(500 MHz, d6-DMSO): δ 12.75 (s, 1H), 8.16 (s, 1H), 7.65–6.92 (m, 12H), 2.74 (q, J = 
7.6 Hz, 2H), 1.30 (t, J = 7.6 Hz, 3H). 13C NMR (125 MHz, d6-DMSO): δ 158.0, 150.0, 
139.9, 136.1, 133.9, 133.7, 131.6, 131.2, 129.2, 128.9, 128.9, 128.3, 128.2, 127.3, 
121.2, 120.8, 116.9, 113.7, 107.4, 40.7, 40.5, 40.2, 39.9, 39.6, 39.4, 39.1, 28.2, 15.9. 








8-Methoxy-2,3-diphenylchromeno[4,3-b]pyrrol-4(1H)-one (3-3da, 92%): 1H NMR 
(500 MHz, d6-DMSO): δ 12.59 (s, 1H), 8.18 (d, J = 8.4 Hz, 1H), 7.51–7.08 (m, 10H), 
7.18–6.78 (m, 2H), 3.85 (s, 3H). 13C NMR (125 MHz, d6-DMSO): δ 160.6, 158.0, 
153.3, 136.7, 133.8, 133.1, 131.7, 131.2, 128.9, 128.8, 128.2, 128.1, 127.2, 123.2, 
120.8, 112.2, 107.2, 105.6, 101.7, 56.1, 40.7, 40.5, 40.2, 39.9, 39.6, 39.4, 39.1. HRMS 










8-Fluoro-2,3-diphenylchromeno[4,3-b]pyrrol-4(1H)-one (3-3ea, 72%): 1H NMR 
(500 MHz, d6-DMSO): δ 12.76 (s, 1H), 8.07 (dd, J = 9.2, 3.0 Hz, 1H), 7.45 (m, 1H), 
7.40–7.23 (m, 11H). 13C NMR (125 MHz, d6-DMSO): δ 159.5, 157.6, 148.0, 135.0, 
135.0, 134.4, 133.5, 131.4, 131.2, 129.0, 128.8, 128.4, 128.2, 127.4, 121.3, 119.1, 
118.9, 116.4, 116.2, 114.9, 114.8, 108.0, 107.8, 107.7, 40.7, 40.5, 40.2, 39.9, 39.6, 








8-Bromo-2,3-diphenylchromeno[4,3-b]pyrrol-4(1H)-one (3-3fa, 89%): 1H NMR 
(500 MHz, d6-DMSO): δ 12.81 (s, 1H), 8.54 (d, J = 2.2 Hz, 1H), 7.62 (dd, J = 8.8, 2.2 
Hz, 1H), 7.45–7.22 (m, 11H). 13C NMR (125 MHz, d6-DMSO): δ 157.4, 150.7, 134.5, 
133.4, 131.7, 131.4, 131.1, 129.0, 128.7, 128.4, 128.3, 127.4, 124.6, 121.4, 119.4, 
116.4, 115.9, 107.9, 40.7, 40.5, 40.2, 39.9, 39.6, 39.4, 39.1. HRMS (ESI) Calcd for 










8-Chloro-2,3-diphenylchromeno[4,3-b]pyrrol-4(1H)-one (3-3ga, 79%): 1H NMR 
(500 MHz, d6-DMSO): δ 12.80 (s, 1H), 8.39 (d, J = 2.3 Hz, 1H), 7.52–7.42 (m, 2H), 
7.40–7.20 (m, 10H). 13C NMR (125 MHz, d6-DMSO): δ 157.4, 150.3, 134.6, 134.5, 
133.4, 131.4, 131.1, 129.0, 128.8, 128.7, 128.5, 128.4, 128.3, 127.4, 121.6, 121.4, 
119.0, 115.4, 107.9, 40.7, 40.5, 40.2, 39.9, 39.6, 39.4, 39.1. HRMS (ESI) Calcd for 








7-Methoxy-2,3-diphenylchromeno[4,3-b]pyrrol-4(1H)-one (3-3ha, 95%): 1H NMR 
(500 MHz, d6-DMSO): δ 12.69 (s, 1H), 7.84 (d, J = 2.5 Hz, 1H), 7.54–7.15 (m, 11H), 
7.02 (dd, J = 8.9, 2.5 Hz, 1H), 3.85 (s, 3H). 13C NMR (125 MHz, d6-DMSO): δ 158.0, 
156.0, 146.1, 136.0, 133.9, 133.7, 131.6, 131.2, 129.0, 128.9, 128.3, 128.2, 127.3, 
121.2, 118.2, 116.8, 114.2, 107.5, 104.9, 56.2, 40.7, 40.5, 40.2, 39.9, 39.6, 39.4, 39.1. 









7-Chloro-2,3-diphenylchromeno[4,3-b]pyrrol-4(1H)-one (3-3ia, 97%): 1H NMR 
(500 MHz, d6-DMSO): δ 12.83 (s, 1H), 8.26 (d, J = 8.4 Hz, 1H), 7.56 (s, 1H), 
7.51–7.42 (m, 1H), 7.40–7.21 (m, 10H). 13C NMR (125 MHz, d6-DMSO): δ 157.3, 
152.1, 135.1, 134.3, 133.5, 133.3, 131.4, 131.1, 129.0, 128.9, 128.4, 128.2, 127.3, 
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124.7, 123.5, 121.3, 117.2, 113.0, 107.2, 40.7, 40.5, 40.2, 39.9, 39.6, 39.4, 39.1. 









6-Methyl-2,3-diphenylchromeno[4,3-b]pyrrol-4(1H)-one (3-3ja, 60%): 1H NMR 
(500 MHz, d6-DMSO): δ 12.74 (s, 1H), 8.12 (d, J = 7.5 Hz, 1H), 7.60–6.85 (m, 12H), 
2.42 (s, 3H). 13C NMR (125 MHz, d6-DMSO): δ 157.3, 149.6, 135.8, 133.5, 133.2, 
131.1, 130.7, 130.1, 128.5, 128.4, 127.8, 127.7, 126.8, 125.4, 123.5, 120.6, 119.4, 
113.1, 106.8, 40.7, 40.5, 40.2, 39.9, 39.6, 39.4, 39.1, 15.8. HRMS (ESI) Calcd for 










7,8-Dimethyl-2,3-diphenylchromeno[4,3-b]pyrrol-4(1H)-one (3-3ka, 96%): 1H 
NMR (500 MHz, d6-DMSO, 373 K): δ 12.66 (s, 1H), 8.05 (s, 1H), 7.65–6.85 (m, 
11H), 2.33 (s, 6H). 13C NMR (125 MHz, d6-DMSO, 373 K): δ 158.1, 150.2, 138.6, 
136.3, 133.8, 133.4, 132.7, 131.7, 131.2, 128.9, 128.8, 128.2, 128.2, 127.2, 122.3, 
121.1, 117.6, 111.4, 107.0, 40.7, 40.5, 40.2, 39.9, 39.6, 39.4, 39.1, 20.1, 19.6. HRMS 










1,2-Diphenylbenzo[7,8]chromeno[4,3-b]pyrrol-11(3H)-one (3-3la, 98%): 1H NMR 
(500 MHz, d6-DMSO): δ 12.79 (s, 1H), 8.36 (d, J = 8.0 Hz, 1H), 8.32 (d, J = 8.6 Hz, 
1H), 7.97 (d, J = 8.0 Hz, 1H), 7.86 (d, J = 8.6 Hz, 1H), 7.65 (t, J = 7.2 Hz, 1H), 7.60 
(t, J = 7.1 Hz, 1H), 7.42–7.23 (m, 10H). 13C NMR (125 MHz, d6-DMSO): δ 157.7, 
147.3, 136.8, 134.1, 133.7, 133.4, 131.6, 131.2, 129.0, 128.9, 128.6, 128.3, 128.2, 
127.6, 127.3, 124.4, 123.4, 121.8, 121.2, 119.5, 109.2, 107.3, 40.7, 40.5, 40.2, 39.9, 






1-Isobutyl-2,3-diphenylchromeno[4,3-b]pyrrol-4(1H)-one [3-3ma, Cu(OAc)2 (2.0 
equiv.), N2 atmosphere, 120 oC, 24 h, 60%]: 1H NMR (500 MHz, d6-DMSO, 298 
K): δ 8.08 (d, J = 8.0 Hz, 1H), 7.60–7.36 (m, 6H), 7.32–7.26 (m, 2H), 7.24–7.11 (m, 
5H), 4.25 (s, 2H), 2.16–1.70 (m, 1H), 0.67 (d, J = 5.9 Hz, 6H). 13C NMR (125 MHz, 
d6-DMSO, 298 K): δ 157.5, 151.8, 139.1, 133.9, 133.4, 132.3, 131.3, 130.8, 129.2, 
129.1, 128.9, 127.6, 126.9, 124.8, 122.7, 122.3, 117.9, 114.3, 107.7, 53.1, 40.5, 40.3, 












6,6-Dimethyl-2,3-diphenyl-6,7-dihydro-1H-indol-4(5H)-one (3-3na, 80 oC, 48 h, 
85%): 1H NMR (500 MHz, d6-DMSO): δ 11.68 (s, 1H), 7.73–6.72 (m, 10H), 2.76 (s, 
2H), 2.24 (s, 2H), 1.10 (s, 6H). 13C NMR (125 MHz, d6-DMSO): δ 192.4, 143.5, 
135.6, 132.6, 131.0, 129.4, 128.7, 127.9, 127.7, 127.0, 126.5, 119.6, 117.3, 53.4, 40.5, 
40.3, 40.2, 40.0, 39.8, 39.7, 39.5, 36.7, 35.3, 28.7. HRMS (ESI) Calcd for [C22H21NO 







2,3-Diphenyl-6,7-dihydro-1H-indol-4(5H)-one (3-3oa, 80 oC, 48 h, 80%): 1H NMR 
(500 MHz, d6-DMSO, 298 K): δ 11.73 (s, 1H), 7.21 (m, 10H), 2.87 (t, J = 5.8 Hz, 2H), 
2.33 (t, J = 6.0 Hz, 2H), 2.12–2.03 (m, 2H).  13C NMR (125 MHz, d6-DMSO): δ 
193.0, 144.7, 135.8, 132.6, 131.0, 129.2, 128.7, 127.9, 127.7, 127.0, 126.5, 119.8, 
118.5, 40.5, 40.3, 40.2, 40.0, 39.8, 39.7, 39.5, 39.3, 23.8, 23.0. HRMS (ESI) Calcd for 









2,3-Di-p-tolylchromeno[4,3-b]pyrrol-4(1H)-one (3-3ab, 94%): 1H NMR (500 MHz, 
d6-DMSO): δ 12.68 (s, 1H), 8.26 (d, J = 7.6 Hz, 1H), 7.51–7.45 (m, 1H), 7.44–7.34 
(m, 2H), 7.29–7.23 (m, 2H), 7.22–7.16 (m, 4H), 7.15–7.10 (m, 2H), 2.32 (s, 3H), 2.30 
(s, 3H). 13C NMR (125 MHz, d6-DMSO): δ 157.9, 151.7, 137.7, 136.2, 135.6, 133.9, 
131.0, 130.7, 129.5, 129.2, 128.9, 128.8, 128.7, 124.5, 122.2, 120.8, 117.1, 114.0, 
107.4, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 39.1, 21.3, 21.2. HRMS (ESI) Calcd for 







2,3-Bis(4-methoxyphenyl)chromeno[4,3-b]pyrrol-4(1H)-one (3-3ac, 95%): 1H 
NMR (500 MHz, d6-DMSO): δ 12.63 (s, 1H), 8.25 (d, J = 7.6 Hz, 1H), 7.41 (m, 3H), 
7.29 (d, J = 8.6 Hz, 2H), 7.21 (d, J = 8.5 Hz, 2H), 6.94 (d, J = 8.6 Hz, 2H), 6.88 (d, J 
= 8.5 Hz, 2H), 3.77 (s, 3H), 3.76 (s, 3H). 13C NMR (125 MHz, d6-DMSO): δ 159.3, 
158.6, 157.9, 151.6, 135.4, 133.7, 132.3, 130.2, 129.1, 125.9, 124.4, 124.1, 122.1, 
120.1, 117.1, 114.5, 114.1, 113.7, 107.4, 55.7, 55.4, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 







2,3-Bis(4-chlorophenyl)chromeno[4,3-b]pyrrol-4(1H)-one (3-3ad, 80 oC, 24 h, 
86%): 1H NMR (500 MHz, d6-DMSO, 373 K): δ 12.58 (s, 1H), 8.26 (d, J = 7.2 Hz, 
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1H), 7.66–7.12 (m, 11H). 13C NMR (125 MHz, d6-DMSO, 373 K): δ 157.7, 152.1, 
136.3, 133.4, 133.1, 132.9, 132.6, 132.4, 130.6, 130.4, 129.5, 129.0, 128.3, 124.4, 
122.3, 120.6, 117.1, 114.0, 107.8, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 39.1. HRMS 







2,3-Bis(4-(trifluoromethyl)phenyl)chromeno[4,3-b]pyrrol-4(1H)-one (3-3ae, 80 oC, 
24 h, 80%): 1H NMR (500 MHz, d6-DMSO): δ 12.75 (s, 1H), 8.29 (d, J = 7.4 Hz, 
1H), 7.81–7.49 (m, 9H), 7.47–7.33 (m, 2H). 13C NMR (125 MHz, d6-DMSO): δ 157.6, 
152.2, 137.9, 136.9, 135.5, 133.1, 131.9, 129.7, 129.6, 129.2, 128.9, 128.5, 128.3, 
126.0, 125.8, 125.7, 125.1, 125.0, 124.5, 123.8, 123.5, 122.4, 121.3, 117.2, 113.9, 
107.9, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 39.1. HRMS (ESI) Calcd for [C25H13F6NO2 – 








2,3-Di-o-tolylchromeno[4,3-b]pyrrol-4(1H)-one (3-3af, 80 oC, 24 h, 84%): 1H 
NMR (500 MHz, d6-DMSO): δ 12.82 (s, 1H), 8.16 (d, J = 7.6 Hz, 1H), 7.54–7.32 (m, 
3H), 7.32–7.07 (m, 6H), 7.05–6.95 (m, 2H), 2.12 (s, 6H). 13C NMR (125 MHz, 
d6-DMSO): δ 157.8, 151.7, 137.7, 137.6, 135.3, 134.1, 133.5, 131.6, 131.6, 131.4, 
130.5, 129.7, 129.1, 129.0, 127.4, 125.9, 125.3, 124.4, 121.8, 121.0, 117.1, 114.1, 
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107.6, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 39.1, 20.1, 20.0. HRMS (ESI) Calcd for 








2,3-Di-m-tolylchromeno[4,3-b]pyrrol-4(1H)-one (3-3ag, 90%): 1H NMR (500 MHz, 
d6-DMSO): δ 12.74 (s, 1H), 8.29 (d, J = 7.7 Hz, 1H), 7.50–7.47 (m, 1H), 7.45–7.35 
(m, 2H), 7.28 (s, 1H), 7.24–7.17 (m, 2H), 7.17–7.10 (m, 3H), 7.09–7.02 (m, 2H), 2.29 
(s, 3H), 2.27 (s, 3H). 13C NMR (125 MHz, d6-DMSO): δ 157.8, 151.7, 138.0, 137.0, 
135.7, 134.0, 133.7, 131.8, 131.5, 129.3, 128.9, 128.7, 128.3, 128.0, 127.9, 126.1, 
124.5, 122.2, 121.3, 117.1, 114.0, 107.4, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 39.1, 21.5. 










2,3-Bis(3,5-dimethylphenyl)chromeno[4,3-b]pyrrol-4(1H)-one (3-3ah, 93%): 1H 
NMR (500 MHz, d6-DMSO): δ 12.65 (s, 1H), 8.29 (dd, J = 7.6, 1.1 Hz, 1H), 
7.50–7.44 (m, 1H), 7.44–7.34 (m, 2H), 6.99 (s, 2H), 6.96–6.93 (m, 2H), 6.91 (s, 2H), 
2.23 (s, 6H), 2.20 (s, 6H). 13C NMR (125 MHz, d6-DMSO): δ 157.8, 151.7, 137.7, 
136.8, 135.6, 134.0, 133.6, 131.5, 129.6, 129.3, 128.9, 128.7, 126.5, 124.4, 122.2, 
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121.3, 117.1, 114.0, 107.5, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 39.1, 21.4. HRMS (ESI) 






2,3-Di(naphthalen-1-yl)chromeno[4,3-b]pyrrol-4(1H)-one (3-3ai, 62%): 1H NMR 
(500 MHz, d6-DMSO, 373 K): δ 12.91 (s, 1H), 8.27 (d, J = 7.7 Hz, 1H), 7.96–7.78 (m, 
5H), 7.73 (m, 1H), 7.59–7.25 (m, 11H). 13C NMR (125 MHz, d6-DMSO, 373 K): δ 
157.6, 152.3, 136.0, 134.2, 133.7, 133.6, 133.5, 132.9, 132.1, 129.8, 129.6, 129.2, 
128.9, 128.5, 128.2, 127.7, 126.9, 126.6, 126.4, 126.1, 125.9, 125.7, 125.4, 125.3, 
124.4, 122.2, 121.1, 117.2, 114.6, 109.0, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 39.1. 







2,3-Di(thiophen-2-yl)chromeno[4,3-b]pyrrol-4(1H)-one (3-3aj, 80 oC, 24 h, 60%): 
1H NMR (500 MHz, d6-DMSO): δ 12.91 (s, 1H), 8.25 (d, J = 7.6 Hz, 1H), 7.61 (d, J = 
5.1 Hz, 1H), 7.57 (d, J = 5.1 Hz, 1H), 7.53–7.45 (m, 2H), 7.44–7.35 (m, 2H), 
7.21–7.16 (m, 1H), 7.16–7.07 (m, 2H). 13C NMR (125 MHz, d6-DMSO): δ 157.4, 
151.9, 136.1, 133.5, 132.3, 129.9, 129.7, 128.1, 127.7, 127.6, 127.5, 124.6, 122.4, 
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117.2, 113.7, 113.6, 108.3, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 39.1. HRMS (ESI) Calcd 




H   
2,3-Diethylchromeno[4,3-b]pyrrol-4(1H)-one (3-3ak, 80 oC, 24 h, 63%): 1H NMR 
(500 MHz, d6-DMSO): δ 12.07 (s, 1H), 7.99 (d, J = 7.3 Hz, 1H), 7.43–7.29 (m, 3H), 
2.68 (qd, J = 7.4, 4.7 Hz, 4H), 1.24 (t, J = 7.6 Hz, 3H), 1.14 (t, J = 7.4 Hz, 3H). 13C 
NMR (125 MHz, d6-DMSO): δ 158.6, 151.4, 135.8, 134.0, 128.4, 124.3, 121.3, 120.5, 
117.1, 114.4, 106.8, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 39.1, 18.74, 17.6, 16.8, 15.4. 







3-3al (88%, r.r ~ 5:4): 1H NMR (500 MHz, d6-DMSO): δ 12.78 (m, 1H), 8.27 (m, 
1H), 7.70–6.90 (m, 12H), 0.26 (m, 9H). 13C NMR (125 MHz, d6-DMSO): δ 157.9, 
157.8, 151.7, 151.6, 139.9, 138.1, 135.9, 134.1, 134.0, 133.9, 133.7, 133.0, 132.0, 
131.6, 131.1, 130.5, 129.3, 129.1, 128.9, 128.3, 128.2, 128.0, 127.3, 124.5, 122.2, 
121.3, 121.0, 117.1, 113.9, 107.5, 107.2, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 39.1, -0.6, 









3-3am (92%, r.r ~ 2:1): 1H NMR (500 MHz, d6-DMSO): δ 12.72 (s, 1H), 8.35–8.13 
(m, 1H), 7.57–7.09 (m, 10H), 7.02–6.80 (m, 2H), 3.77 (m, 3H). 13C NMR (125 MHz, 
d6-DMSO): δ 159.3, 158.6, 157.9, 157.8, 151.7, 151.6, 135.7, 135.5, 134.0, 133.8, 
133.6, 132.2, 131.7, 131.1, 130.2, 129.3, 129.2, 128.9, 128.8, 128.1, 127.1, 125.6, 
124.5, 123.8, 122.1, 122.1, 120.9, 120.2, 117.1, 114.4, 114.0, 113.7, 107.4, 107.3, 
55.6, 55.4, 40.7, 40.4, 40.2, 39.9, 39.6, 39.3, 39.0. HRMS (ESI) Calcd for [C24H17NO3 





3-3ao (80 oC, 24 h, 81%, r.r ~ 1:1): 1H NMR (500 MHz, d6-DMSO): δ 12.82 (s, 1H), 
8.25 (m, 1H), 7.60–7.08 (m, 12H). 13C NMR (125 MHz, d6-DMSO): δ 163.1, 162.7, 
161.1, 160.8, 157.9, 157.8, 151.7, 135.9, 135.8, 134.1, 133.4, 133.1, 133.0, 131.4, 
131.1, 131.0, 129.9, 129.4, 129.0, 128.9, 128.4, 128.2, 128.0, 127.3, 124.5, 122.2, 
122.1, 121.1, 120.0, 117.1, 116.0, 115.9, 115.2, 115.0, 113.9, 107.4, 107.3, 40.7, 40.4, 










3-3ap (80 oC, 24 h, 83%, r.r ~ 2:1): 1H NMR (500 MHz, d6-DMSO): δ 12.85 (s, 1H), 
8.34–8.19 (m, 1H), 7.55–7.34 (m, 9H), 7.32–7.13 (m, 1H), 7.12–7.00 (m, 1H). 13C 
NMR (125 MHz, d6-DMSO): δ 157.6, 157.6, 151.8, 151.8, 136.0, 135.8, 135.3, 134.2, 
133.3, 132.9, 131.3, 129.5, 129.3, 129.0, 128.8, 128.4, 128.3, 127.9, 127.5, 127.3, 
127.2, 127.0, 126.7, 124.5, 122.3, 122.3, 121.7, 117.2, 117.1, 113.8, 113.8, 113.5, 
107.8, 107.6, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 39.1. HRMS (ESI) Calcd for 







3-3aq (85%, r.r ~ 2:1): 1H NMR (500 MHz, d6-DMSO): δ 12.74 (s, 1H), 8.25 (m, 
1H), 7.55–7.12 (m, 9H), 6.94 (m, 2H), 3.78 (m, 3H). 13C NMR (125 MHz, 
d6-DMSO): δ 163.0, 162.7, 161.1, 160.7, 159.5, 158.7, 157.9, 151.7, 151.6, 135.7, 
135.5, 134.2, 133.1, 132.7, 132.2, 131.0, 130.3, 130.1, 129.3, 128.3, 128.2, 125.5, 
124.5, 123.7, 122.1, 121.0, 119.1, 117.1, 116.1, 115.9, 115.2, 115.0, 114.5, 114.0, 
113.8, 107.4, 107.3, 55.7, 55.5, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 39.1. HRMS (ESI) 









3-Methyl-2-phenylchromeno[4,3-b]pyrrol-4(1H)-one (3-3ar, 80 oC, 24 h, 70%): 
1H NMR (500 MHz, d6-DMSO): δ 12.48 (s, 1H), 8.19 (d, J = 7.0 Hz, 1H), 7.69–7.60 
(m, 2H), 7.59–7.49 (m, 2H), 7.48–7.27 (m, 4H), 2.47 (s, 3H). 13C NMR (125 MHz, 
d6-DMSO): δ 158.9, 151.7, 135.1, 133.4, 131.8, 130.6, 129.1, 128.9, 128.2, 127.9, 
124.4, 121.9, 117.1, 115.8, 114.1, 108.5, 40.8, 40.5, 40.2, 39.9, 39.7, 39.4, 39.1, 10.9. 







Ethyl 4-oxo-3-phenyl-1,4-dihydrochromeno[4,3-b]pyrrole-2-carboxylate (3-3as, 
80 oC, 24 h, 40%): 1H NMR (300 MHz, d6-DMSO): δ 13.38 (s, 1H), 8.51 (dd, J = 7.8, 
1.2 Hz, 1H), 7.63–7.49 (m, 1H), 7.48–7.24 (m, 7H), 4.15 (q, J = 7.1 Hz, 2H), 1.06 (t, 
J = 7.1 Hz, 3H). 13C NMR (75 MHz, d6-DMSO): δ 160.6, 157.2, 152.3, 137.3, 132.5, 
131.0, 130.9, 130.7, 127.7, 127.2, 124.6, 123.4, 123.4, 117.2, 113.3, 107.8, 60.8, 40.8, 
40.5, 40.2, 39.9, 39.7, 39.4, 39.1, 14.1. HRMS (ESI) Calcd for [C20H15NO2 – H] - 
332.0928, found 332.0928. 
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Methyl 2-(2-hydroxyphenyl)-4,5-diphenyl-1H-pyrrole-3-carboxylate (3-4): A 
mixture of 3-3aa (0.2 mmol), MeI (2.4 mmol) and KOH (2.8 mmol) in DMSO (2.0 
mL) was stirred at 80 oC for 1 h. The crude product was cooled down and then 
purified by column chromatography on silica gel (eluent: EtOAc/Hexane = 1/8) to 
afford the desired product 3-4 in 86% yield. 1H NMR (500 MHz, CDCl3): δ 8.08 (d, J 
= 8.0 Hz, 1H), 7.55–7.13 (m, 13H), 3.98 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 
158.3, 152.2, 137.8, 135.0, 132.8, 131.5, 130.9, 130.3, 128.6, 128.6, 128.3, 127.5, 
126.7, 123.7, 122.8, 121.2, 118.1, 114.8, 107.5, 77.3, 77.0, 76.8, 35.4. HRMS (ESI) 
Calcd for [C24H19NO3 + H] + 371.1074, found 371.1060. 





























N-(3-benzoyl-2-oxo-2H-chromen-4-yl)benzamide (3-5): A mixture of 3-3aa (0.2 
mmol), iodobenzene diacetate (0.6 mmol) in 1,4-dioxane (2.0 mL) was stirred at r.t. in 
air under UV light (Rayonet UV reactor, 366 nm) for 12 h. The crude product was 
purified by column chromatography on silica gel (eluent: EtOAc/Hexane = 1/3) to 
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afford the desired product 3-5 in 87% yield. 1H NMR (500 MHz, CDCl3): δ 10.11 (s, 
1H), 8.00–7.88 (m, 4H), 7.84–7.74 (m, 1H), 7.73–7.65 (m, 1H), 7.61 (m, 2H), 7.49 (m, 
4H), 7.41 (m, 1H), 7.35 (m, 1H). 13C NMR (125 MHz, CDCl3): δ 194.2, 166.2, 159.3, 
153.9, 150.3, 137.0, 134.1, 133.9, 133.3, 132.2, 129.3, 129.0, 128.5, 127.9, 127.0, 
124.3, 117.2, 115.8, 115.6, 77.3, 77.0, 76.8. HRMS (ESI) Calcd for [C23H15NO4 + Na] 
+ 392.0893, found 392.0892. 
3.4.5 X-ray Crystallographic Analysis 
The configuration of the product 3-3da was assigned by X-ray crystallographic 
analysis (Figure 3.2). The other products of 3-3 were assigned by analogy. 




Table 3.5 Crystal data and structure refinement for 3-3da 
Empirical formula  C27 H26 N O4.50 S1.50 
Formula weight  484.58 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.474(7) Å α = 83.130(11)°. 
 b = 10.492(7) Å β = 71.200(10)°. 
 c = 11.959(8) Å γ = 72.255(10)°. 
Volume 1184.5(14) Å3 
Z 2 
Density (calculated) 1.359 Mg/m3 
Absorption coefficient 0.218 mm-1 
F(000) 510 
Crystal size 0.60 x 0.32 x 0.30 mm3 
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Theta range for data collection 1.80 to 27.50°. 
Index ranges -13<=h<=13, -13<=k<=13, -15<=l<=15 
Reflections collected 10136 
Independent reflections 4976 [R(int) = 0.0719] 
Completeness to theta = 27.50° 91.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9375 and 0.8804 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4976 / 47 / 370 
Goodness-of-fit on F2 1.700 
Final R indices [I>2sigma(I)] R1 = 0.1688, wR2 = 0.4412 
R indices (all data) R1 = 0.1957, wR2 = 0.4609 
Largest diff. peak and hole 1.207 and -1.131 e.Å-3 
The configuration of compound 3-5 was assigned by X-ray crystallographic analysis 
(Figure 3.3). 




Table 3.6 Crystal data and structure refinement for 3-5 
Empirical formula  C23 H15 N O4 
Formula weight  369.36 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 11.9460(8) Å α = 90°. 
 b = 9.8327(6) Å β = 95.4020(10)°. 
 c = 14.9424(10) Å γ = 90°. 
Volume 1747.4(2) Å3 
Z 4 
Density (calculated) 1.404 Mg/m3 
Absorption coefficient 0.097 mm-1 
F(000) 768 
Crystal size 0.42 x 0.37 x 0.23 mm3 
Theta range for data collection 2.09 to 27.49°. 
Index ranges -15<=h<=15, -12<=k<=11, -19<=l<=15 
Reflections collected 11913 
Independent reflections 3989 [R(int) = 0.0317] 
Completeness to theta = 27.49° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9780 and 0.9604 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3989 / 0 / 257 
Goodness-of-fit on F2 1.051 
Final R indices [I>2sigma(I)] R1 = 0.0461, wR2 = 0.1093 
R indices (all data) R1 = 0.0526, wR2 = 0.1131 







Direct Access to Highly Substituted 1-Naphthols through 
Palladium-Catalyzed Oxidative Annulation of 
































The Pd-catalyzed oxidative annulation coupling of benzoylacetates with alkynes 
is described. This process provides a concise route to the synthesis of highly 







The synthesis of aromatic and heterocyclic molecules is a hot topic due to the 
presence of these skeletal motifs in countless natural products and synthetic 
compounds that display important chemical, biological and medicinal properties.[119] 
1-Naphthol and its derivatives fall into this category. For example, mollugin (Figure 
4.1A) and its analogues have shown anti-viral activity against the hepatitis B 
virus.[120] Pentacycline (Figure 4.1B) indicates a broad spectrum of anti-bacterial 
activity against both Gram-positive and Gram-negative organisms.[121] The class of 
peryenequinone natural products (Figure 4.1C) have been identified as potent protein 
kinase C inhibitors and photodynamic cancer therapies.[122] Nigerone (Figure 4.1D) 
exhibits anti-tumor and anti-bacterial activities.[123] 



















































Despite some methods available for constructing 1-naphthol scaffolds,[124] these 
methods suffer from drawbacks such as high reaction temperature, rarely used starting 
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materials, multiple synthetic steps and limited substrate scope. Recently, 
transition-metal-catalyzed direct C-H functionalizations have attracted much attention 
due to its atom-economy, simple protocol and environmentally benign features.[99] 
While the transition-metal-catalyzed oxidative annulation reactions through direct 
C-H functionalization have proven to be a powerful tool in the assembly of numerous 
structural motifs, a detailed survey of the literature reveals that the one-step synthesis 
of highly substituted 1-naphthols from readily available starting materials has so far 
remained a major challenge. Very recently, Youn’s group reported a Pd(II)-catalyzed 
method to prepare 1-naphthols from alkenyl 1,3-dicarbonyl compounds or ar-
yl-substituted alkenyl β-ketoesters (Scheme 4.1a).[125] Wang and co-workers reported 
an example of Rh(III)-catalyzed cascade oxidative annulation reaction of ben-
zoylacetonitriles with alkynes, affording substituted naphthopyrans through in situ 
formed 1-naphthols as intermediates (Scheme 4.1b).[126] As part of our continued in-
terest in transition-metal-mediated C-C bond-forming processes,[101] we have devel-
oped a Pd-catalyzed oxidative annulation reaction of readily available benzoylacetates 
with unactivated internal alkynes, providing an efficient method for the preparation of 
substituted 1-naphthols (Scheme 4.1c). 

















































4.2 Results and Discussion 
4.2.1 Reaction Optimization 
Our investigation began with the Pd-catalyzed oxidative annulation of 
benzoylacetate 4-1a and diphenylacetylene 4-2a to give the corresponding 1-naphthol 
4-3aa (Table 4.1). Based on optimization experiments, the best results were obtained 
using Pd(OAc)2 as the catalyst and Cu(OAc)2 as the oxidant in DMSO (Table 4.1, 
entry 20). Under such conditions, conversion was complete within 24 h at 80 oC. No 
reaction was observed in the absence of Pd-catalyst (Table 4.1, entry 1). Variation of 
oxidants (Table 4.1, entries 6-12) or solvents (Table 4.1, entries 13-18) led to a 
significant decrease in yields. A low yield was achieved at a higher temperature due to 
the potential decomposition of starting materials (Table 4.1, entry 20). However, a 
lower temperature also led to a slow reaction conversion (Table 4.1, entry 21). More-
over, the yield was highly sensitive to the loading of catalyst Pd(OAc)2. When the 
loading of Pd(OAc)2 was decreased proportionally from 20 mol% to 10 mol%, a sig-
nificant decrease in yield was observed (Table 4.1, entry 18 vs entry 2). However, the 
use of 100 mol% Pd(OAc)2 did not improve the yield (Table 4.1, entry 19). Notably, 
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the amount of oxidant Cu(OAc)2 was identified to be another crucial factor (Table 4.1, 
entry 20 vs entry 18). Additionally, an inert atmosphere (N2) was essential to avoid the 
side aerobic oxidation of alkynes. 



















Entry Catalyst Oxidant Solvent Yield [%][b] 
  1[c, d] -- Cu(OAc)2 DMSO -- 
2 Pd(OAc)2 Cu(OAc)2 DMSO 22 
3 Pd(PPh3)2Cl2 Cu(OAc)2 DMSO 24 
4 Pd(TFA)2 Cu(OAc)2 DMSO 16 
5 PdCl2 Cu(OAc)2 DMSO 15 
 6[d] Pd(OAc)2 AgOAc DMSO -- 
7 Pd(OAc)2 CuOAc DMSO 12 
 8[d] Pd(OAc)2 CuCl2 DMSO -- 
9 Pd(OAc)2 PhI(OAc)2 DMSO < 5% 
 10[d] Pd(OAc)2 Oxones DMSO -- 
 11[d] Pd(OAc)2 K2S2O8 DMSO -- 
 12[d] Pd(OAc)2 BQ DMSO -- 
 13[d] Pd(OAc)2 Cu(OAc)2 Anisole -- 
 14[d] Pd(OAc)2 Cu(OAc)2 1,4-Dioxane -- 
 15[d] Pd(OAc)2 Cu(OAc)2 EtOH -- 
 16[d] Pd(OAc)2 Cu(OAc)2 MeCN -- 
17 Pd(OAc)2 Cu(OAc)2 DMA < 5% 
 18[e] Pd(OAc)2 Cu(OAc)2 DMSO 50 
 19[f] Pd(OAc)2 Cu(OAc)2 DMSO 51 
 20[g] Pd(OAc)2 Cu(OAc)2 DMSO 76 
 21[h] Pd(OAc)2 Cu(OAc)2 DMSO 24 
[a] Reaction conditions: DMSO (2.0 mL), 4-1a (0.2 mmol, 1.0 equiv.), 4-2a (0.4 mmol, 2.0 equiv.), Pd(OAc)2 (10 
mol%), Cu(OAc)2 (2.0 equiv.), 80 oC, 24 h, N2. [b] Isolated yield after column purification. [c] No catalyst. [d] No 
desired product. [e] Pd(OAc)2 (20 mol%). [f] Pd(OAc)2 (100 mol%). [g] Cu(OAc)2 (3.0 equiv.). [h] 120 oC. 
4.2.2 Substrate Scope 
With the optimized reaction condition in hand, our attention turned to an 
evaluation of the substrate scope of this reaction. Given the great value of 
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benzoylacetates, we utilized diphenylacetylene 4-2a to examine the substrate scope of 
4-1. To our delight, the optimized reaction condition allowed the oxidative 
annulations of benzoylacetates containing a variety of functional groups, delivering 
the corresponding 1-naphthol products 4-3 in moderate to high yields (Table 4.2). 
Notably, methoxy (Table 4.2, 4-3ca and 4-3oa), trifluoromethyl (Table 4.2, 4-3da, 
4-3ha and 4-3na) and bromo (Table 4.2, 4-3ga and 4-3ma) were valuable functional 
groups amenable for further decoration of the products. Excellent regioselectivity was 
observed when 3-bromo-substituted β-ketoester was employed (only one regioisomer 
was detected), favoring activation of the less hindered C-H bond (Table 4.2, 4-3ga). 
However, 3-fluoro- or 3-trifluoro-substituted benzoylacetates led to poor 
regioselectivity (Table 4.2, 4-3fa and 4-3ha). It is noteworthy that substrates bearing 
naphthalene ring and anthracene ring were also well tolerated, leading to valuable 
π-conjugated aromatic compounds (Table 4.2, 4-3pa and 4-3qa). 

























































































































































































































































































Encouraged by these results, we next explored the substrate scope of internal 
alkynes 4-2 that could potentially react with 4-1a in order to study the generality of 
the method (Table 4.3). The reaction showed broad substrate tolerance among internal 
alkynes. Electron-rich alkynes afforded high reaction yields (Table 4.3, 4-3ab to 
4-3ad, 4-3ah to 4-3ag), while electron-deficient alkynes were slightly less facile 
(Table 4.3, 4-3ae to 4-3ag). Heteroaryl, aliphatic and ester-containing alkynes were 
all tolerated (Table 4.3, 4-3ap, 4-3aq and 4-3ar). When asymmetrical internal alkynes 
were employed, two regioisomers were observed (Table 4.3, 4-3al to 4-aq). For 
highly electron-deficient internal alkyne 4-2r, only one regioisomer was formed 
(Table 4.3, 4-3ar). 
























































































































































































































































4.2.3 Competition Experiments 
To further understand the electronic effects, two competition experiments were 
conducted (Scheme 4.2). Electron-rich benzoylacetate 4-1j generally proceeded 
slightly faster than electron-deficient benzoylacetate 4-1l when they reacted with 
diphenylacetylene 4-2a (Scheme 4.2a, 4-3ja:4-3la = 5:4). Similarly, electron-rich 
alkyne 4-2b proceeded slightly faster than electron-deficient alkyne 4-2e (Scheme 
4.2b, 4-3ab:4-3ae = 10:7). These results implied that the electronic effects of 
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functional groups from both benzoylacetates 4-1 and internal alkynes 4-2 may have 
some effects on chemoselectivity.  



























































































4.2.4 Synthetic Transformations 
The versatility of this Pd-catalyzed oxidative annulation was also investigated. 
4-3aa was quantitatively converted to an important Tf-protected 1-naphthol 4-4 by the 
addition of 1.5 equivalents of trifluoromethanesulfonic anhydride (Tf2O) (Scheme 
4.3a). Under conditions of diphenyliodonium trifluoromethanesulfonate (Ph2IOTf) 
and potassium tert-butoxide (KOtBu), 4-3aa was converted to a diaryl ether 4-5 with 
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high yield (Scheme 4.3b). Followed with a reduction of 4-3aa, intermediate 4-6 was 
generated and further converted to a polycyclic dihydropyran 4-7 in high yield 
(Scheme 4.3c). 





















































Further manipulation of intermediate 4-4 offered an additional synthetic 
opportunity. For example, OTf group in 4-4 could be replaced by an alkyne group to 
afford 4-8 in 93% yield via Pd(PPh3)2Cl2-catalyzed Sonogashira coupling (Scheme 
4.4a). Pd(OAc)2-promoted Heck type alkenation of 4-4 led to the formation of 4-9 in 
94% yield (Scheme 4.4b). If formic acid was employed to react with 4-4, a reductive 
product 4-10 was obtained in quantitative yield (Scheme 4.4c). Gratifyingly, 
Pd(PPh3)4-promoted Suzuki coupling of 4-4 with 1-naphthyl boronic acid readily af-
forded binaphthyl product 4-11 (Scheme 4.4d), which could potentially be used as 
ligand in organometallic and coordination chemistry, or as functional material due to 
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its extended π-conjugated system. When 4-4 reacted with phenylboronic acid or iso-
butylboronic acid, Pd(PPh3)4-promoted Suzuki couplings also took place, respectively 
affording aryl- or alkyl- functionalized products 4-12 and 4-13 (Scheme 4.4e and 
Scheme 4.4f).   




































































Reaction conditions: a) 4-4 (0.1 mmol), phenylacetylene (0.3 mmol), Pd(PPh3)2Cl2 (10 mol%), CuBr (5 mol%), 
DIPEA (0.3 mmol), DMF (1.0 mL), 80 oC, 5 h, N2, 93% yield. b) 4-4 (0.1 mmol), ethyl acrylate (1.0 mmol), 
Pd(OAc)2 (20 mol%), PPh3 (60 mol%), toluene (1.0 mL), 110 oC, 6 h, N2, 94% yield. c) 4-4 (0.1 mmol), HCOOH 
(0.3 mmol), Pd(PPh3)4 (10 mol%), TEA (3.0 mmol), DMF (1.0 mL), 80 oC, 2 h, N2, 99% yield. d)  4-4 (0.1 mmol), 
1-naphthylboronic acid (0.15 mmol), Pd(PPh3)4 (10 mol%), K2CO3 (0.15 mmol), 4Å MS (50 mg), toluene (1.0 
mL), 80 oC, 2 h, N2, 98% yield. e) 4-4 (0.1 mmol), phenylboronic acid (0.15 mmol), Pd(PPh3)4 (10 mol%), K2CO3 
(0.15 mmol), toluene (1.0 mL), 80 oC, 2 h, N2, 97% yield. f) 4-4 (0.1 mmol), isobutylboronic acid (0.15 mmol), 
Pd(PPh3)4 (10 mol%), K2CO3 (0.15 mmol), toluene (1.0 mL), 80 oC, 2 h, N2, 45% yield. 
In addition to indicate the potentially synthetic practicability, a gram-scale syn-






























4.2.5 Mechanistic Investigation 
To gain insight into the mechanism, a significant kinetic isotope effect was 
measured by using 4-1a and 4-1r as substrates (Scheme 4.6). A KIE value of KH/KD = 
3.0 was obtained, suggesting that the cleavage of ortho-C-H bond of the phenyl ring 
was involved in the rate-determining step.[127] 



















































On the basis of known transition-metal-catalyzed C-H activation/oxidative an-
nulation reactions, we proposed a plausible mechanism (Scheme 4.7). Formation of 
substituted 1-naphthol 4-3aa presumably commences with the palladation of ben-
zoylacetate 4-1a to yield the palladium intermediate 4-14. The following syn-addition 
of intermediate 4-14 to diphenylacetylene 4-2a generates the vinylpalladium interme-
diate 4-15. Finally, intramolecular palladation of 4-15 leads to the formation of pal-
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ladabenzocycloheptanone 4-16. The catalytic cycle is completed by the liberation of 
product 4-3aa along with Pd(0) through reductive elimination.  


































In summary, we have developed an efficient synthesis of highly substituted 
1-naphthols. The method utilizes simple and readily available benzoylacetates and 
unactivated internal alkynes as starting materials and employs a direct 
Pd(II)-catalyzed oxidative annulation procedure involving C-H activation. The mild 
reaction condition, broad substrate scope compatability and the significance of 
1-naphthol scaffold should render this method attractive for both synthetic and me-
dicinal chemistry. We expect this new method to complement the existing methods to 




4.4 Experimental Section 
4.4.1 General information 
Chemicals and solvents were purchased from commercial suppliers and used as 
received. 1H and 13C NMR spectra were recorded on a Bruker ACF300 (300 MHz) or 
AMX500 (500 MHz) spectrometer. Chemical shifts were reported in parts per million 
(ppm) and the residual solvent peak was used as an internal reference. Multiplicity 
was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), 
dd (doublet of doublet), bs (broad singlet). Coupling constants were reported in Hertz 
(Hz). Low resolution mass spectra were obtained on a Finnigan/MAT LCQ spectrom-
eter in ESI mode or a Finnigan/MAT 95XL-T mass spectrometer in EI mode. All high 
resolution mass spectra were obtained on a Finnigan/MAT 95XL-T mass spectrome-
ter. For thin layer chromatography (TLC), Merck pre-coated TLC plates (Merck 60 
F254) were used. Compounds were visualized with a UV light at 254 nm. Flash 
chromatography separations were performed on Merck 60 (0.040-0.063 mm) mesh 
silica gel.  
The starting materials 4-1a to 4-1r were prepared according to the known pro-
cedures.[128] The substrates 4-2a, 4-2l, 4-2q and 4-2r are commercially available. The 
other substrates of 4-2 were prepared according to related reports.[104]  
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Methyl 1-hydroxy-3,4-diphenyl-2-naphthoate (4-3aa): 4-1a (0.2 mmol), 4-2a (0.4 
mmol), Pd(OAc)2 (0.04 mmol, 20 mol%) and Cu(OAc)2 (0.6 mmol, 3.0 equiv.) were 
added into DMSO (2.0 mL). The mixture was stirred at 80 oC under N2 atmosphere 
for 24 h. Work-up: The crude mixture was cooled down to room temperature and 
poured into ethyl acetate (40 mL), which was washed with brine (4*10 mL), dried 
with MgSO4 and filtered. The solvent was removed to obtain crude product, which 
was purified by column chromatography on silica gel, eluted by hexane to afford 53.9 
mg (76% yield) of the desired product 4-3aa as yellow solid. 1H NMR (500 MHz, 
CDCl3): δ 12.23 (s, 1H), 8.55 (d, J = 8.0 Hz, 1H), 7.58–7.47 (m, 2H), 7.40 (d, J = 8.0 
Hz, 1H), 7.23–7.15 (m, 3H), 7.13–7.01 (m, 5H), 7.00–6.94 (m, 2H), 3.42 (s, 3H). 13C 
NMR (125 MHz, CDCl3): δ 172.6, 160.5, 141.9, 138.8, 137.3, 135.7, 131.7, 131.4, 
129.8, 127.6, 126.8, 126.5, 125.8, 125.8, 124.2, 124.0, 106.6, 77.4, 77.2, 76.9, 51.9. 










Methyl 1-hydroxy-8-methyl-3,4-diphenyl-2-naphthoate (4-3ba) was isolated by 
column chromatography on silica gel, eluted by hexane to afford 64.8 mg (88% yield) 
of the desired product as white solid. 1H NMR (500 MHz, CDCl3): δ 12.59 (s, 1H), 
7.34–7.12 (m, 6H), 7.11–6.99 (m, 5H), 6.98–6.92 (m, 2H), 3.39 (s, 3H), 3.07 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ 173.1, 163.4, 142.2, 139.6, 138.3, 137.5, 137.2, 131.7, 
131.6, 129.7, 129.2, 127.7, 126.8, 126.4, 125.6, 125.4, 123.8, 107.0, 77.4, 77.2, 76.9, 







Methyl 1-hydroxy-8-methoxy-3,4-diphenyl-2-naphthoate (4-3ca) was isolated by 
column chromatography on silica gel, eluted by ethyl acetate/hexane = 1/10 to afford 
62.3 mg (81% yield) of the desired product as yellow solid. 1H NMR (500 MHz, 
CDCl3): δ 10.05 (s, 1H), 7.32–7.25 (m, 1H), 7.24–7.03 (m, 11H), 6.86 (d, J = 7.7 Hz, 
1H), 4.10 (s, 3H), 3.54 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 168.7, 156.7, 151.5, 
139.2, 138.9, 137.9, 136.1, 131.7, 130.3, 130.0, 127.8, 127.3, 127.2, 126.7, 126.6, 
121.1, 117.7, 114.1, 105.0, 77.4, 77.2, 76.9, 56.7, 52.1. HRMS (ESI) calcd for 









Methyl 1-hydroxy-3,4-diphenyl-8-(trifluoromethyl)-2-naphthoate (4-3da) was 
isolated by column chromatography on silica gel, eluted by hexane to afford 56.6 mg 
(67% yield) of the desired product as white solid. 1H NMR (500 MHz, CDCl3): δ  
12.45 (s, 1H), 8.02 (d, J = 7.4 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.47 (t, J = 8.0 Hz, 
1H), 7.24–7.15 (m, 3H), 7.13–7.04 (m, 3H), 7.01 (d, J = 6.7 Hz, 2H), 6.96 (d, J = 7.1 
Hz, 2H), 3.41 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 172.5, 159.2, 141.4, 138.9, 
138.8, 137.3, 131.9, 131.8, 131.7, 129.5, 128.0, 127.9, 127.7, 127.2, 127.0, 126.9, 
126.8, 126.7, 126.6, 126.4, 126.1, 125.8, 123.6, 121.5, 120.7, 109.3, 77.4, 77.2, 76.9, 







Methyl 1-hydroxy-7-methyl-3,4-diphenyl-2-naphthoate (4-3ea) was isolated by 
column chromatography on silica gel, eluted by hexane to afford 53.8 mg (73% yield) 
of the desired product as yellow solid (only one regioisomer). 1H NMR (500 MHz, 
CDCl3): δ 12.15 (s, 1H), 8.31 (s, 1H), 7.36–7.24 (m, 2H), 7.22–7.13 (m, 3H), 
7.11–6.99 (m, 5H), 6.98–6.93 (m, 2H), 3.41 (s, 3H), 2.55 (s, 3H). 13C NMR (125 
MHz, CDCl3): δ 172.7, 160.0, 142.0, 139.0, 136.3, 135.7, 134.0, 131.9, 131.7, 131.3, 
130.0, 127.6, 126.8, 126.4, 125.7, 124.3, 123.0, 106.7, 77.4, 77.2, 76.9, 51.9, 21.8. 









4-3fa was isolated by column chromatography on silica gel, eluted by hexane to af-
ford 47.7 mg (64% yield) of the desired product as two inseparable regioisomers (r.r. 
~ 5:4 based on 1H NMR). 1H NMR (500 MHz, CDCl3): δ 12.26–12.07 (m, 1H), 
8.57–7.98 (m, 1H), 7.51–7.36 (m, 1H), 7.29–7.14 (m, 2H), 7.14–6.99 (m, 7H), 
6.99–6.87 (m, 2H), 3.44–3.38 (m, 3H). 13C NMR (125 MHz, CDCl3): δ 172.4, 172.3, 
161.8, 160.2, 159.9, 159.8, 159.5, 158.2, 141.6, 141.2, 140.9, 140.8, 139.1, 138.6, 
136.6, 132.7, 131.6, 131.4, 130.7, 129.9, 129.8, 129.6, 127.8, 127.7, 127.0, 126.9, 
126.8, 126.7, 126.6, 126.1, 125.9, 125.8, 125.4, 125.3, 125.2, 120.3, 119.6, 119.4, 
115.9, 115.7, 108.0, 107.9, 107.5, 77.4, 77.2, 76.9, 52.1, 52.0. HRMS (ESI) calcd for 







Methyl 7-bromo-1-hydroxy-3,4-diphenyl-2-naphthoate (4-3ga) was isolated by 
column chromatography on silica gel, eluted by hexane to afford 46.8 mg (54% yield) 
of the desired product as yellow solid (only one isomer based on 1H NMR and 13C 
NMR). 1H NMR (500 MHz, CDCl3): δ 12.14 (s, 1H), 8.68 (d, J = 2.1 Hz, 1H), 7.54 
(dd, J = 8.9, 2.0 Hz, 1H), 7.29–7.23 (m, 1H), 7.23–7.14 (m, 3H), 7.13–7.03 (m, 3H), 
7.02–6.98 (m, 2H), 6.97–6.93 (m, 2H), 3.42 (s, 3H). 13C NMR (125 MHz, CDCl3): δ  
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172.3, 159.3, 141.5, 138.3, 137.8, 134.2, 132.9, 131.6, 131.4, 129.7, 128.7, 127.8, 
126.9, 126.7, 126.4, 126.0, 125.4, 120.1, 107.6, 77.4, 77.2, 76.9, 52.1. HRMS (ESI) 







4-3ha was isolated by column chromatography on silica gel, eluted by hexane to af-
ford 54.1 mg (64% yield) of the desired product as two inseparable regioisomers (r.r. 
~ 5:4 based on 1H NMR). 1H NMR (500 MHz, CDCl3): δ 12.26–12.06 (m, 1H), 
8.47–7.90 (m, 1H), 7.53–7.35 (m, 1H), 7.25–7.14 (m, 2H), 7.14–6.99 (m, 7H), 
6.98–6.89 (m, 2H), 3.44–3.38 (m, 3H). 13C NMR (125 MHz, CDCl3): δ 172.4, 172.3, 
161.7, 160.2, 159.9, 159.8, 159.5, 158.2, 141.6, 141.2, 140.8, 139.0, 138.6, 136.6, 
132.7, 131.6, 131.5, 131.4, 130.7, 130.6, 129.9, 129.8, 129.6, 129.5, 127.8, 127.7, 
127.6, 127.0, 126.9, 126.8, 126.7, 126.6, 126.5, 126.1, 126.0, 125.9, 125.8, 125.3, 
125.2, 125.1, 120.3, 120.3, 119.6, 119.4, 115.9, 115.7, 108.0, 107.9, 107.5, 107.4, 








Methyl 6-(tert-butyl)-1-hydroxy-3,4-diphenyl-2-naphthoate (4-3ia) was isolated by 
column chromatography on silica gel, eluted by hexane to afford 67.3 mg (82% yield) 
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of the desired product as white solid. 1H NMR (500 MHz, CDCl3): δ 12.19 (s, 1H), 
8.46 (d, J = 8.8 Hz, 1H), 7.63 (dd, J = 8.8, 1.7 Hz, 1H), 7.34 (d, J = 1.6 Hz, 1H), 
7.23–7.13 (m, 3H), 7.11–7.00 (m, 5H), 6.99–6.91 (m, 2H), 3.40 (s, 3H), 1.24 (s, 9H). 
13C NMR (125 MHz, CDCl3): δ 172.7, 160.4, 152.9, 142.1, 139.0, 137.3, 135.8, 131.7, 
131.5, 129.9, 127.6, 126.8, 126.4, 125.7, 124.5, 123.7, 122.3, 122.2, 106.0, 77.4, 77.2, 








Methyl 1-hydroxy-6-methyl-3,4-diphenyl-2-naphthoate (4-3ja) was isolated by 
column chromatography on silica gel, eluted by hexane to afford 66.3 mg (90% yield) 
of the desired product as yellow solid. 1H NMR (500 MHz, CDCl3): δ 12.21 (s, 1H), 
8.43 (d, J = 8.5 Hz, 1H), 7.40–7.35 (m, 1H), 7.24–7.13 (m, 4H), 7.11–6.99 (m, 5H), 
6.99–6.92 (m, 2H), 3.40 (s, 3H), 2.39 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 172.7, 
160.6, 142.1, 140.1, 139.0, 137.4, 136.0, 131.7, 130.9, 129.8, 127.9, 127.6, 126.8, 
126.4, 126.0, 125.7, 124.0, 122.4, 105.9, 77.4, 77.2, 76.9, 51.8, 22.3. HRMS (ESI) 









Methyl 1-hydroxy-3,4,6-triphenyl-2-naphthoate (4-3ka) was isolated by column 
chromatography on silica gel, eluted by hexane to afford 47.3 mg (55% yield) of the 
desired product as yellow solid. 1H NMR (500 MHz, CDCl3): δ 12.23 (s, 1H), 8.61 (d, 
J = 8.6 Hz, 1H), 7.80 (dd, J = 8.8, 1.5 Hz, 1H), 7.60 (s, 1H), 7.55–7.48 (m, 2H), 
7.43–7.37 (m, 2H), 7.36–7.30 (m, 1H), 7.23–7.14 (m, 3H), 7.12–7.02 (m, 5H), 
7.02–6.92 (m, 2H), 3.43 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 172.6, 160.4, 142.4, 
141.9, 140.9, 138.7, 137.9, 136.1, 131.7, 129.8, 129.0, 127.9, 127.7, 127.6, 126.9, 
126.6, 125.8, 125.4, 124.8, 124.7, 123.4, 106.7, 77.4, 77.2, 76.9, 51.9. HRMS (ESI) 







Methyl 6-fluoro-1-hydroxy-3,4-diphenyl-2-naphthoate (4-3la) was isolated by 
column chromatography on silica gel, eluted by hexane to afford 57.3 mg (77% yield) 
of the desired product as light-yellow solid. 1H NMR (500 MHz, CDCl3): δ 12.31 (s, 
1H), 8.55 (dd, J = 9.1, 6.0 Hz, 1H), 7.31–7.25 (m, 1H), 7.24–7.16 (m, 3H), 7.14–7.05 
(m, 3H), 7.04–6.92 (m, 5H), 3.43 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 172.5, 
164.6, 162.6, 160.5, 141.6, 138.7, 138.4, 137.7, 137.6, 131.5, 130.9, 130.9, 129.6, 
127.8, 127.2, 127.1, 126.9, 126.7, 125.9, 121.2, 115.8, 115.6, 110.9, 110.7, 106.2, 










Methyl 6-bromo-1-hydroxy-3,4-diphenyl-2-naphthoate (4-3ma) was isolated by 
column chromatography on silica gel, eluted by hexane to afford 38.9 mg (45% yield) 
of the desired product as yellow solid. 1H NMR (500 MHz, CDCl3): δ 12.20 (s, 1H), 
8.38 (d, J = 8.9 Hz, 1H), 7.60 (dd, J = 8.9, 1.8 Hz, 1H), 7.54 (d, J = 1.7 Hz, 1H), 
7.24–7.14 (m, 3H), 7.13–7.03 (m, 3H), 7.02–6.97 (m, 2H), 6.97–6.91 (m, 2H), 3.41 (s, 
3H). 13C NMR (125 MHz, CDCl3): δ 172.4, 160.3, 141.5, 138.8, 138.0, 136.9, 131.6, 
130.6, 129.7, 129.3, 129.0, 127.9, 126.9, 126.8, 126.0, 125.9, 125.0, 122.8, 107.0, 








Methyl 1-hydroxy-3,4-diphenyl-6-(trifluoromethyl)-2-naphthoate (4-3na) was 
isolated by column chromatography on silica gel, eluted by hexane to afford 60.8 mg 
(72% yield) of the desired product as white solid. 1H NMR (500 MHz, CDCl3): δ  
12.16 (s, 1H), 8.65 (d, J = 8.7 Hz, 1H), 7.74–7.66 (m, 2H), 7.26–7.15 (m, 3H), 
7.13–7.03 (m, 3H), 7.03–6.99 (m, 2H), 6.97–6.93 (m, 2H), 3.43 (s, 3H). 13C NMR 
(125 MHz, CDCl3): δ 172.3, 159.8, 141.3, 138.9, 137.7, 134.9, 132.1, 131.6, 131.5, 
131.4, 131.1, 130.9, 129.6, 127.9, 127.4, 127.0, 126.1, 125.7, 125.3, 125.3, 124.4, 
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124.3, 123.1, 121.5, 121.4, 120.9, 108.5, 77.4, 77.2, 76.9, 52.2. HRMS (ESI) calcd for 







Methyl 6-fluoro-1-hydroxy-8-methoxy-3,4-diphenyl-2-naphthoate (4-3oa) was 
isolated by column chromatography on silica gel, eluted by ethyl acetate/hexane = 1/8 
to afford 60.3 mg (75% yield) of the desired product as yellow solid. 1H NMR (500 
MHz, CDCl3): δ 9.88 (s, 1H), 7.24–7.15 (m, 3H), 7.14–7.05 (m, 5H), 7.03 (d, J = 6.8 
Hz, 2H), 6.75 (dd, J = 11.1, 1.9 Hz, 1H), 6.65 (dd, J = 9.9, 1.7 Hz, 1H), 4.09 (s, 3H), 
3.52 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 168.6, 162.3, 160.3, 158.5, 158.4, 151.8, 
139.0, 138.4, 136.6, 136.5, 131.5, 130.0, 129.9, 129.8, 127.9, 127.3, 126.9, 126.8, 
117.0, 111.3, 104.4, 104.3, 96.6, 96.4, 77.4, 77.2, 76.9, 57.0, 52.1. HRMS (ESI) calcd 






Methyl 1-hydroxy-3,4-diphenylanthracene-2-carboxylate (4-3pa) was isolated by 
column chromatography on silica gel, eluted by hexane to afford 60.7 mg (75% yield) 
of the desired product as yellow solid (only one regioisomer). 1H NMR (500 MHz, 
CDCl3): δ 12.70 (s, 1H), 9.16 (s, 1H), 8.11 (d, J = 8.1 Hz, 1H), 7.90 (s, 1H), 7.79 (d, J 
= 8.0 Hz, 1H), 7.53–7.42 (m, 2H), 7.32–7.17 (m, 3H), 7.15–6.94 (m, 7H), 3.44 (s, 3H). 
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13C NMR (125 MHz, CDCl3): δ 172.8, 162.1, 142.1, 139.1, 135.7, 134.1, 133.2, 131.8, 
131.3, 129.9, 129.1, 128.5, 127.8, 127.1, 126.8, 126.6, 126.0, 125.9, 125.7, 124.4, 






Methyl 11-hydroxy-8,9-diphenyltetraphene-10-carboxylate (4-3qa) was isolated 
by column chromatography on silica gel, eluted by hexane to afford 63.6 mg (70% 
yield) of the desired product as yellow solid (only one regioisomer). 1H NMR (500 
MHz, CDCl3): δ 12.69 (s, 1H), 9.89 (s, 1H), 8.96 (d, J = 8.2 Hz, 1H), 7.89–7.80 (m, 
2H), 7.73 (t, J = 7.4 Hz, 1H), 7.68–7.60 (m, 2H), 7.55 (d, J = 9.0 Hz, 1H), 7.33–7.21 
(m, 3H), 7.18–7.00 (m, 7H), 3.46 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 172.8, 
161.7, 142.0, 139.0, 136.4, 133.7, 133.4, 132.1, 131.8, 131.0, 130.8, 129.9, 128.7, 
128.5, 127.7, 127.4, 127.3, 126.8, 126.6, 126.1, 125.7, 123.5, 123.1, 118.7, 105.6, 









Methyl 1-hydroxy-3,4-di-p-tolyl-2-naphthoate (4-3ab) was isolated by column 
chromatography on silica gel, eluted by hexane to afford 65.0 mg (85% yield) of the 
desired product as light-yellow solid. 1H NMR (500 MHz, CDCl3): δ 12.05 (s, 1H), 
8.51 (d, J = 8.0 Hz, 1H), 7.56–7.44 (m, 2H), 7.39 (d, J = 8.2 Hz, 1H), 7.02 (d, J = 7.7 
Hz, 2H), 6.94–6.88 (m, 4H), 6.85 (d, J = 7.9 Hz, 2H), 3.42 (s, 3H), 2.31 (s, 3H), 2.26 
(s, 3H). 13C NMR (125 MHz, CDCl3): δ 172.7, 160.1, 138.9, 137.3, 136.0, 135.9, 
135.8, 135.0, 131.5, 131.4, 129.7, 129.6, 128.4, 127.6, 126.9, 125.6, 124.2, 123.9, 
107.0, 77.4, 77.2, 76.9, 51.9, 21.4, 21.3. HRMS (ESI) calcd for [C26H22O3 – H] - 






Methyl 3,4-bis(4-(tert-butyl)phenyl)-1-hydroxy-2-naphthoate (4-3ac) was isolated 
by column chromatography on silica gel, eluted by hexane to afford 70.0 mg (75% 
yield) of the desired product as yellow solid. 1H NMR (500 MHz, CDCl3): δ 12.14 (s, 
1H), 8.55–8.49 (m, 1H), 7.56–7.47 (m, 3H), 7.16 (d, J = 8.2 Hz, 2H), 7.05 (d, J = 8.2 
Hz, 2H), 6.90 (d, J = 8.1 Hz, 2H), 6.83 (d, J = 8.1 Hz, 2H), 3.41 (s, 3H), 1.26 (s, 9H), 
1.23 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 172.8, 160.2, 149.0, 148.3, 139.0, 137.7, 
135.8, 131.7, 131.3, 129.6, 129.5, 127.0, 125.6, 124.2, 124.0, 123.4, 106.8, 77.4, 77.2, 









Methyl 1-hydroxy-3,4-bis(4-methoxyphenyl)-2-naphthoate (4-3ad) was isolated 
by column chromatography on silica gel, eluted by ethyl acetate/hexane = 1/100 to 
afford 68.8 mg (83% yield) of the desired product as light-yellow solid. 1H NMR (500 
MHz, CDCl3): δ 12.08 (s, 1H), 8.54–8.47 (m, 1H), 7.55–7.46 (m, 2H), 7.41 (d, J = 7.8 
Hz, 1H), 6.93 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 6.76 (d, J = 8.5 Hz, 2H), 
6.66 (d, J = 8.5 Hz, 2H), 3.78 (s, 3H), 3.75 (s, 3H), 3.46 (s, 3H). 13C NMR (125 MHz, 
CDCl3): δ 172.7, 160.1, 158.1, 157.6, 137.2, 136.1, 134.5, 132.6, 131.3, 131.2, 130.8, 
129.7, 126.8, 125.7, 124.2, 124.0, 113.2, 112.4, 107.1, 77.4, 77.2, 76.9, 55.3, 55.2, 






Methyl 3,4-bis(4-fluorophenyl)-1-hydroxy-2-naphthoate (4-3ae) was isolated by 
column chromatography on silica gel, eluted by hexane to afford 53.1 mg (68% yield) 
of the desired product as light-yellow solid. 1H NMR (500 MHz, CDCl3): δ 12.32 (s, 
1H), 8.57–8.51 (m, 1H), 7.59–7.48 (m, 2H), 7.35 (d, J = 8.1 Hz, 1H), 7.00–6.87 (m, 
6H), 6.85–6.78 (m, 2H), 3.46 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 172.4, 162.6, 
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162.2, 160.9, 160.7, 160.3, 137.8, 136.5, 135.7, 134.6, 133.1, 131.2, 131.1, 130.6, 
130.1, 126.6, 126.1, 124.4, 124.2, 114.9, 114.8, 114.1, 113.9, 106.4, 77.4, 77.2, 76.9, 






Methyl 3,4-bis(4-chlorophenyl)-1-hydroxy-2-naphthoate (4-3af) was isolated by 
column chromatography on silica gel, eluted by hexane to afford 53.3 mg (63% yield) 
of the desired product as yellow solid. 1H NMR (500 MHz, CDCl3): δ 12.37 (s, 1H), 
8.62–8.50 (m, 1H), 7.61–7.52 (m, 2H), 7.34 (d, J = 7.9 Hz, 1H), 7.27–7.20 (m, 2H), 
7.17–7.09 (m, 2H), 6.99–6.95 (m, 2H), 6.94–6.90 (m, 2H), 3.49 (s, 3H). 13C NMR 
(125 MHz, CDCl3): δ 172.3, 161.1, 140.2, 137.1, 136.1, 135.5, 132.9, 132.8, 132.0, 
131.0, 130.2, 128.2, 127.3, 126.5, 126.2, 124.5, 124.2, 106.2, 77.4, 77.2, 76.9, 52.1. 






Methyl 1-hydroxy-3,4-bis(4-(trifluoromethyl)phenyl)-2-naphthoate (4-3ag) was 
isolated by column chromatography on silica gel, eluted by hexane to afford 35.3 mg 
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(36% yield) of the desired product as white solid. 1H NMR (500 MHz, CDCl3): δ  
12.46 (s, 1H), 8.57 (d, J = 8.0 Hz, 1H), 7.63–7.51 (m, 2H), 7.48 (d, J = 8.0 Hz, 2H), 
7.38 (d, J = 8.1 Hz, 2H), 7.29–7.25 (m, 1H), 7.14 (d, J = 8.0 Hz, 2H), 7.09 (d, J = 8.0 
Hz, 2H), 3.41 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 172.0, 161.5, 145.4, 142.4, 
135.9, 135.2, 131.9, 130.5, 130.0, 129.9, 129.3, 129.1, 128.8, 128.6, 128.3, 126.5, 
126.4, 125.4, 125.3, 124.9, 124.8, 124.6, 124.4, 124.1, 124.0, 123.2, 123.1, 105.8, 







4-3ah was isolated by column chromatography on silica gel, eluted by hexane to af-
ford 60.0 mg (78% yield) of the desired product as two inseparable regioisomers (r.r. 
~ 1:1 based on 1H NMR). 1H NMR (500 MHz, CDCl3): δ 12.13–12.07 (m, 1H), 
8.55–8.49 (m, 1H), 7.55–7.46 (m, 2H), 7.43–7.38 (m, 1H), 7.11–7.04 (m, 1H), 
7.01–6.92 (m, 2H), 6.87–6.72 (m, 5H), 3.43 (s, 3H), 2.25–2.21 (m, 3H), 2.20–2.16 (m, 
3H). 13C NMR (125 MHz, CDCl3): δ 172.7, 160.2, 141.7, 138.8, 138.7, 137.3, 137.0, 
136.9, 136.1, 136.0, 135.8, 132.5, 132.4, 131.6, 131.5, 130.6, 130.5, 129.7, 128.8, 
128.7, 127.4, 127.3, 127.1, 127.0, 126.9, 126.6, 126.4, 125.7, 124.2, 123.9, 106.8, 









4-3ai was isolated by column chromatography on silica gel, eluted by ethyl ace-
tate/hexane = 1/100 to afford 72.9 mg (88% yield) of the desired product as two in-
separable regioisomers (r.r. ~ 1:1 based on 1H NMR). 1H NMR (500 MHz, CDCl3): δ  
12.17–12.10 (m, 1H), 8.56–8.48 (m, 1H), 7.59–7.39 (m, 3H), 7.20–7.08 (m, 1H), 
7.07–6.98 (m, 1H), 6.78–6.56 (m, 5H), 6.55–6.48 (m, 1H), 3.71–3.60 (m, 6H), 3.46 (s, 
3H). 13C NMR (125 MHz, CDCl3): δ 172.5, 160.4, 160.3, 159.1, 159.0, 158.6, 158.5, 
143.1, 140.1, 136.8, 135.6, 131.1, 129.8, 128.7, 128.5, 127.9, 127.8, 126.9, 125.9, 
124.3, 124.2, 124.0, 122.7, 117.2, 117.0, 115.3, 112.7, 112.5, 112.1, 106.6, 77.4, 77.2, 







Methyl 3,4-bis(3,5-dimethylphenyl)-1-hydroxy-2-naphthoate (4-3aj) was isolated 
by column chromatography on silica gel, eluted by hexane to afford 58.3 mg (71% 
yield) of the desired product as yellow solid. 1H NMR (500 MHz, CDCl3): δ 12.04 (s, 
1H), 8.57–8.39 (m, 1H), 7.54–7.46 (m, 2H), 7.46–7.42 (m, 1H), 6.78 (s, 1H), 6.66 (s, 
1H), 6.64 (s, 2H), 6.59 (s, 2H), 3.45 (s, 3H), 2.20 (s, 6H), 2.15 (s, 6H). 13C NMR (125 
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MHz, CDCl3): δ 172.8, 159.9, 141.5, 138.6, 137.4, 136.6, 135.8, 135.7, 131.7, 129.5, 
127.8, 127.1, 125.6, 124.0, 123.9, 106.9, 77.4, 77.2, 76.9, 51.9, 21.3, 21.2. HRMS 




4-3ak was isolated by column chromatography on silica gel, eluted by hexane to af-
ford 71.9 mg (79% yield) of the desired product as two inseparable regioisomers (r.r. 
~ 1:1 based on 1H NMR). 1H NMR (500 MHz, CDCl3): δ 12.32–12.26 (m, 1H), 
8.63–8.57 (m, 1H), 7.75–7.45 (m, 10H), 7.45–7.30 (m, 5H), 7.29–7.16 (m, 2H), 3.28 
(s, 3H). 13C NMR (125 MHz, CDCl3): δ 172.6, 160.6, 139.5, 139.4, 137.2, 136.4, 
136.3, 136.0, 133.0, 132.8, 132.7, 132.1, 131.7, 131.5, 130.8, 130.3, 129.9, 129.8, 
129.6, 128.7, 128.5, 128.1, 127.9, 127.8, 127.7, 127.6, 127.5, 127.3, 126.9, 126.2, 
125.9, 125.8, 125.7, 125.4, 124.4, 124.1, 106.9, 77.4, 77.2, 76.9, 51.9. HRMS (ESI) 





4-3al was isolated by column chromatography on silica gel, eluted by hexane to af-
ford 63.1 mg (74% yield) of the desired product as two inseparable regioisomers (r.r. 
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~ 4:1 based on 1H NMR). 1H NMR (500 MHz, CDCl3): δ 12.16–12.11 (m, 1H), 
8.56–8.50 (m, 1H), 7.56–7.46 (m, 2H), 7.44–7.38 (m, 1H), 7.36–7.30 (m, 2H), 
7.25–7.13 (m, 1H), 7.11–6.90 (m, 6H), 3.44–3.35 (m, 3H), 0.26–0.18 (m, 9H). 13C 
NMR (125 MHz, CDCl3): δ 172.6, 160.4, 142.3, 141.8, 139.2, 138.8, 138.2, 137.3, 
137.2, 135.8, 135.7, 132.6, 131.7, 131.4, 131.3, 131.0, 129.8, 129.2, 127.6, 126.9, 
126.8, 126.4, 125.8, 125.7, 124.3, 124.0, 106.8, 106.7, 77.4, 77.2, 76.9, 51.9, -1.0. 





4-3am was isolated by column chromatography on silica gel, eluted by ethyl ace-
tate/hexane = 1:100 to afford 61.5 mg (80% yield) of the desired product as two in-
separable regioisomers (r.r. ~ 1.5:1 based on 1H NMR). 1H NMR (500 MHz, CDCl3): 
δ 12.18–12.04 (m, 1H), 8.55–8.50 (m, 1H), 7.56–7.45 (m, 2H), 7.44–7.35 (m, 1H), 
7.24–7.05 (m, 3H), 7.05–6.95 (m, 2H), 6.95–6.84 (m, 2H), 6.77–6.60 (m, 2H), 
3.79–3.71 (m, 3H), 3.49–3.38 (m, 3H). 13C NMR (125 MHz, CDCl3): δ 172.7, 172.6, 
160.3, 158.2, 157.7, 142.1, 139.1, 137.6, 136.9, 136.2, 135.8, 134.4, 132.7, 131.7, 
131.1, 130.9, 129.8, 129.7, 127.7, 126.9, 126.8, 126.4, 125.8, 125.7, 124.3, 124.2, 
124.0, 113.2, 112.4, 107.0, 106.8, 77.4, 77.2, 76.9, 55.3, 52.1, 51.9. HRMS (ESI) 







4-3ao was isolated by column chromatography on silica gel, eluted by hexane to af-
ford 49.2 mg (66% yield) of the desired product as two inseparable regioisomers (r.r. 
~ 1.2:1 based on 1H NMR). 1H NMR (500 MHz, CDCl3): δ 12.29–12.21 (m, 1H), 
8.57–8.51 (m, 1H), 7.58–7.47 (m, 2H), 7.41–7.33 (m, 1H), 7.25–7.15 (m, 2H), 
7.15–7.05 (m, 1H), 7.04–6.86 (m, 5H), 6.83–6.76 (m, 1H), 3.49–3.39 (m, 3H). 13C 
NMR (125 MHz, CDCl3): δ 172.5, 162.6, 162.2, 160.7, 160.6, 160.3, 141.8, 138.8, 
137.9, 137.7, 136.1, 135.8, 134.8, 134.7, 133.2, 131.8, 131.6, 131.3, 130.3, 129.9, 
129.8, 127.8, 127.0, 126.9, 126.6, 126.0, 125.9, 124.4, 124.2, 124.1, 114.8, 114.6, 
113.9, 113.7, 106.6, 106.5, 77.4, 77.2, 76.9, 52.0, 51.9. HRMS (ESI) calcd for 





4-3ap was isolated by column chromatography on silica gel, eluted by hexane to af-
ford 33.2 mg (46% yield) of the desired product as two inseparable regioisomers (r.r. 
~ 2:1 based on 1H NMR). 1H NMR (500 MHz, CDCl3): δ 12.40–12.00 (m, 1H), 
8.55–8.45 (m, 1H), 7.65–7.01 (m, 9H), 6.92–6.53 (m, 2H), 3.68–3.13 (m, 3H). 13C 
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NMR (125 MHz, CDCl3): δ 172.4, 172.4, 161.3, 160.2, 142.7, 141.8, 139.9, 139.5, 
138.7, 136.7, 135.5, 133.5, 131.7, 131.3, 130.2, 129.9, 129.8, 129.7, 129.4, 129.3, 
127.7, 127.1, 126.9, 126.8, 126.6, 126.3, 126.2, 126.1, 126.0, 125.8, 125.2, 124.7, 
124.3, 124.1, 124.0, 123.5, 107.5, 106.8, 77.4, 77.2, 76.9, 52.4, 52.0. HRMS (ESI) 






4-3aq was isolated by column chromatography on silica gel, eluted by hexane to af-
ford 51.0 mg (87% yield) of the desired product as two inseparable regioisomers (r.r. 
~ 1:1 based on 1H NMR). 1H NMR (500 MHz, CDCl3): δ 12.49 (s, 1H), 8.53–8.36 (m, 
1H), 7.52–7.46 (m, 2H), 7.46–7.40 (m, 3H), 7.24–7.16 (m, 3H), 4.01 (s, 3H), 2.33 (s, 
3H). 13C NMR (125 MHz, CDCl3): δ 172.5, 160.4, 160.3, 159.1, 159.0, 158.6, 158.5, 
143.1, 140.1, 136.8, 135.6, 131.1, 129.8, 128.7, 128.5, 127.9, 127.8, 126.9, 125.9, 
124.3, 124.2, 124.0, 122.7, 117.2, 117.0, 115.3, 112.7, 112.5, 112.1, 106.6, 77.4, 77.2, 






1-Ethyl 3-methyl 4-hydroxy-2-phenylnaphthalene-1,3-dicarboxylate (4-3ar) was 
isolated by column chromatography on silica gel, eluted by ethyl acetate/hexane = 
1/50 to afford 35.0 mg (50% yield) of the desired product as white solid. 1H NMR 
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(500 MHz, CDCl3): δ 12.40 (s, 1H), 8.50 (d, J = 8.4 Hz, 1H), 7.61–7.50 (m, 2H), 
7.48–7.36 (m, 4H), 7.36–7.29 (m, 2H), 4.00–3.91 (m, 5H), 1.00 (t, J = 7.2 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ 170.7, 168.7, 161.3, 136.9, 135.8, 131.1, 130.3, 130.0, 
129.5, 128.1, 127.9, 126.9, 126.8, 125.0, 124.2, 102.2, 77.4, 77.2, 76.9, 61.1, 52.8, 
13.9. HRMS (ESI) calcd for [C21H18O5 – H] - 349.1081, found 349.1095. 
















































A mixture of 4-1j (19.2 mg, 0.1 mmol, 0.5 equiv.), 4-1l (19.6 mg, 0.1 mmol, 0.5 
equiv.), 4-2a (71.3 mg, 0.4 mmol, 2.0 equiv.), Pd(OAc)2 (9.0 mg, 0.04 mmol, 20 
mol %) and Cu(OAc)2 (109.0 mg, 0.6 mmol, 3.0 equiv.) were weighted in a Schlenk 
tube equipped with a stir bar. DMSO (2.0 mL) was added and the mixture was stirred 
at 80 °C for 12 h under N2 atmosphere. Work-up: The reaction mixture was cooled 
down to room temperature and then diluted with ethyl acetate (40 mL). The mixture 
was washed with brine (4*10 mL). The organic phase was dried with MgSO4. The 
mixture was filtered and then solvent was removed under reduced pressure to get 
crude product, which was purified by flash column chromatography on a short pad of 
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silica gel, eluted by hexane to afford a mixture. According to the 1H NMR spectrum, 











































A mixture of 4-1a (35.6 mg, 0.2 mmol, 1.0 equiv.), 4-2b (41.3 mg, 0.2 mmol, 1.0 
equiv.), 4-2e (42.8 mg, 0.2 mmol, 1.0 equiv.), Pd(OAc)2 (9.0 mg, 0.04 mmol, 20 
mol %) and Cu(OAc)2 (109.0 mg, 0.6 mmol, 3.0 equiv.) were weighted in a Schlenk 
tube equipped with a stir bar. DMSO (2.0 mL) was added and the mixture was stirred 
at 80 °C for 12 h under N2 atmosphere. Work-up: The reaction mixture was cooled 
down to room temperature and then diluted with ethyl acetate (40 mL). The mixture 
was washed with brine (4*10 mL). The organic phase was dried with MgSO4. The 
mixture was filtered and then the solvent was removed under reduced pressure to get 
the crude product, which was purified by flash column chromatography on a short pad 
of silica gel, eluted by hexane to afford a mixture. According to its 1H NMR spectrum, 
the mixture contained 4-3ab and 4-3ae in a rough ratio of 10:7.  
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4.4.4. Kinetic Study 
Independent Deuterium Competition Experiment  
Two sets of reactions were carried out in a parallel manner following the general pro-
cedure for 12 h. In each case, 4-2a was allowed to react with 4-1a and 4-1r. The ratio 
of 4-3aa to 4-3ra is 1.5:1, which was calculated according to the isolated yields from 






























































































































A mixture of 4-1a (17.8 mg, 0.1 mmol, 0.5 equiv.), 4-1r (18.3 mg, 0.1 mmol, 0.5 
equiv.), 4-2a (71.3 mg, 0.4 mmol, 2.0 equiv.), Pd(OAc)2 (9.0 mg, 0.04 mmol, 20 
mol %) and Cu(OAc)2 (109.0 mg, 0.6 mmol, 3.0 equiv.) were weighted in a Schlenk 
tube equipped with a stir bar. DMSO (2.0 mL) was added and the mixture was stirred 
at 80 °C for 12 h under N2 atmosphere. Work-up: The reaction mixture was cooled 
down to room temperature and then diluted with ethyl acetate (50 mL). The mixture 
was washed with brine (4*10 mL). The organic phase was dried with MgSO4. The 
mixture was filtered and then the solvent was removed under reduced pressure to af-
ford the crude product, which was purified by flash column chromatography on a 
short pad of silica gel, eluted by hexane to afford a mixture. According to its 1H NMR 
spectrum, the ratio of 4-3aa to 4-3ra is 3:1.   




























4-1a (891.0 mg, 5.0 mmol), 4-2a (1780.0 mg, 10.0 mmol), Pd(OAc)2 (224.5 mg, 1.0 
mmol, 20 mol%) and Cu(OAc)2 (2724.0 mg, 15.0 mmol, 3.0 equiv.) were added into 
DMSO (50 mL). The mixture was stirred at 80 ℃ under N2 atmosphere for 60 h. 
Work-up: The crude mixture was cooled down to room temperature and poured into 
ethyl acetate (500 mL), which was washed with brine (4*100 mL), dried with MgSO4 
and filtered. The solvent was removed to obtain crude product, which was purified by 
column chromatography on silica gel, eluted by hexane to afford the desired product 
4-3aa as yellow solid (1.24 g, 70% yield). 














Methyl 3,4-diphenyl-1-(trifluoromethylsulfonyloxy)-2-naphthoate (4-4): 4-3aa 
(354.4 mg, 1.0 mmol) was dissolved in DCM (5.0 mL) and then cooled to -78 oC. 
Triethylamine (TEA, 253.0 μL, 1.5 mmol) was added and then trifluoromethanesul-
fonic anhydride (Tf2O, 208.0 μL, 1.5 mmol) was added within 5 minutes via a syringe. 
The resulting solution was gradually warmed to room temperature and stirred for 2 h 
until 4-3aa had been completely consumed as determined by TLC. Work-up: The 
solvent was removed under reduced pressure to get crude product, which was purified 
by flash column chromatography on silica gel, eluted by ethyl acetate/hexane = 1/100 
to afford pure product 4-4 as yellow solid (480.0 mg, 99% yield). 1H NMR (500 MHz, 
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CDCl3): δ 8.28 (d, J = 8.6 Hz, 1H), 7.70 (t, J = 7.6 Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 
7.58–7.51 (m, 1H), 7.30–7.23 (m, 3H), 7.18–7.13 (m, 3H), 7.13–7.04 (m, 4H), 3.52 (s, 
3H). 13C NMR (125 MHz, CDCl3): δ 165.6, 140.9, 140.4, 138.2, 137.3, 136.7, 134.5, 
131.0, 130.0, 128.7, 128.3, 128.0, 127.6, 127.5, 127.2, 126.4, 126.0, 122.5, 122.0, 
120.0, 117.4, 114.9, 77.4, 77.2, 76.9, 52.5. HRMS (EI) calcd for [C25H17O5F3S] + 
486.0749, found 486.0743. 























4-3aa 4-5  
Methyl 1-phenoxy-3,4-diphenyl-2-naphthoate (4-5): 4-3aa (35.4 mg, 0.1 mmol), 
diphenyliodonium trifluoromethanesulfonate (Ph2IOTf, 86.0 mg, 0.2 mmol), potas-
sium tert-butoxide (KOtBu, 22.4 mg, 0.2 mmol) and THF (1.0 mL) were added in a 
Schlenk tube. Then the mixture was stirred at 70 °C for 2 h until 4-3aa had been 
completely consumed as determined by TLC. Work-up: The solvent was removed 
under reduced pressure to obtain crude product, which was purified by flash column 
chromatography on silica gel, eluted by ethyl acetate/hexane = 1/50 to afford pure 
product 4-5 as yellow solid (40.5 mg, 94% yield). 1H NMR (500 MHz, CDCl3): δ  
8.06–7.98 (m, 1H), 7.66–7.58 (m, 1H), 7.48–7.40 (m, 2H), 7.33–7.21 (m, 5H), 
7.19–7.08 (m, 7H), 7.05–6.97 (m, 3H), 3.35 (s, 3H). 13C NMR (125 MHz, CDCl3): δ  
167.5, 159.5, 147.1, 138.8, 138.2, 136.8, 136.5, 134.6, 131.5, 130.3, 129.7, 127.9, 
 154 
 
127.8, 127.5, 127.0, 126.9, 126.7, 126.2, 123.2, 122.3, 116.1, 77.4, 77.2, 76.9, 52.1. 
HRMS (EI) calcd for [C30H22O3] + 430.1569, found 430.1567. 























2-(Hydroxymethyl)-3,4-diphenylnaphthalen-1-ol (4-6): Lithium aluminium hydride 
(LiAlH4, 19.0 mg, 0.5 mmol) was suspended in dry THF (1.0 mL) and a solution of 
4-3aa (70.9 mg, 0.2 mmol) in dry THF (1.0 mL) was added within 30 minutes via a 
syringe at 0 oC. After completion of the addition, the mixture was stirred at 0 oC for 
another 1.5 h until 4-3aa had been completely consumed as determined by TLC. 
Work-up: At 0 oC, the resulting mixture was carefully quenched by ethyl aceate. The 
crude mixture was directly purified by flash column chromatography on silica gel, 
eluted by ethyl acetate/hexane = 1/4 to afford pure product 4-6 as yellow solid (59.4 
mg, 91% yield). 1H NMR (500 MHz, d6-Acetone): δ 8.36 (d, J = 8.4 Hz, 1H), 
7.53–7.44 (m, 1H), 7.41–7.32 (m, 2H), 7.26–6.98 (m, 10H), 4.77 (s, 2H). 13C NMR 
(125 MHz, d6-Acetone): δ 205.3, 152.3, 139.7, 139.5, 137.9, 132.8, 131.5, 130.0, 
127.4, 127.4, 126.4, 126.2, 126.1, 124.7, 124.6, 121.7, 115.9, 62.7, 29.4, 29.3, 29.1, 



















2,5,6-Triphenyl-3,4-dihydro-2H-benzo[h]chromene (4-7): 4-6 (32.7 mg, 0.1 mmol), 
styrene (114.0 μL, 1.0 mmol), montmorillonite K10 (20.0 mg), lithium perchlorate 
(LiClO4, 21.3 mg, 0.2 mmol) and nitromethane (2.0 mL) were added in a Schlenk 
tube. Then the mixture was stirred at 80 °C for 1 h until 4-6 had been completely 
consumed as determined by TLC. Work-up: The solvent was removed to obtain crude 
product, which was purified by flash column chromatography on silica gel, eluted by 
ethyl acetate/hexane = 1/100 to afford pure product 4-7 as white solid (41.0 mg, 99% 
yield). 1H NMR (500 MHz, CDCl3): δ 8.41 (d, J = 8.4 Hz, 1H), 7.58 (d, J = 7.4 Hz, 
2H), 7.54–7.43 (m, 4H), 7.41–7.34 (m, 2H), 7.30–7.21 (m, 3H), 7.21–7.10 (m, 5H), 
7.08–7.03 (m, 1H), 7.02–6.97 (m, 1H), 5.37–5.20 (m, 1H), 2.84–2.73 (m, 1H), 
2.54–2.46 (m, 1H), 2.33–2.24 (m, 1H), 2.18–2.02 (m, 1H). 13C NMR (125 MHz, 
CDCl3): δ 149.5, 142.2, 140.2, 139.7, 139.6, 132.3, 131.8, 131.7, 131.1, 130.4, 130.3, 
128.7, 127.9, 127.7, 127.4, 126.7, 126.4, 126.3, 126.1, 126.0, 125.2, 124.7, 121.7, 




































Methyl 3,4-diphenyl-1-(phenylethynyl)-2-naphthoate (4-8): 4-4 (48.6 mg, 0.1 
mmol), phenylacetylene (33.0 μL, 0.3 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (Pd(PPh3)2Cl2, 7.0 mg, 0.01 mmol), copper(I) bromide (CuBr, 0.7 mg, 
0.005 mmol), diisopropylethylamine (DIPEA, 52.0 μL, 0.3 mmol) and DMF (1.0 mL) 
were added to an oven-dried 5-mL flask. The flask was capped and then backfilled 
with nitrogen (this was repeated two additional times). The reaction mixture was 
heated to 80 °C for 5 h until 4-4 had been completely consumed as determined by 
TLC. Work-up: The reaction mixture was cooled down to room temperature and then 
diluted with ethyl acetate (50 mL). The organic phase was washed with brine (4*10 
mL) and dried with MgSO4. The solvent was removed under reduced pressure to get 
crude product, which was purified by flash column chromatography on silica gel, 
eluted by ethyl acetate/hexane = 1/40 to afford pure product 4-8 as yellow solid (41.0 
mg, 93% yield). 1H NMR (500 MHz, CDCl3): δ 8.59 (d, J = 8.3 Hz, 1H), 7.68–7.59 
(m, 4H), 7.53–7.46 (m, 1H), 7.44–7.36 (m, 3H), 7.29–7.21 (m, 3H), 7.19–7.06 (m, 
7H), 3.64 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 169.2, 140.0, 138.8, 138.1, 136.6, 
135.6, 132.8, 132.2, 131.9, 131.2, 130.3, 128.9, 128.6, 127.8, 127.7, 127.5, 127.4, 
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127.1, 127.0, 126.9, 123.2, 118.3, 98.5, 85.1, 77.4, 77.2, 76.9, 52.3. HRMS (EI) calcd 
for [C32H22O2] + 438.1620, found 438.1617. 
































(E)-Methyl 1-(3-ethoxy-3-oxoprop-1-enyl)-3,4-diphenyl-2-naphthoate (4-9): 4-4 
(48.6 mg, 0.1 mmol), ethyl acrylate (106.4 μL, 1.0 mmol), palladium(II) aceate 
(Pd(OAc)2, 4.4 mg, 0.02 mmol), triphenylphosphine (PPh3, 15.7 mg, 0.06 mmol), po-
tassium carbonate (K2CO3, 27.6 mg, 0.2 mmol) and toluene (1.0 mL) were added to 
an oven-dried 5-mL flask. The flask was capped and then backfilled with nitrogen 
(this was repeated two additional times). The reaction mixture was heated to 110 °C 
for 6 h until 4-4 had been completely consumed as determined by TLC. Work-up: The 
reaction mixture was cooled down to room temperature and solvent was removed un-
der reduced pressure to get crude product, which was purified by flash column chro-
matography on silica gel, eluted by ethyl acetate/hexane = 1/15 to afford pure product 
4-9 as white solid (40.5 mg, 94% yield). 1H NMR (500 MHz, CDCl3): δ 8.33 (d, J = 
16.2 Hz, 1H), 8.14 (d, J = 8.5 Hz, 1H), 7.64–7.54 (m, 2H), 7.51–7.43 (m, 1H), 
7.28–7.20 (m, 3H), 7.17–7.07 (m, 7H), 6.38 (d, J = 16.2 Hz, 1H), 4.32 (q, J = 7.1 Hz, 
2H), 3.47 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 169.3, 
166.2, 141.4, 140.4, 138.8, 138.2, 135.7, 132.9, 132.5, 131.1, 130.3, 130.0, 127.8, 
 158 
 
127.7, 127.5, 127.4, 127.1, 127.0, 126.3, 125.3, 77.4, 77.2, 76.9, 60.9, 52.1, 14.4. 
HRMS (EI) calcd for [C29H24O4] + 436.1675, found 436.1684. 




























Methyl 3,4-diphenyl-2-naphthoate (4-10): 4-4 (48.6 mg, 0.1 mmol), formic acid 
(11.5 μL, 0.3 mmol), tetrakis(triphenylphosphine)palladium(0)  (Pd(PPh3)4, 11.5 mg, 
0.01 mmol), triethylamine (TEA, 41.6 μL, 0.3 mmol) and DMF (1.0 mL) were added 
to an oven-dried 5-mL flask. The flask was capped and then backfilled with nitrogen 
(this was repeated two additional times). The reaction mixture was heated to 80 °C for 
2 h until 4-4 had been completely consumed as determined by TLC. Work-up: The 
reaction mixture was cooled down to room temperature and diluted with ethyl acetate 
(50 mL). The organic phase was washed with brine (4*10 mL) and dried with MgSO4. 
The solvent was removed under reduced pressure to get crude product, which was pu-
rified by flash column chromatography on silica gel, eluted by ethyl acetate/hexane = 
1/40 to afford pure product 4-10 as white solid (34.8 mg, 99% yield). 1H NMR (500 
MHz, CDCl3): δ 8.41 (s, 1H), 8.03–7.95 (m, 1H), 7.58–7.52 (m, 2H), 7.50–7.45 (m, 
1H), 7.29–7.19 (m, 3H), 7.17–7.08 (m, 5H), 7.07–6.99 (m, 2H), 3.61 (s, 3H). 13C 
NMR (125 MHz, CDCl3): δ 169.2, 140.3, 140.0, 138.5, 137.2, 134.0, 131.9, 131.2, 
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130.4, 130.0, 129.9, 128.9, 128.2, 127.8, 127.2, 127.1, 126.9, 126.6, 126.4, 77.4, 77.2, 
76.9, 52.2. HRMS (EI) calcd for [C24H18O2] + 338.1307, found 338.1302. 


































Methyl 3,4-diphenyl-1,1'-binaphthyl-2-carboxylate (4-11): 4-4 (48.6 mg, 0.1 
mmol), 1-naphthylboronic acid (25.8 mg, 1.5 mmol), tetrakis- 
(triphenylphosphine)palladium(0) (Pd(PPh3)4, 11.5 mg, 0.01 mmol), potassium car-
bonate (K2CO3, 20.7 mg, 0.15 mmol), 4Å MS (50.0 mg) and toluene (1.0 mL) were 
added to an oven-dried 5-mL flask. The flask was capped and then backfilled with 
nitrogen (this was repeated two additional times). The reaction mixture was heated to 
80 °C for 2 h until 4-4 had been completely consumed as determined by TLC. 
Work-up: The reaction mixture was cooled down to room temperature and solvent 
was removed under reduced pressure to get crude product, which was purified by 
flash column chromatography on silica gel, eluted by ethyl acetate/hexane = 1/30 to 
afford pure product 4-11 as white solid (45.2 mg, 98% yield). 1H NMR (500 MHz, 
CDCl3): δ 8.01–7.90 (m, 2H), 7.69 (d, J = 8.5 Hz, 1H), 7.62–7.55 (m, 2H), 7.53–7.46 
(m, 2H), 7.44–7.04 (m, 14H), 2.96 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 169.3, 
139.4, 139.2, 138.6, 135.6, 135.6, 135.5, 134.0, 133.5, 133.2, 132.8, 132.1, 131.5, 
131.3, 130.6, 130.3, 128.6, 128.5, 128.2, 127.9, 127.8, 127.4, 127.2, 127.1, 127.0, 
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126.8, 126.5, 126.3, 126.0, 125.3, 77.4, 77.2, 76.9, 51.4. HRMS (EI) calcd for 
[C34H24O2] + 464.1776, found 464.1781. 































Methyl 1,3,4-triphenyl-2-naphthoate (4-12): 4-4 (48.6 mg, 0.1 mmol), phenyl-
boronic acid (18.3 mg, 0.15 mmol), tetrakis(triphenylphosphine)palladium(0) 
(Pd(PPh3)4, 11.5 mg, 0.01 mmol), potassium carbonate (K2CO3, 20.7 mg, 0.15 mmol) 
and toluene (1.0 mL) were added to an oven-dried 5-mL flask. The flask was capped 
and then backfilled with nitrogen (this was repeated two additional times). The reac-
tion mixture was heated to 80 °C for 2 h until 4-4 had been completely consumed as 
determined by TLC. Work-up: The reaction mixture was cooled down to room tem-
perature and then solvent was removed under reduced pressure to get crude product, 
which was purified by flash column chromatography on silica gel, eluted by ethyl ac-
etate/hexane = 1/30 to afford pure product 4-12 as white solid (40.0 mg, 97% yield). 
1H NMR (500 MHz, CDCl3): δ 7.7–7.67 (m, 1H), 7.66–7.61 (m, 1H), 7.53–7.40 (m, 
7H), 7.30–7.22 (m, 3H), 7.21–7.09 (m, 7H), 3.18 (s, 3H). 13C NMR (125 MHz, 
CDCl3): δ 169.6, 139.3, 138.9, 138.6, 138.0, 137.1, 135.3, 133.1, 133.0, 131.6, 131.3, 
130.5, 130.4, 128.2, 127.9, 127.8, 127.4, 127.2, 127.1, 127.0, 126.9, 126.8, 126.4, 
77.4, 77.2, 76.9, 51.6. HRMS (EI) calcd for [C30H22O2] + 414.1620, found 414.1616. 
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Methyl 1-isobutyl-3,4-diphenyl-2-naphthoate (4-13): 4-4 (48.6 mg, 0.1 mmol), 
isobutylboronic acid (18.3 mg, 1.5 mmol), tetrakis(triphenylphosphine)palladium(0) 
(Pd(PPh3)4, 11.5 mg, 0.01 mmol), potassium carbonate (K2CO3, 20.7 mg, 0.15 mmol) 
and toluene (1.0 mL) were added to an oven-dried 5-mL flask. The flask was capped 
and then backfilled with nitrogen (this was repeated two additional times). The reac-
tion mixture was heated to 80 °C for 2 h until 4-4 had been completely consumed as 
determined by TLC. Work-up: The reaction mixture was cooled down to room tem-
perature and solvent was removed under reduced pressure to get crude product, which 
was purified by flash column chromatography on silica gel, eluted by ethyl ace-
tate/hexane = 1/50 to afford pure product 4-13 as yellow solid (17.1 mg, 45% yield). 
1H NMR (500 MHz, CDCl3): δ 8.17 (d, J = 8.6 Hz, 1H), 7.59 (d, J = 8.5 Hz, 1H), 
7.57–7.50 (m, 1H), 7.45–7.38 (m, 1H), 7.29–7.17 (m, 3H), 7.16–7.01 (m, 7H), 3.42 (s, 
3H), 3.08 (d, J = 7.1 Hz, 2H), 2.28–2.16 (m, 1H), 1.02 (d, J = 6.5 Hz, 6H). 13C NMR 
(125 MHz, CDCl3): δ 170.7, 139.8, 138.8, 137.7, 135.6, 134.7, 133.4, 133.2, 131.4, 
130.4, 127.8, 127.7, 127.3, 126.8, 126.7, 126.6, 126.1, 125.2, 77.4, 77.2, 76.9, 51.6, 
39.2, 30.3, 23.1. HRMS (EI) calcd for [C28H26O2] + 394.1933, found 394.1930. 
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4.4.16 X-ray Crystallographic Analysis 
The configuration of the product 4-3oa was assigned by X-ray crystallographic 
analysis (Figure 4.2). The other products of 4-3 were assigned by analogy. 
Figure 4.2 X-ray structure of 4-3oa 
 
Table 4.4 Crystal data and structure refinement for 4-3oa 
Empirical formula  C25 H19 F O4 
Formula weight  402.40 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 6.1889(8) Å α = 90°. 
 b = 20.382(3) Å β = 98.036(3)°. 
 c = 14.951(2) Å  γ = 90°. 
Volume 1867.5(4) Å3 
Z 4 
Density (calculated) 1.431 Mg/m3 
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Absorption coefficient 0.103 mm-1 
F(000) 840 
Crystal size 0.50 x 0.30 x 0.28 mm3 
Theta range for data collection 1.70 to 27.48°. 
Index ranges -8<=h<=7, -21<=k<=26, -19<=l<=19 
Reflections collected 13050 
Independent reflections 4261 [R(int) = 0.0265] 
Completeness to theta = 27.48° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9717 and 0.9503 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4261 / 0 / 277 
Goodness-of-fit on F2 1.121 
Final R indices [I>2sigma(I)] R1 = 0.0418, wR2 = 0.1152 
R indices (all data) R1 = 0.0492, wR2 = 0.1306 








Iron-catalyzed Ene-type Propargylation of Diarylethylenes 



























The Iron-catalyzed ene-type reaction of propargylic alcohols with 1,1-diaryl al-
kenes is described. This process provides a concise route to the synthesis of a bi-
ologically and pharmaceutically important diarylalkenyl propargylic 1,4-enyne 









Iron as one of the most abundant metals on the earth has attracted much attention 
in modern catalysis. Owing to its inexpensive and environmental benign characteris-
tics, considerable efforts have focused on Fe-catalysis, which resulted in a series of 
novel Fe-catalyzed organic transformations.[129] 
The propargylic moiety is widely distributed in medicinal and organic chemistry 
due to the high synthetic value of alkyne functionality. The electron-rich triple bond, 
in combination with the acidic feature of the terminal acetylenic H-atom, makes it a 
versatile entity for further transformations. Various natural products, fine chemicals 
and pharmaceuticals containing propargylic subunits have been reported.[130] Conse-
quently, efficient routes to this important scaffold are desirable. One attractive method 
is the Brønsted acid catalyzed propargylation.[131] Another efficient way for making 
this propargylic moiety is the direct propargylation of (hetero)arenes with propargyl 
alcohols via metal catalyzed Friedel-Crafts type reaction (Scheme 5.1a). Since the 
discovery by Nicolas in 1988,[132] the propargylation of aromatic systems has attracted 
much attention. In 2002, Uemura and co-workers discovered that a stoichiometric 
amount of Ru-allenylidene reacted with 2-methylfuran, affording 5-propargylated 
2-methylfuran.[133a] Subsequently catalytic versions were developed via 
Ru-complexes.[133] In 2004, Toste and co-workers developed a mild Re-catalyzed 
propargylation of electron-rich arenes.[134] The example of Fe-catalyzed nucleophilic 
substitution of propargylic alcohols was disclosed by Zhan’s group in 2006.[135] More 
recently, Yoshimatsu et al. developed a Sc-catalyzed propargylation,[136] utilizing 
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(hetero)arenes, allylsilanes and vinyl silyl ethers as nucleophilies. However, the 
methods described above used α-arylated propargylic alcohols as highly reactive al-
kylation reagents via Friedel-Crafts-type reactions. Herein, we have developed an 
Fe-catalyzed ene-type alkylation reaction of 1,1-diarylethylenes with propargyl alco-
hols (Scheme 5.1b).  























































5.2 Results and Discussion 
We began our investigation by examining FeCl3-catalyzed reactions of various 
alkenes 5-1 with 1-phenyl-2-propyn-1-ol 5-2a. The initial results showed that the use 
of a catalytic amount of anhydrous FeCl3 (10 mol%) could not enable a reaction be-
tween styrene and 1-phenyl-2-propyn-1-ol 5-2a (Table 5.1, entry 1). Meanwhile, we 
also tested the reactivities of trans-stilbene and cyclopentene. The results showed that 
a sluggish reaction or no reaction happened within 48 h (Table 5.1, entry 2 and entry 
3). When we tried to use a strong electron-withdrawing group (Cl) or a elec-
tron-donating group (Me), no desired compound was obtained (Table 5.1, entry 4 and 
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entry 5). Surprisingly, if 1,1-diphenylethylene was used, the reaction went smoothly 
and efficiently (Table 5.1, entry 6). We deduced that the phenyl group played a criti-
cal role on stabilizing the cationic intermediate during the ene-type reaction. 












































































Having this finding in hand, we started to optimize this ene-type substitution re-
action conditions. During our investigation of different metal salts catalyzed reaction 
of 1,1-diphenylethylene 5-1a with 1-phenylprop-2-yn-1-ol 5-2a in CH3CN, 
FeCl3·6H2O was discovered to be the most efficient and afforded the highest yield of 
5-3aa (Table 5.2).  























Entry Catalyst Yield [%][b]  
1 FeCl3 74 
2 FeCl3 ·6H2 O 77 
3 FeBr3 56 
4 Fe2(SO4)3·H2O < 10 
5 Fe(acac)3 < 10 
6 Fe(NO3)3·9H2O 52 
7 FeCl2 15 
8 FeBr2 < 10 
9 Fe(OAc)2 < 10 
10 Fe(BF4)2·6H2O 51 
11 FeSO4·7H2O < 10 
12 Fe(ClO4)2·H2O 24 
13 FeS  < 10 
14 CuCl2  < 10 
15 CuCl  < 10 
16 AgOAc  < 10 
17 Zn(OTf)2 18 
[a] Reaction conditions: 1,1-diphenylethylene 5-1a (0.24 mmol, 1.2 equiv.), 1-phenylprop-2-yn-1-ol 5-2a (0.2 
mmol, 1.0 equiv), Cat. (10 mol%), 80 oC, MeCN (1.0 mL), 2 h. [b] Yield of isolated product after column chroma-
tography. 
Subsequently, we examined other reaction parameters in order to improve the 
reaction efficiency (Table 5.3). In general, higher reaction yields were obtained in less 
polar solvents (Table 5.3, entries 7-9). No reaction happened when high polar solvents 
were used (Table 5.3, entries 12-13). In addition, oxygen involved solvents were also 
not suitable for the reaction (Table 5.3, entries 10-11). We deduced that oxygen in-
volved solvents, such as THF and 1,4-dioxane, coordinated with Fe-catalyst and re-
sulted in the loss of Fe-catalytic activity. Either Lower or higher temperature did not 
favor this process (Table 5.3, entries 3-5).  






















Entry T [oC] Solvent Yield [%][b]  
1 80  DCE 74 
2 80  CH3 CN 77 
3 100 CH3CN 80 
4 60 CH3CN 70 
5 25 CH3CN 58 
6 80 Toluene 29 
7 80 EtOAc 62 
8 80 CH3NO2 70 
9 80 PhCF3 54 
10 80 1,4-Dioxane  < 10 
11 80 THF  < 10 
12 80 MeOH  < 10 
13 80 DMSO  < 10 
[a] Reaction conditions: 1,1-diphenylethylene 5-1a (0.24 mmol, 1.2 equiv.), 1-phenylprop-2-yn-1-ol 5-2a (0.2 
mmol, 1.0 equiv), FeCl3·6H2O (10 mol%), solvent (1.0 mL), 2 h. [b] Yield of isolated product after column chro-
matography. 
With the optimized reaction condition in hand, we then explored the substrate 
scope of this FeCl3·6H2O-catalyzed ene-type substitution reaction of 
1,1-diphenylethylene 5-1a with propargylic alcohols 5-2 (Table 5.4). A wide range of 
propargylic alcohols, with R1 being electron-donating groups or electron-withdrawing 
groups, as well as naphthalene ring or heterocyclic ring, all provided the desired 
products 5-3 in moderate to high yields (Table 5.4, 5-3aa to 5-3ar). It is noteworthy 
that alkenyl group could also be applied to R1 position (Table 5.4, 5-3as). Besides H, 
the R2 group could be aryl, heteroaryl or aliphatic substitutes (Table 5.4, 5-3at to 
5-3ay).  






















































































































































































































































































































Various symmetric and asymmetric 1,1-diphenylethylenes 5-2 were also exam-
ined and moderate to excellent yields were obtained (Table 5.5). Notably, asymmetric 
1,1-diphenylethylene 5-1d provided a good yield, but with poor regioselectivity (Z/E  
~ 1:1, Table 5.4, 5-3da). Heteroaryl propargylic alcohol 5-2r also reacted with 
1,1-diphenylethylenes to afford the desired products in moderate yields (Table 5.5, 
5-3br to 5-3cr).  




































































































Our postulated reaction pathway is summarized in Scheme 5.2. In the initial step, 
FeCl3·6H2O triggers the dehydroxylation of propargylic alcohol 5-2a to form the in-
termediate propargyl cation 5-4, which is in equilibrium with the corresponding 
sp2-hybridized allenylium cation 5-5. The subsequent ene-type nucleophilic addition 
of 1,1-diphenylethylene 5-1a to propargyl cation 5-4 leads to the intermediate 5-6. 
Finally, intermediate 5-6 undergoes a dehydrogenation step to afford the diarylalkenyl 
propargylic complex 5-3aa.  































In summary, we have developed an Fe-catalyzed reaction of propargylic alcohols 
with 1,1-diarylalkenes, which enabled us to trigger an ene-type substitution process to 
afford the diarylalkenyl propargylic 1,4-enyne framework in moderate to high chemi-
cal yields. Further manipulation of these compounds and the extension of this strategy 
to other substrates are currently underway. 
5.4 Experimental Section 
5.4.1 General Information 
Chemicals and solvents were purchased from commercial suppliers and used as 
received. 1H and 13C NMR spectra were recorded on a Bruker ACF300 (300 MHz) or 
AMX500 (500 MHz) spectrometer. Chemical shifts were reported in parts per million 
(ppm), and the residual solvent peak was used as an internal reference. Multiplicity 
was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), 
dd (doublet of doublet), bs (broad singlet). Coupling constants were reported in Hertz 
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(Hz). Low resolution mass spectra were obtained on a Finnigan/MAT LCQ 
spectrometer in ESI mode or a Finnigan/MAT 95XL-T mass spectrometer in EI mode. 
All high resolution mass spectra were obtained on a Finnigan/MAT 95XL-T mass 
spectrometer. For thin layer chromatography (TLC), Merck pre-coated TLC plates 
(Merck 60 F254) were used. Compounds were visualized with a UV light at 254 nm. 
Flash chromatography separations were performed on Merck 60 (0.040-0.063 mm) 
mesh silica gel.  
Starting materials 5-1a and 5-2a were commercially available. 5-1b to 5-1d,[137] 
and 5-2b to 5-2y[138] were prepared according to related literatures. 
















Pent-1-en-4-yne-1,1,3-triyltribenzene (5-3aa): To a solution of 5-1a (0.2 mmol) and 
5-2a (0.24 mmol) in CH3CN (1.0 mL), FeCl3·6H2O (10 mol%) was added. The reac-
tion mixture was stirred at 80 oC for 2 h. The crude product was purified by column 
chromatography on silica gel, eluted by hexane to afford the desired product 5-3aa as 
oil (77% yield). 1H NMR (300 MHz, CDCl3): δ 7.46–7.22 (m, 15H), 6.16 (d, J = 10.2 
Hz, 1H), 4.52 (dd, J = 10.2, 2.5 Hz, 1H), 2.40 (d, J = 3.0 Hz, 1H). 13C NMR (75 MHz, 
CDCl3): δ 142.1, 141.6, 140.0, 139.0, 129.8, 128.6, 128.5, 128.1, 127.6, 127.5, 127.3, 






Me   
(3-o-Tolylpent-1-en-4-yne-1,1-diyl)dibenzene (5-3ab, 3 h, 72% yield): 1H NMR 
(300 MHz, CDCl3): δ 7.72 (d, J = 7.5 Hz, 1H), 7.51–7.12 (m, 14H), 6.14 (d, J = 9.9 
Hz, 1H), 4.62 (dd, J = 9.9, 2.5 Hz, 1H), 2.44 (d, J = 2.5 Hz, 1H), 2.03 (s, 3H). 13C 
NMR (75 MHz, CDCl3): δ 142.3, 141.8, 139.1, 138.6, 135.7, 130.5, 129.9, 128.3, 
128.1, 127.7, 127.5, 127.3, 127.0, 126.4, 85.1, 77.4, 77.0, 76.6, 71.3, 34.8, 19.1. 
HRMS (EI) calcd for [C24H20] + 308.1565, found 308.1578. 
Ph
Ph
EtO   
(3-(2-Ethoxyphenyl)pent-1-en-4-yne-1,1-diyl)dibenzene (5-3ac, 2 h, 74% yield): 
1H NMR (300 MHz, CDCl3): δ 7.58 (dd, J = 7.6, 1.6 Hz, 1H), 7.44–7.15 (m, 12H), 
6.99–6.95 (m, 1H), 6.81 (d, J = 8.1 Hz, 1H), 6.12 (d, J = 9.8 Hz, 1H), 4.88 (dd, J = 
9.8, 2.5 Hz, 1H), 3.92 (m, 3H), 2.31 (d, J = 2.6 Hz, 1H), 1.17 (t, J = 7.0 Hz, 2H). 13C 
NMR (75 MHz, CDCl3): δ 155.8, 142.2, 141.8, 139.4, 130.0, 129.0, 128.5, 128.1, 
128.0, 127.7, 127.3, 127.2, 120.7, 111.7, 85.6, 77.4, 77.0, 76.6, 70.2, 63.7, 31.6, 14.7. 







(3-(2-(Allyloxy)phenyl)pent-1-en-4-yne-1,1-diyl)dibenzene (5-3ad, 2 h, 84% yield): 
1H NMR (300 MHz, CDCl3): δ 7.60 (dd, J = 7.6, 1.7 Hz, 1H), 7.46–7.18 (m, 12H), 
7.02–6.98 (m, 1H), 6.85–6.78 (m, 1H), 6.16 (d, J = 9.9 Hz, 1H), 5.89–5.79 (m, 1H), 
5.27–5.11 (m, 2H), 4.90 (dd, J = 9.9, 2.5 Hz, 1H), 4.52–4.34 (m, 2H), 2.32 (d, J = 2.6 
Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 155.4, 142.1, 142.0, 139.3, 133.3, 130.0, 
129.1, 128.5, 128.1, 128.0, 127.8, 127.6, 127.3, 121.0, 117.1, 112.1, 85.4, 77.4, 77.0, 
76.6, 70.3, 68.9, 31.8. HRMS (EI) calcd for [C26H22O] + 350.1671, found 350.1683. 
Ph
Ph
Cl   
(3-(2-Chlorophenyl)pent-1-en-4-yne-1,1-diyl)dibenzene (5-3ae, 24 h, 52% yield): 
1H NMR (300 MHz, CDCl3): δ 7.73 (dd, J = 8.1, 1.6 Hz, 1H), 7.46–7.16 (m, 14H), 
6.01 (d, J = 9.7 Hz, 1H), 4.82 (dd, J = 9.7, 2.5 Hz, 1H), 2.41 (d, J = 2.6 Hz, 1H). 13C 
NMR (75 MHz, CDCl3): δ 143.4, 141.8, 139.1, 138.0, 133.3, 129.9, 129.7, 129.1, 
128.3, 128.2, 128.1, 127.7, 127.6, 127.2, 126.3, 84.2, 77.4, 77.0, 76.6, 71.7, 35.1. 
HRMS (EI) calcd for [C23H17Cl] + 328.1019, found 328.1018. 
Ph
Ph
Br   
(3-(2-Bromophenyl)pent-1-en-4-yne-1,1-diyl)dibenzene (5-3af, 12 h, 73% yield): 
1H NMR (300 MHz, CDCl3): δ 7.63 (dd, J = 7.8, 1.6 Hz, 1H), 7.38 (dd, J = 8.0, 1.1 
Hz, 1H), 7.33–7.05 (m, 12H), 7.02–6.98 (m, 1H), 5.87 (d, J = 9.6 Hz, 1H), 4.70 (dd, J 
= 9.6, 2.5 Hz, 1H), 2.30 (d, J = 2.5 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 143.5, 
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141.9, 139.9, 139.1, 133.1, 130.0, 129.3, 128.6, 128.2, 128.1, 127.8, 127.6, 126.4, 





(3-(3-Phenoxyphenyl)pent-1-en-4-yne-1,1-diyl)dibenzene (5-3ag, 2 h, 73% yield): 
1H NMR (300 MHz, CDCl3): δ 7.44–7.19 (m, 13H), 7.15–7.08 (m, 2H), 7.03 (ddd, J 
= 6.4, 3.1, 1.4 Hz, 3H), 6.87 (dd, J = 8.1, 1.8 Hz, 1H), 6.13 (d, J = 10.2 Hz, 1H), 4.48 
(dd, J = 10.1, 2.4 Hz, 1H), 2.39 (d, J = 2.5 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ  
157.6, 157.0, 142.5, 142.0, 141.5, 138.9, 129.8, 128.5, 128.2, 127.7, 127.6, 127.5, 
123.3, 122.0, 119.0, 117.8, 117.1, 83.9, 77.4, 77.0, 76.6, 72.0, 36.9. HRMS (EI) calcd 




(3-(3-Chlorophenyl)pent-1-en-4-yne-1,1-diyl)dibenzene (5-3ah, 24 h, 50% yield): 
1H NMR (300 MHz, CDCl3): δ 7.58–7.06 (m, 15H), 6.11 (d, J = 10.1 Hz, 1H), 4.49 
(dd, J = 10.1, 2.4 Hz, 1H), 2.43 (d, J = 2.5 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 
142.8, 142.0, 141.3, 138.8, 134.5, 129.8, 129.7, 128.6, 128.2, 127.8, 127.7, 127.5, 
127.2, 125.6, 83.6, 77.4, 77.0, 76.6, 72.3, 36.8. HRMS (EI) calcd for [C23H17Cl] + 







(3-(4-Isopropylphenyl)pent-1-en-4-yne-1,1-diyl)dibenzene (5-3ai, 2 h, 85% yield): 
1H NMR (300 MHz, CDCl3): δ 7.48–7.18 (m, 15H), 6.18 (d, J = 10.2 Hz, 1H), 4.51 
(dd, J = 10.2, 2.4 Hz, 1H), 3.01–2.81 (m, 1H), 2.39 (d, J = 2.5 Hz, 1H), 1.26 (d, J = 
6.9 Hz, 6H). 13C NMR (75 MHz, CDCl3): δ 147.6, 141.9, 141.6, 139.1, 137.3, 129.9, 
128.5, 128.2, 128.1, 127.5, 127.2, 126.7, 84.6, 77.4, 77.0, 76.6, 71.5, 36.7, 33.7, 24.0. 





(3-(4-Methoxyphenyl)pent-1-en-4-yne-1,1-diyl)dibenzene (5-3aj, 1 h, 85% yield): 
1H NMR (300 MHz, CDCl3): δ 7.44–7.21 (m, 12H), 6.90–6.83 (m, 2H), 6.13 (d, J = 
10.2 Hz, 1H), 4.46 (dd, J = 10.2, 2.5 Hz, 1H), 3.80 (s, 3H), 2.39 (d, J = 2.5 Hz, 1H). 
13C NMR (75 MHz, CDCl3): δ 158.6, 141.8, 141.6, 139.1, 132.1, 129.8, 128.5, 128.4, 
128.3, 128.1, 127.6, 127.5, 114.0, 84.7, 77.4, 77.0, 76.6, 71.5, 55.3, 36.3. HRMS (EI) 





(3-(4-(Benzyloxy)phenyl)pent-1-en-4-yne-1,1-diyl)dibenzene (5-3ak, 1.5 h, 61% 
yield): 1H NMR (300 MHz, CDCl3): δ 7.48–7.23 (m, 18H), 7.00–6.90 (m, 2H), 6.15 
(d, J = 10.2 Hz, 1H), 5.07 (s, 2H), 4.49 (dd, J = 10.1, 2.5 Hz, 1H), 2.40 (d, J = 2.5 Hz, 
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1H). 13C NMR (75 MHz, CDCl3): δ 157.8, 141.8, 141.6, 139.1, 137.0, 132.4, 129.8, 
128.6, 128.5, 128.3, 128.1, 127.9, 127.6, 127.5, 127.4, 115.0, 84.6, 77.4, 77.0, 76.6, 





(3-(4-(Allyloxy)phenyl)pent-1-en-4-yne-1,1-diyl)dibenzene (5-3al, 1 h, 76% yield): 
1H NMR (300 MHz, CDCl3): δ 7.47–7.21 (m, 12H), 6.91–6.84 (m, 2H), 6.13 (d, J = 
10.1 Hz, 1H), 6.10–5.98 (m, 1H), 5.41 (dd, J = 17.3, 1.6 Hz, 1H), 5.29 (dd, J = 10.5, 
1.4 Hz, 1H), 4.62–4.44 (m, 2H), 4.46 (dd, J = 10.2, 2.5 Hz, 1H), 2.39 (d, J = 2.5 Hz, 
1H). 13C NMR (75 MHz, CDCl3): δ 157.6, 141.8, 141.6, 139.1, 133.3, 132.3, 129.8, 
128.5, 128.3, 128.1, 127.6, 127.5, 117.6, 114.9, 84.7, 77.4, 77.0, 76.6, 71.6, 68.9, 36.3. 





(3-(4-Fluorophenyl)pent-1-en-4-yne-1,1-diyl)dibenzene (5-3am, 6 h, 75% yield): 
1H NMR (300 MHz, CDCl3): δ 7.48–7.20 (m, 12H), 7.05–6.96 (m, 2H), 6.11 (d, J = 
10.1 Hz, 1H), 4.49 (dd, J = 10.1, 2.2 Hz, 1H), 2.41 (d, J = 2.5 Hz, 1H). 13C NMR (75 
MHz, CDCl3): δ 142.3, 141.4, 138.9, 129.8, 128.9, 128.8, 128.6, 128.2, 127.8, 127.7, 
127.6, 127.5, 115.5, 115.2, 84.2, 77.4, 77.0, 76.6, 72.0, 36.4. HRMS (EI) calcd for 







(3-(4-Chlorophenyl)pent-1-en-4-yne-1,1-diyl)dibenzene (5-3an, 8 h, 44% yield): 
1H NMR (300 MHz, CDCl3): δ 7.44–7.16 (m, 14H), 6.07 (d, J = 10.1 Hz, 1H), 4.46 
(dd, J = 10.1, 2.5 Hz, 1H), 2.38 (d, J = 2.5 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 
142.5, 141.4, 138.9, 138.5, 132.8, 129.7, 128.7, 128.6, 128.2, 127.7, 127.5, 83.8, 77.4, 





(3-(4-Bromophenyl)pent-1-en-4-yne-1,1-diyl)dibenzene (5-3ao, 12 h, 72% yield): 
1H NMR (300 MHz, CDCl3): δ 7.49–7.16 (m, 14H), 6.09 (d, J = 10.1 Hz, 1H), 4.47 
(dd, J = 10.1, 2.4 Hz, 1H), 2.41 (d, J = 2.5 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 
142.6, 141.4, 139.1, 138.9, 131.7, 129.7, 129.1, 128.6, 128.2, 127.7, 127.5, 127.4, 
120.9, 83.8, 77.4, 77.0, 76.6, 72.2, 36.6. HRMS (EI) calcd for [C23H17Br] + 372.0514, 




1-(1,1-Diphenylpent-1-en-4-yn-3-yl)naphthalene (5-3ap, 2 h, 90% yield): 1H NMR 
(300 MHz, CDCl3): δ 7.92–7.84 (m, 2H), 7.81 (d, J = 8.2 Hz, 1H), 7.62 (d, J = 8.4 Hz, 
1H), 7.56–7.42 (m, 7H), 7.39–7.35 (m, 1H), 7.27–7.13 (m, 5H), 6.24 (d, J = 9.9 Hz, 
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1H), 5.18 (dd, J = 9.9, 2.4 Hz, 1H), 2.53 (d, J = 2.5 Hz, 1H). 13C NMR (75 MHz, 
CDCl3): δ 142.3, 141.8, 139.1, 136.1, 133.9, 130.7, 130.0, 128.7, 128.5, 128.2, 128.1, 
127.9, 127.7, 127.5, 125.9, 125.6, 125.0, 123.6, 84.9, 77.4, 77.0, 76.6, 72.3, 34.8. 




2-(1,1-Diphenylpent-1-en-4-yn-3-yl)naphthalene (5-3aq, 2 h, 79% yield): 1H NMR 
(300 MHz, CDCl3): δ 7.87 (dd, J = 7.3, 4.0 Hz, 2H), 7.81 (d, J = 8.2 Hz, 1H), 7.61 (d, 
J = 8.5 Hz, 1H), 7.55–7.41 (m, 7H), 7.38–7.34 (m, 1H), 7.27–7.14 (m, 5H), 6.23 (d, J 
= 9.9 Hz, 1H), 5.16 (dd, J = 9.9, 2.5 Hz, 1H), 2.52 (d, J = 2.5 Hz, 1H). 13C NMR (75 
MHz, CDCl3): δ 142.3, 141.8, 139.1, 136.1, 134.0, 130.7, 130.0, 128.7, 128.5, 128.2, 
128.1, 127.9, 127.7, 127.5, 125.9, 125.6, 125.0, 123.6, 84.9, 77.4, 77.0, 76.6, 72.3, 





2-(1,1-Diphenylpent-1-en-4-yn-3-yl)thiophene (5-3ar, 2 h, 73% yield): 1H NMR 
(300 MHz, CDCl3): δ 7.44–7.23 (m, 10H), 7.19 (dd, J = 5.1, 1.1 Hz, 1H), 7.01–6.98 
(m, 1H), 6.94 (dd, J = 5.1, 3.5 Hz, 1H), 6.20 (d, J = 10.0 Hz, 1H), 4.71–4.64 (m, 1H), 
2.40 (d, J = 2.5 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 143.8, 142.6, 141.4, 138.7, 
129.7, 128.5, 128.2, 127.7, 127.6, 127.1, 126.9, 124.6, 83.6, 77.4, 77.0, 76.6, 71.3, 






(3-Ethynylpenta-1,4-diene-1,1,5-triyl)tribenzene (5-3as, 2 h, 76% yield, Z/E ~ 
1:1): 1H NMR (300 MHz, CDCl3): δ 7.53–7.21 (m, 30H), 6.73 (dd, J = 15.8, 1.4 Hz, 
1H), 6.53 (dd, J = 16.0, 6.3 Hz, 1H), 6.26 (dd, J = 8.9, 3.8 Hz, 2H), 6.12 (d, J = 10.0 
Hz, 1H), 5.65–5.59 (m, 1H), 4.33 (dd, J = 9.5, 7.0 Hz, 1H), 4.20–4.07 (m, 1H), 2.94 
(d, J = 2.2 Hz, 1H), 2.45 (d, J = 2.4 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 147.6, 
145.7, 142.9, 142.8, 142.2, 141.8, 141.6, 139.4, 139.0, 136.9, 130.6, 130.2, 129.7, 
129.6, 128.7, 128.5, 128.4, 128.2, 128.1, 127.6, 127.5, 127.4, 126.7, 126.4, 109.3, 
108.1, 83.6, 82.2, 81.8, 77.4, 77.0, 76.6, 71.9, 48.3, 45.8, 34.6. HRMS (EI) calcd for 





2-(1,1,5-Triphenylpent-1-en-4-yn-3-yl)thiophene (5-3at，0.5 h, 44% yield): 1H 
NMR (300 MHz, CDCl3): δ 7.39–7.12 (m, 15H), 7.10 (dd, J = 5.1, 1.1 Hz, 1H), 
6.96–6.92 (m, 1H), 6.85 (dd, J = 5.1, 3.5 Hz, 1H), 6.17 (d, J = 10.0 Hz, 1H), 4.79 (d, J 
= 9.9 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 144.7, 142.3, 141.5, 138.8, 131.7, 129.8, 
128.5, 128.2, 128.1, 127.7, 127.6, 127.5, 126.9, 124.5, 123.3, 89.1, 83.4, 77.4, 77.0, 






Pent-1-en-4-yne-1,1,3,5-tetrayltetrabenzene (5-3au，0.5 h, 81% yield): 1H NMR 
(300 MHz, CDCl3): δ 7.38–7.07 (m, 20H), 6.11 (d, J = 10.1 Hz, 1H), 4.61 (d, J = 10.1 
Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 141.7, 140.6, 139.2, 131.7, 129.9, 128.6, 
128.5, 128.2, 128.1, 127.9, 127.5, 127.4, 126.9, 123.6, 89.8, 84.0, 77.4, 77.0, 76.6, 





(3-(4-Isopropylphenyl)pent-1-en-4-yne-1,1,5-triyl)tribenzene (5-3av，0.5 h, 60% 
yield): 1H NMR (300 MHz, CDCl3): δ 7.51–7.42 (m, 4H), 7.41–7.36 (m, 5H), 
7.34–7.19 (m, 10H), 6.25 (d, J = 10.1 Hz, 1H), 4.72 (d, J = 10.1 Hz, 1H), 2.94–2.90 
(m, 1H), 1.27 (d, J = 6.9 Hz, 6H). 13C NMR (75 MHz, CDCl3): δ 147.5, 141.8, 141.5, 
139.3, 138.0, 131.7, 130.0, 128.7, 128.5, 128.2, 128.1, 127.8, 127.6, 127.5, 127.4, 
127.3, 126.7, 123.7, 90.1, 83.8, 77.3, 77.0, 76.8, 37.5, 33.7, 24.0. HRMS (EI) calcd 






(5-(4-tert-Butylphenyl)pent-1-en-4-yne-1,1,3-triyl)tribenzene (5-3aw, 0.5 h, 60% 
yield): 1H NMR (300 MHz, CDCl3): δ 7.45 (dd, J = 7.7, 4.5 Hz, 6H), 7.41–7.33 (m, 
7H), 7.29–7.23 (m, 6H), 6.25 (d, J = 10.1 Hz, 1H), 4.75 (d, J = 10.1 Hz, 1H), 1.33 (s, 
9H). 13C NMR (75 MHz, CDCl3): δ 151.1, 141.8, 141.6, 140.8, 139.2, 131.4, 130.0, 
128.7, 128.6, 128.5, 128.1, 127.6, 127.5, 127.4, 126.8, 125.2, 120.6, 89.0, 84.0, 77.3, 






3-(3,5,5-Triphenylpent-4-en-1-ynyl)thiophene (5-3ax, 2 h, 43% yield): 1H NMR 
(300 MHz, CDCl3): δ 7.49–7.30 (m, 10H), 7.29–7.21 (m, 7H), 7.15 (dd, J = 5.0, 1.1 
Hz, 1H), 6.22 (d, J = 10.1 Hz, 1H), 4.71 (d, J = 10.1 Hz, 1H). 13C NMR (75 MHz, 
CDCl3): δ 141.7, 140.6, 139.2, 130.1, 129.9, 128.6, 128.5, 128.4, 128.2, 128.1, 127.5, 
127.4, 126.9, 125.1, 122.6, 89.3, 79.0, 77.4, 77.0, 76.6, 37.9. HRMS (EI) calcd for 






(5-Cyclopropylpent-1-en-4-yne-1,1,3-triyl)tribenzene (5-3ay, 2 h, 53% yield): 1H 
NMR (300 MHz, CDCl3): δ 7.41 (t, J = 7.4 Hz, 2H), 7.38–7.27 (m, 7H), 7.25–7.20 (m, 
6H), 6.10 (d, J = 10.2 Hz, 1H), 4.44 (dd, J = 10.1, 0.8 Hz, 1H), 1.35–1.29 (m, 1H), 
0.79–0.74 (m, 2H), 0.72–0.67 (m, 2H). 13C NMR (75 MHz, CDCl3): δ 141.9, 141.2, 
141.0, 139.3, 129.9, 129.3, 128.4, 128.1, 127.5, 127.4, 127.3, 126.6, 87.1, 77.4, 77.0, 
76.6, 75.3, 37.2, 8.3, 0.2. HRMS (EI) calcd for [C26H22] + 334.1727, found 334.1727.  
Me Me  
4,4'-(3-Phenylpent-1-en-4-yne-1,1-diyl)bis(methylbenzene) (5-3ba, 2 h, 98% 
yield): 1H NMR (300 MHz, CDCl3): δ 7.32–7.20 (m, 4H), 7.19–7.09 (m, 5H), 
7.08–7.02 (m, 2H), 6.98 (d, J = 8.1 Hz, 2H), 6.01 (d, J = 10.1 Hz,1H), 4.45 (dd, J = 
10.1, 2.5 Hz, 1H), 2.32 (s, 3H), 2.31 (d, J = 2.5 Hz, 1H), 2.24 (s, 3H). 13C NMR (75 
MHz, CDCl3): δ 141.9, 140.2, 139.0, 137.3, 137.2, 136.2, 129.7, 129.1, 128.8, 128.6, 
127.5, 127.3, 127.0, 126.9, 84.6, 77.4, 77.0, 76.6, 71.6, 37.0, 21.3, 21.1. HRMS (EI) 
calcd for [C25H22] + 322.1722, found 322.1727. 
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Br Br  
4,4'-(3-Phenylpent-1-en-4-yne-1,1-diyl)bis(bromobenzene) (5-3ca, 11 h, 85% 
yield): 1H NMR (300 MHz, CDCl3): δ 7.50–7.43 (m, 2H), 7.31–7.13 (m, 8H), 
7.10–7.04 (m, 2H), 6.98–6.91 (m, 2H), 6.03 (d, J = 10.2 Hz, 1H), 4.34 (dd, J = 10.2, 
2.5 Hz, 1H), 2.30 (d, J = 2.5 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ 140.0, 139.4, 
137.4, 131.9, 131.5, 131.4, 129.1, 128.8, 127.2, 122.1, 121.9, 83.8, 77.4, 77.0, 76.6, 
72.2, 37.1. HRMS (EI) calcd for [C23H16Br2] + 451.9619, found 451.9636. 
Br  
(1-(4-Bromophenyl)pent-1-en-4-yne-1,3-diyl)dibenzene (5-3da, 2 h, 75% yield, 
Z/E ~ 1:1): 1H NMR (300 MHz, CDCl3): δ 7.61–7.55 (m, 1H), 7.49–7.18 (m, 12H), 
7.14–7.04 (m, 1H), 6.18–6.14 (m, 1H), 4.58–4.38 (m, 1H), 2.43–2.41 (m, 1H).  13C 
NMR (75 MHz, CDCl3): δ 141.1, 141.0, 140.1, 139.7, 138.5, 138.0, 131.8, 131.6, 
131.3, 129.8, 129.1, 128.7, 128.6, 128.3, 127.9, 127.8, 127.5, 127.3, 127.2, 127.1, 
121.8, 121.6, 84.1, 84.0, 77.4, 77.0, 76.6, 72.0, 71.9, 37.1. HRMS (EI) calcd for 






2-(1,1-Di-p-tolylpent-1-en-4-yn-3-yl)thiophene (5-3br, 2 h, 73% yield): 1H NMR 
(300 MHz, CDCl3): δ 7.28–7.11 (m, 9H), 7.06 (dd, J = 2.9, 1.7 Hz, 1H), 7.00 (dd, J = 
5.0, 3.5 Hz, 1H), 6.20 (d, J = 10.0 Hz, 1H), 4.76 (dd, J = 10.0, 1.4 Hz, 1H), 2.46–2.44 
(m, 4H), 2.38 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 144.1, 142.5, 138.8, 137.5, 
137.3, 135.8, 129.6, 129.2, 128.9, 127.5, 126.8, 126.1, 124.5, 83.9, 77.4, 77.0, 76.6, 




2-(1,1-Bis(4-bromophenyl)pent-1-en-4-yn-3-yl)thiophene (5-3cr, 2 h, 57% yield): 
1H NMR (300 MHz, CDCl3): δ 7.63–7.57 (m, 2H), 7.48–7.42 (m, 2H), 7.26 (dd, J = 
5.0, 1.3 Hz, 1H), 7.24–7.19 (m, 2H), 7.17–7.11 (m, 2H), 7.05–6.97 (m, 2H), 6.23 (d, J 
= 10.1 Hz, 1H), 4.68–4.64 (m, 1H), 2.46 (d, J = 2.5 Hz, 1H). 13C NMR (75 MHz, 
CDCl3): δ 143.1, 140.5, 139.8, 137.0, 131.9, 131.5, 131.4, 129.2, 128.1, 127.0, 124.9, 
124.7, 122.3, 122.1, 83.0, 77.4, 77.0, 76.6, 71.8, 32.8. HRMS (EI) calcd for 
[C21H14Br2S] + 455.9183, found 457.9165. 
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5.4.3 X-ray Crystallographic Analysis  
The configuration of the product 5-3ap was assigned by X-ray crystallographic 
analysis (Figure 5.1). The other products of 5-3 were assigned by analogy. 
Figure 5.1 X-ray structure of 5-3ap 
 
Table 5.6 Crystal data and structure refinement for 5-3ap 
Empirical formula  C27 H20 
Formula weight  344.43 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 13.908(2) Å  α = 90°. 
 b = 11.0651(18) Å β = 91.176(4)°. 
 c = 12.376(2) Å γ = 90°   




Density (calculated) 1.201 Mg/m3 
Absorption coefficient 0.068 mm-1 
F(000) 728 
Crystal size 0.54 x 0.26 x 0.22 mm3 
Theta range for data collection 2.35 to 27.50°. 
Index ranges -17<=h<=18, -13<=k<=14, -16<=l<=15 
Reflections collected 13484 
Independent reflections 4363 [R(int) = 0.0326] 
Completeness to theta = 27.50° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9852 and 0.9643 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4363 / 0 / 244 
Goodness-of-fit on F2 1.049 
Final R indices [I>2sigma(I)] R1 = 0.0494, wR2 = 0.1195 
R indices (all data) R1 = 0.0607, wR2 = 0.1256 







Facile Synthesis of 4-Substituted 3,4-Dihydrocoumarins via 






























N-Methylmorpholine-catalyzed double decarboxylation process is described. 
This process provides a convenient route to synthesize a biologically important 









3,4-Dihydrocoumarins have attracted considerable attention due to their various 
biological activities, such as aldose reductase inhibition,[139] protein kinases,[140] anti-
herpetic[141] and favoring agent to a diverse set of foods (soft drinks, yogurt, muf-
fins).[142] In addition, the 3,4-dihydrocoumarin scaffold is discovered in a number of 
important natural compounds as exemplified by Calomelanol A–C and E–J (Figure 
6.1).[143]  



































































In view of their wide biological application, we wonder whether it would be pos-
sible to assemble 3,4-dihydrocoumarins via an efficient process. In fact, several 
common methods have been reported, but most of these traditional approaches suffer 
from harsh reaction conditions, limited substrate generality, a large excess of expen-
sive transition metals, corrosive organic acids or laborious multistep procedure.[144] 
Despite the need for metal- free and enviromentally benign methods, organocatalytic 
strategies for the synthesis of 3,4-dihydrocoumarins have been rarely reported. In 
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2007, Kwon et al. discovered a tertiary-phosphine-catalyzed intramolecular [3+2] 
annulation strategy to construct cyclopentene-fused dihydrocoumarins in good to ex-
cellent yields (Scheme 6.1a). [144w] Afterwards, Lectka’s group documented an effi-
cient [4+2] cycloaddition reaction of ortho-quinone methides with silyl ketene acetals 
to afford a variety of alkyl- and aryl-substituted 3,4-dihydrocoumarins (Scheme 6.1b). 
[144l] In 2009, Zeitler and co-workers reported a one-pot, atom-economical 
N-heterocyclic carbine (NHC)-catalyzed redox lactonization reaction of 
o-hydroxycinnamaldehydes in the presence of oxidants (Scheme 6.1c). [144h] Most re-
cently, Hong reported an amine-thiourea-catalyzed Michael-acetalization process 
which could generate the 3,4-dihydrocoumarin scaffolds in synthetic useful yields 
(Scheme 6.1d).[144m] Herein, we have developed an organocatalytic double decarbox-
ylation strategy to conveniently afford 4-substituted 3,4-dihydrocoumarins using 
readily available amine catalyst under mild reaction conditions (Scheme 6.1e). 

























































































6.2 Results and Discussion 
Two comparison experiments were initially carried out in the presence of a cata-
lytic amount of triethylamine (TEA) (Scheme 6.2). Not surprisingly, thioester 6-1a 
did not react with coumarin 6-2a due to the high pKa of α-protons (Scheme 6.2a). 
Unfortunately, malonic acid half thioester 6-1b also had no reaction with coumarin 
6-2a (Scheme 6.2b). We deduce that the activity of coumarin 6-2a might be a crucial 
issue. Towards this end, another controlled experiment was designed. Couma-
rin-3-carboxylic acid 6-2b was introduced, affording the desired product 6-3bb in a 
synthetically useful yield (Scheme 6.2c). In view of the structure of couma-
rin-3-carboxylic acid 6-2b, the C3-carboxylic acid group may be helpful in improving 
the electrophilicity of C4 position and prompting the conjugate addition to generate 
product 6-3bb. 































































































Having this finding in hand, we then started to optimize the catalyst first, utiliz-
ing malonic acid half thioester 6-1b and coumarin-3-carboxylic acid 6-2b as model 
substrates. In the presence of i-butylamine I and pyridine VI, no reaction happened 
(Table 6.1, entry 1 and entry 6). Next, we examined pyrrolidine II. Interestingly, pyr-
rolidine II afforded a 44% yield (Table 6.1, entry 2). Following that, a series of ter-
tiary amines, such as triethylamine III, N,N-diisopropylethylamine IV, 
N-methylmorpholine V and 4-dimethylaminopyridine VII were investigated (Table 
6.1, entries 3-5 and 7). Finally, N-methylmorpholine V was approved to be the most 
efficient catalyst (Table 6.1, entry 5). In addition, several inorganic bases were also 
investigated, but showed no catalytic activity (Table 6.1, entries 8-11). 




















6-1b 6-2b 6-3bb  
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[a] Reaction conditions: 6-1b (0.2 mmol, 1.0 equiv.), 6-2b (0.24 mmol, 1.2 equiv.), Cat. (20 mol%), THF (0.4 mL), 6 
h, r.t.. [b] Isolated yield after flash column purification. 
In order to achieve a high chemical yield, we further investigated other parame-
ters (Table 6.2). Results showed that less polar solvents were poor reaction media 
(Table 6.2, entries 1-8). Ethanol and water also led a sluggish reaction (Table 6.2, en-
try9 and entry 10). A basic polar solvent was generally essential for a good chemical 
yield (Table 6.2, entry 11). Lowering catalyst amount caused a decrease of the reac-
tion yield (Table 6.2, entry 12). Gratifyingly, if the ratio of 6-1b/6-2b was adjusted 
from 1:1.2 to 1.2:1, 90% yield was obtained with a longer reaction time (Table 6.2, 
entry 13). However, if we further increased the ratio of 6-1b/6-2b to 1.5:1, the yield 
had no obvious improvement (Table 6.2, entry 14). 

























Entry Solvent  Yield [%][b] 
1 Et2O 36 
2 DCM  < 10 
Entry Catalyst Yield [%][b] 
1 i-Butylamine (I)  < 10 
2 Pyrrolidine (II) 44 
3 TEA (III) 56 
4 DIPEA (IV) 41 
5 N-Methylmorpholine (V) 66 
6 Pyridine (VI)  < 10 
7 DMAP (VII) 49 
8 NaOAc (VIII)  < 10 
9 Li2CO3 (IX)  < 10 
10 Cs2CO3 (X)  < 10 
11 NaOH (XI)  < 10 
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3 Toluene  < 10 
4 EtOAc  < 10 
5 Acetone 46 
6 MeCN  < 10 
7 THF 66 
8 1,4-Dioxane 73 
9 EtOH  < 10 
10 H2O  < 10 
11 DMF 82 
 12[c] DMF 76 
 13[d] DMF 90 
 14[e] DMF 90 
[a] Reaction conditions: 6-1b (0.2 mmol, 1.0 equiv.), 6-2b (0.24 mmol, 1.2 equiv.), Cat. V (20 mol%), solvent (0.4 
mL), 6 h, r.t.. [b] Isolated yield after flash column purification. [c] Cat. V (10 mol%), 12 h. [d] 6-1b (0.24 mmol, 1.2 
equiv.), 6-2b (0.2 mmol, 1.0 equiv.), Cat. V (20 mol%), 12 h, r.t.. [e] 6-1b (0.3 mmol, 1.5 equiv.), 6-2b (0.2 mmol, 
1.0 equiv.), Cat. V (20 mol%), 12 h, r.t.. 
Having established the optimal reaction condition, we subsequently explored the 
substrate scope of this transformation (Table 6.3). A number of couma-
rin-3-carboxylic acids 6-2c to 6-2j bearing electron donating and elec-
tron-withdrawing substituents were successfully applied to the double decarboxyla-
tion process, affording the corresponding products in moderate to excellent yields 
(Table 6.3 6-3bc to 6-3bj).  








































































































































Furthermore, a diverse set of malonic acid half-thioesters were examined (Table 
6.4). It was demonstrated that the substitution pattern of the phenyl ring on thioester 
had little influence on the reaction (Table 6.4, 6-3cb to 6-3fb). The alkyl substituted 
malonic acid half-thioesters 6-1g and 6-1h also efficiently participated in the decar-
boxylation process to respectively generate the corresponding 4-alkyl thioester 
3,4-dihydrocoumarins 6-3gb and 6-3hb.  
























































































































In addition to malonic acid half-thioesters, several other α- functionalized car-
boxylic acids 6-1i to 6-1m were introduced to this process and the desired products 
6-3ib to 6-3mb were achieved in high to excellent yields (Table 6.5). 









































































































In summary, we have developed an efficient and convenient double decarboxyla-
tion process for the synthesis of 4-substituted 3,4-dihydrocoumarin in moderate to 
excellent yields. We hope that the double decarboxylation strategy could be applied to 
efficiently synthesize some other useful structures. Manipulation of the products and 
further extenstion of our proposed decarboxylation strategy are undergoing in our 
group. 
6.4 Experimental Section 
6.4.1 General Information 
Chemicals and solvents were purchased from commercial suppliers and used as 
received. 1H and 13C NMR spectra were recorded on a Bruker ACF300 (300 MHz) or 
AMX500 (500 MHz) spectrometer. Chemical shifts were reported in parts per million 
(ppm), and the residual solvent peak was used as an internal reference. Multiplicity 
was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), 
dd (doublet of doublet), bs (broad singlet). Coupling constants were reported in Hertz 
(Hz). Low resolution mass spectra were obtained on a Finnigan/MAT LCQ spectrom-
eter in ESI mode or a Finnigan/MAT 95XL-T mass spectrometer in EI mode. All high 
resolution mass spectra were obtained on a Finnigan/MAT 95XL-T spectrometer. For 
thin layer chromatography (TLC), Merck pre-coated TLC plates (Merck 60 F254) 
were used. Compounds were visualized with a UV light at 254 nm. Further visualiza-
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tion was achieved by staining with iodine. Flash chromatography separations were 
performed on Merck 60 (0.040-0.063 mm) mesh silica gel.  
Starting materials of  6-1[145] and 6-2[146] were prepared according to related 
literatures, respectively. 

























S-phenyl 2-(2-oxochroman-4-yl)ethanethioate (6-3bb): To a solution of 6-1b (0.24 
mmol) and 6-2b (0.2 mmol) in DMF (0.4 mL), N-methylmorpholine V (20 mol%) 
was added. The reaction mixture was stirred at r.t. for 12 h. The crude product was 
purified by column chromatography on silica gel, eluted by hexane/ethyl acetate to 
afford the desired product 6-3bb (90% yield). 1H NMR (300 MHz, CDCl3): δ  
7.49–7.20 (m, 7H), 7.18–7.01 (m, 2H), 3.67 (ddd, J = 12.4, 7.2, 5.2 Hz, 1H), 
3.06–2.69 (m, 4H). 13C NMR (75 MHz, CDCl3): δ 195.0, 167.2, 151.3, 134.4, 129.7, 
129.3, 129.0, 127.6, 126.9, 124.7, 124.5, 117.3, 77.4, 77.0, 76.6, 47.3, 34.3, 31.9. 




OMe    
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S-phenyl 2-(2-oxochroman-4-yl)ethanethioate (6-3bc, 12 h, 96% yield): 1H NMR 
(300 MHz, CDCl3): δ 7.48–7.31 (m, 5H), 7.13–7.01 (m, 1H), 6.90 (dd, J = 8.3, 1.3 Hz, 
1H), 6.80 (dd, J = 7.7, 1.0 Hz, 1H), 3.90 (s, 3H), 3.73–3.59 (m, 1H), 3.03–2.75 (m, 
4H). 13C NMR (75 MHz, CDCl3): δ 195.0, 166.6, 147.8, 140.6, 134.4, 129.7, 129.3, 
126.9, 125.6, 124.7, 119.0, 111.7, 77.4, 77.0, 76.6, 56.1, 47.3, 34.2, 32.2. HRMS (ESI) 




   
S-phenyl 2-(8-allyl-2-oxochroman-4-yl)ethanethioate (6-3bd, 12 h, 94% yield): 1H 
NMR (300 MHz, CDCl3): δ 7.46–7.33 (m, 5H), 7.21-7.14 (m, 1H), 7.12–7.03 (m, 2H), 
6.08–5.85 (m, 1H), 5.11 (tt, J = 3.0, 1.7 Hz, 1H), 5.07 (dq, J = 3.3, 1.7 Hz, 1H), 3.66 
(ddd, J = 10.0, 7.0, 5.0 Hz, 1H), 3.47 (dd, J = 6.6, 1.0 Hz, 2H), 3.03–2.75 (m, 4H). 
13C NMR (75 MHz, CDCl3): δ 195.0, 167.2, 149.1, 135.7, 134.4, 129.7, 129.3, 128.7, 
126.9, 125.6, 124.5, 124.4, 116.4, 77.4, 77.0, 76.6, 47.3, 34.3, 33.6, 32.1. HRMS (ESI) 






S-phenyl 2-(6-methoxy-2-oxochroman-4-yl)ethanethioate (6-3be, 12 h, 91% yield): 
1H NMR (300 MHz, CDCl3): δ 7.47–7.31 (m, 5H), 7.01 (d, J = 8.9 Hz, 1H), 6.82 (dd, 
J = 8.9, 3.0 Hz, 1H), 6.73 (d, J = 2.9 Hz, 1H), 3.77 (s, 3H), 3.61 (ddd, J = 12.3, 7.2, 
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5.1 Hz, 1H), 3.03–2.75 (m, 4H). 13C NMR (75 MHz, CDCl3): δ 195.1, 167.2, 160.1, 
152.1, 134.4, 129.7, 129.3, 128.2, 127.0, 116.2, 110.7, 102.7, 77.4, 77.0, 76.6, 55.5, 







S-phenyl 2-(6-fluoro-2-oxochroman-4-yl)ethanethioate (6-3bf, 24 h, 82% yield): 
1H NMR (300 MHz, CDCl3): δ 7.48–7.31 (m, 5H), 7.12–6.87 (m, 3H), 3.64 (ddd, J = 
12.4, 7.2, 5.2 Hz, 1H), 3.05–2.73 (m, 4H). 13C NMR (75 MHz, CDCl3): δ 194.8, 
166.7, 160.7, 157.4, 147.3, 134.4, 129.8, 129.4, 126.7, 126.2, 126.1, 118.7, 118.6, 
115.9, 115.6, 114.5, 114.2, 77.4, 77.0, 76.6, 47.0, 33.9, 31.9. HRMS (ESI) calcd for 





   
S-phenyl 2-(6-chloro-2-oxochroman-4-yl)ethanethioate (6-3bg,24 h, 86% yield): 
1H NMR (300 MHz, CDCl3): δ 7.40–7.26 (m, 5H), 7.23–7.12 (m, 2H), 6.95 (d, J = 
8.6 Hz, 1H), 3.62–3.49 (m, 1H), 2.95–2.70 (m, 4H). 13C NMR (75 MHz, CDCl3): δ  
194.8, 166.5, 149.9, 134.4, 129.8, 129.4, 129.1, 127.6, 126.6, 126.1, 118.7, 77.4, 77.0, 







MeO    
S-phenyl 2-(7-methoxy-2-oxochroman-4-yl)ethanethioate (6-3bh, 24 h, 82% 
yield): 1H NMR (300 MHz, CDCl3): δ 7.50–7.30 (m, 5H), 7.01 (d, J = 8.9 Hz, 1H), 
6.82 (dd, J = 8.9, 3.0 Hz, 1H), 6.73 (d, J = 2.9 Hz, 1H), 3.77 (s, 3H), 3.61 (ddd, J = 
12.4, 7.2, 5.1 Hz, 1H), 2.96–2.79 (m, 4H). 13C NMR (75 MHz, CDCl3): δ 195.0, 
167.4, 156.3, 145.1, 134.4, 129.7, 129.3, 126.9, 125.4, 118.1, 114.2, 112.5, 77.4, 77.0, 





O2N    
S-phenyl 2-(7-nitro-2-oxochroman-4-yl)ethanethioate (6-3bi, 24 h, 60% yield): 1H 
NMR (500 MHz, CDCl3): δ 8.25–8.16 (m, 2H), 7.49–7.31 (m, 5H), 7.21 (d, J = 8.6 
Hz, 1H), 3.82–3.74 (m, 1H), 3.08–2.85 (m, 4H). 13C NMR (125 MHz, CDCl3): δ  
194.5, 165.2, 155.7, 144.3, 134.4, 130.0, 129.4, 126.4, 125.6, 124.9, 123.7, 118.3, 
77.4, 77.0, 76.6, 46.7, 33.6, 31.8. HRMS (ESI) calcd for [C17H13NO5S + Na] + 
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S-phenyl 2-(8-bromo-6-chloro-2-oxochroman-4-yl)ethanethioate (6-bj, 24 h, 74% 
yield): 1H NMR (300 MHz, CDCl3): δ 7.55 (d, J = 2.4 Hz, 1H), 7.48–7.29 (m, 5H), 
7.19 (d, J = 2.3 Hz, 1H), 3.73–3.55 (m, 1H), 3.01–2.73 (m, 4H). 13C NMR (75 MHz, 
CDCl3): δ 194.7, 165.3, 147.2, 134.4, 132.4, 130.0, 129.9, 129.4, 127.4, 126.9, 126.5, 
111.8, 77.4, 77.0, 76.6, 46.8, 33.8, 32.4. HRMS (ESI) calcd for [C17H12BrClO3S + Na] 





   
S-(4-chlorophenyl) 2-(2-oxochroman-4-yl)ethanethioate (6-3cb, 12 h, 94% yield): 
1H NMR (300 MHz, CDCl3): δ 7.43–7.35 (m, 2H), 7.35–7.25 (m, 3H), 7.22 (dd, J = 
7.6, 1.7 Hz, 1H), 7.14 (dd, J = 7.4, 1.2 Hz, 1H), 7.11–7.05 (m, 1H), 3.73–3.59 (m, 
1H), 3.04–2.77 (m, 4H). 13C NMR (75 MHz, CDCl3): δ 194.5, 167.1, 151.3, 136.2, 
135.6, 129.6, 129.1, 127.6, 125.3, 124.7, 124.3, 117.4, 77.4, 77.0, 76.6, 47.4, 34.3, 





   
S-(4-methoxyphenyl) 2-(2-oxochroman-4-yl)ethanethioate (6-3db, 12 h, 97% 
yield): 1H NMR (300 MHz, CDCl3): δ 7.38–7.23 (m, 4H), 7.21–7.08 (m, 2H), 
7.02–6.93 (m, 2H), 3.86 (s, 3H), 3.70 (ddd, J = 12.4, 7.2, 5.2 Hz, 1H), 2.90–2.87 (m, 
4H). 13C NMR (75 MHz, CDCl3): δ 196.1, 167.3, 160.8, 151.3, 136.0, 129.0, 127.6, 
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124.7, 124.5, 117.5, 117.3, 114.9, 77.4, 77.0, 76.6, 55.3, 47.0, 34.3, 31.9. HRMS (ESI) 





   
S-(2-methoxyphenyl) 2-(2-oxochroman-4-yl)ethanethioate (6-3eb, 12 h, 93% 
yield): 1H NMR (300 MHz, CDCl3): δ 7.39–7.29 (m, 1H), 7.26–7.14 (m, 3H), 
7.08–6.95 (m, 2H), 6.92-6.87 (m, 2H), 3.75 (s, 3H), 3.65–3.49 (m, 1H), 2.99–2.61 (m, 
4H). 13C NMR (75 MHz, CDCl3): δ 194.4, 167.3, 159.1, 151.3, 136.5, 132.0, 128.9, 
127.5, 124.7, 124.6, 121.1, 117.2, 115.1, 111.6, 77.4, 77.0, 76.6, 55.9, 47.0, 34.1, 31.8. 






   
S-(3,4-dimethoxyphenyl) 2-(2-oxochroman-4-yl)ethanethioate (6-3fb, 12 h, 96% 
yield): 1H NMR (300 MHz, CDCl3): δ 7.28–7.12 (m, 2H), 7.11–6.96 (m, 2H), 
6.89–6.77 (m, 3H), 3.81 (d, J = 5.8 Hz, 6H), 3.59 (ddd, J = 12.2, 7.3, 5.2 Hz, 1H), 
2.95–2.66 (m, 4H). 13C NMR (75 MHz, CDCl3): δ 196.0, 167.2, 151.3, 150.4, 149.2, 
129.0, 127.7, 127.6, 124.6, 124.5, 117.6, 117.3, 117.1, 111.5, 77.4, 77.0, 76.6, 55.9, 







   
S-isopropyl 2-(2-oxochroman-4-yl)ethanethioate (6-3gb, 12 h, 92% yield): 1H 
NMR (300 MHz, CDCl3): δ 7.31–7.23 (m, 1H), 7.19 (dd, J = 7.6, 1.7 Hz, 1H), 7.11 
(dd, J = 7.4, 1.2 Hz, 1H), 7.08–7.01 (m, 1H), 3.89–3.53 (m, 2H), 2.88–2.72 (m, 4H), 
1.28 (t, J = 6.9 Hz, 6H). 13C NMR (75 MHz, CDCl3): δ 196.7, 167.3, 151.3, 128.9, 
127.5, 124.7, 124.6, 117.2, 77.4, 77.0, 76.6, 47.8, 35.1, 34.2, 31.8, 22.8, 22.7. HRMS 





   
Ethyl 2-((2-(2-oxochroman-4-yl)acetyl)thio)acetate (6-3hb, 12 h, 88% yield): 1H 
NMR (300 MHz, CDCl3): δ 7.27–7.18 (m, 1H), 7.17–7.11 (m, 1H), 7.09–6.95 (m, 
2H), 4.13 (q, J = 7.1 Hz, 2H), 3.66–3.45 (m, 3H), 2.97–2.61 (m, 4H), 1.21 (t, J = 7.1 
Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 194.9, 168.2, 167.1, 151.3, 129.0, 127.4, 
124.7, 124.4, 117.3, 77.4, 77.0, 76.6, 62.0, 47.4, 34.1, 31.9, 31.4, 14.0. HRMS (ESI) 
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Phenyl 2-(2-oxochroman-4-yl)acetate (6-3ib, 24 h, 98% yield): 1H NMR (300 MHz, 
CDCl3): δ 7.34–7.21 (m, 4H), 7.19–7.12 (m, 1H), 7.11–7.00 (m, 2H), 6.98–6.91 (m, 
2H), 3.72–3.53 (m, 1H), 2.90–2.75 (m, 4H). 13C NMR (75 MHz, CDCl3): δ 169.4, 
167.3, 151.4, 150.2, 129.5, 129.1, 127.6, 126.1, 124.8, 124.6, 121.3, 117.4, 77.4, 77.0, 







   
N-(4-isopropylphenyl)-2-(2-oxochroman-4-yl)acetamide (6-3jb, 24 h, 80% yield): 
1H NMR (300 MHz, d6-DMSO): δ 9.86 (s, 1H), 7.44 (d, J = 8.5 Hz, 2H), 7.36–7.25 
(m, 2H), 7.19–7.03 (m, 4H), 3.59 (dd, J = 11.5, 6.6 Hz, 1H), 3.08–3.00 (m, 1H), 
2.93–2.52 (m, 4H), 1.10 (d, J = 6.9 Hz, 6H). 13C NMR (75 MHz, d6-DMSO): δ 168.3, 
167.7, 151.1, 143.4, 136.6, 128.4, 127.9, 126.4, 126.0, 124.3, 119.3, 116.5, 41.0, 40.4, 
40.1, 39.8, 39.5, 39.2, 39.0, 38.7, 33.9, 32.9, 31.2, 24.0. HRMS (ESI) calcd for 
[C20H21NO3 + Na] + 346.1413, found 346.1419. 
O O
O
   
4-(2-Oxo-2-phenylethyl)chroman-2-one (6-3kb, 12 h, 93% yield): 1H NMR (500 
MHz, CDCl3): δ 7.93–7.91 (m, 2H), 7.60–7.57 (m, 1H), 7.48–7.45 (m, 2H), 7.38–7.21 
(m, 2H), 7.19–6.95 (m, 2H), 3.98–3.78 (m, 1H), 3.35–3.24 (m, 2H), 2.98–2.88 (m, 
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2H). 13C NMR (125 MHz, CDCl3): δ 196.8, 167.9, 151.4, 136.3, 133.5, 128.7, 128.0, 
127.9, 125.8, 124.7, 117.1, 77.3, 77.0, 76.8, 42.8, 34.6, 30.4. HRMS (ESI) calcd for 
[C17H15O3 + H] + 267.1021, found: 267.1022. 
O O
CN    
2-(2-Oxochroman-4-yl)acetonitrile (6-3lb, 12 h, 94% yield): 1H NMR (500 MHz, 
CDCl3): δ 7.39–7.34 (m, 1H), 7.33–7.28 (m, 1H), 7.22–7.19 (m, 1H), 7.12–7.11 (m, 
1H), 3.50–3.39 (m, 1H), 3.05–2.84 (m, 2H), 2.69–2.67 (m, 2H). 13C NMR (125 MHz, 
CDCl3): δ 166.0, 151.1, 130.0, 127.3, 125.1, 122.3, 117.6, 116.7, 77.3, 77.0, 76.8, 




4-(4-Nitrobenzyl)chroman-2-one (6-3mb, 12 h, 93% yield): 1H NMR (500 MHz, 
CDCl3): δ 8.13 (d, J = 8.5 Hz, 2H), 7.33–7.23 (m, 1H), 7.21 (d, J = 8.5 Hz, 2H), 
7.13–6.98 (m, 1H), 6.91–6.89 (m, 1H), 3.31–3.27 (m, 1H), 3.03–2.99 (m, 1H), 
2.94–2.89 (m, 1H), 2.84–2.74 (m, 2H). 13C NMR (125 MHz, CDCl3): δ 167.4, 151.2, 
146.9, 145.4, 130.1, 129.0, 127.8, 124.7, 124.5, 123.7, 117.3, 77.3, 77.0, 76.8, 41.0, 
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